
<html lang="en"     class="pb-page"  data-request-id="730593b8-f79f-4429-a14a-32cfcc4d5b82"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-10;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.1c00023;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors" /></meta><meta name="dc.Creator" content="Csaba  Weber" /></meta><meta name="dc.Creator" content="Melinda  Sipos" /></meta><meta name="dc.Creator" content="Attila  Paczal" /></meta><meta name="dc.Creator" content="Balazs  Balint" /></meta><meta name="dc.Creator" content="Vilibald  Kun" /></meta><meta name="dc.Creator" content="Nicolas  Foloppe" /></meta><meta name="dc.Creator" content="Pawel  Dokurno" /></meta><meta name="dc.Creator" content="Andrew J.  Massey" /></meta><meta name="dc.Creator" content="David Lee  Walmsley" /></meta><meta name="dc.Creator" content="Roderick E.  Hubbard" /></meta><meta name="dc.Creator" content="James  Murray" /></meta><meta name="dc.Creator" content="Karen  Benwell" /></meta><meta name="dc.Creator" content="Thomas  Edmonds" /></meta><meta name="dc.Creator" content="Didier  Demarles" /></meta><meta name="dc.Creator" content="Alain  Bruno" /></meta><meta name="dc.Creator" content="Mike  Burbridge" /></meta><meta name="dc.Creator" content="Francisco  Cruzalegui" /></meta><meta name="dc.Creator" content="Andras  Kotschy" /></meta><meta name="dc.Description" content="The kinase DYRK1A is an attractive target for drug discovery programs due to its implication in multiple diseases. Through a fragment screen, we identified a simple biaryl compound that is bound to..." /></meta><meta name="Description" content="The kinase DYRK1A is an attractive target for drug discovery programs due to its implication in multiple diseases. Through a fragment screen, we identified a simple biaryl compound that is bound to..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 12, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00023" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00023" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00023" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00023" /></link>
        
    
    

<title>Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00023" /></meta><meta property="og:title" content="Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0014.jpeg" /></meta><meta property="og:description" content="The kinase DYRK1A is an attractive target for drug discovery programs due to its implication in multiple diseases. Through a fragment screen, we identified a simple biaryl compound that is bound to the DYRK1A ATP site with very high efficiency, although with limited selectivity. Structure-guided optimization cycles enabled us to convert this fragment hit into potent and selective DYRK1A inhibitors. Exploiting the structural differences in DYRK1A and its close homologue DYRK2, we were able to fine-tune the selectivity of our inhibitors. Our best compounds potently inhibited DYRK1A in the cell culture and in vivo and demonstrated drug-like properties. The inhibition of DYRK1A in vivo translated into dose-dependent tumor growth inhibition in a model of ovarian carcinoma." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00023"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00023">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00023&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00023&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00023&amp;href=/doi/10.1021/acs.jmedchem.1c00023" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 6745-6764</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02271" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00039" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Csaba Weber</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Csaba Weber</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Servier Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Csaba++Weber">Csaba Weber</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Melinda Sipos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melinda Sipos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Servier Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melinda++Sipos">Melinda Sipos</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Attila Paczal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Attila Paczal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Servier Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Attila++Paczal">Attila Paczal</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Balazs Balint</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Balazs Balint</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Servier Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Balazs++Balint">Balazs Balint</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Vilibald Kun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vilibald Kun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Servier Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vilibald++Kun">Vilibald Kun</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Nicolas Foloppe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicolas Foloppe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vernalis (R&D) Ltd., Granta Park, CB21 6GB Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicolas++Foloppe">Nicolas Foloppe</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Pawel Dokurno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pawel Dokurno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vernalis (R&D) Ltd., Granta Park, CB21 6GB Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pawel++Dokurno">Pawel Dokurno</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7332-8889" title="Orcid link">http://orcid.org/0000-0002-7332-8889</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Andrew J. Massey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew J. Massey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vernalis (R&D) Ltd., Granta Park, CB21 6GB Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+J.++Massey">Andrew J. Massey</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0276-2573" title="Orcid link">http://orcid.org/0000-0002-0276-2573</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">David Lee Walmsley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Lee Walmsley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vernalis (R&D) Ltd., Granta Park, CB21 6GB Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+Lee++Walmsley">David Lee Walmsley</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Roderick E. Hubbard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roderick E. Hubbard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vernalis (R&D) Ltd., Granta Park, CB21 6GB Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roderick+E.++Hubbard">Roderick E. Hubbard</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">James Murray</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Murray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vernalis (R&D) Ltd., Granta Park, CB21 6GB Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Murray">James Murray</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1007-8218" title="Orcid link">http://orcid.org/0000-0003-1007-8218</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Karen Benwell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Benwell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Vernalis (R&D) Ltd., Granta Park, CB21 6GB Cambridge, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Benwell">Karen Benwell</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Thomas Edmonds</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Edmonds</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Edmonds">Thomas Edmonds</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Didier Demarles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Didier Demarles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Technologie Servier, 27 Rue EugÃ¨ne Vignat, 45000 Orleans, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Didier++Demarles">Didier Demarles</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Alain Bruno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alain Bruno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alain++Bruno">Alain Bruno</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Mike Burbridge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mike Burbridge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mike++Burbridge">Mike Burbridge</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Francisco Cruzalegui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francisco Cruzalegui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francisco++Cruzalegui">Francisco Cruzalegui</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Andras Kotschy</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andras Kotschy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Servier Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d2b3bcb6a0b3a1fcb9bda6a1b1baab92a1b7a0a4bbb7a0fcb1bdbf"><span class="__cf_email__" data-cfemail="9ffef1fbedfeecb1f4f0ebecfcf7e6dfecfaede9f6faedb1fcf0f2">[emailÂ protected]</span></a>. Phone: +36 (1) 881-2000. Fax: +36 (1) 881 2011.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andras++Kotschy">Andras Kotschy</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7675-3864" title="Orcid link">http://orcid.org/0000-0002-7675-3864</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00023&amp;href=/doi/10.1021%2Facs.jmedchem.1c00023" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 6745â6764</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 12, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 January 2021</li><li><span class="item_label"><b>Published</b> online</span>12 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00023" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00023</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6745%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DCsaba%2BWeber%252C%2BMelinda%2BSipos%252C%2BAttila%2BPaczal%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D10%26contentID%3Dacs.jmedchem.1c00023%26title%3DStructure-Guided%2BDiscovery%2Bof%2BPotent%2Band%2BSelective%2BDYRK1A%2BInhibitors%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6764%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00023"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1756</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00023" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Csaba&quot;,&quot;last_name&quot;:&quot;Weber&quot;},{&quot;first_name&quot;:&quot;Melinda&quot;,&quot;last_name&quot;:&quot;Sipos&quot;},{&quot;first_name&quot;:&quot;Attila&quot;,&quot;last_name&quot;:&quot;Paczal&quot;},{&quot;first_name&quot;:&quot;Balazs&quot;,&quot;last_name&quot;:&quot;Balint&quot;},{&quot;first_name&quot;:&quot;Vilibald&quot;,&quot;last_name&quot;:&quot;Kun&quot;},{&quot;first_name&quot;:&quot;Nicolas&quot;,&quot;last_name&quot;:&quot;Foloppe&quot;},{&quot;first_name&quot;:&quot;Pawel&quot;,&quot;last_name&quot;:&quot;Dokurno&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;J. Massey&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Lee Walmsley&quot;},{&quot;first_name&quot;:&quot;Roderick&quot;,&quot;last_name&quot;:&quot;E. Hubbard&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Murray&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Benwell&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Edmonds&quot;},{&quot;first_name&quot;:&quot;Didier&quot;,&quot;last_name&quot;:&quot;Demarles&quot;},{&quot;first_name&quot;:&quot;Alain&quot;,&quot;last_name&quot;:&quot;Bruno&quot;},{&quot;first_name&quot;:&quot;Mike&quot;,&quot;last_name&quot;:&quot;Burbridge&quot;},{&quot;first_name&quot;:&quot;Francisco&quot;,&quot;last_name&quot;:&quot;Cruzalegui&quot;},{&quot;first_name&quot;:&quot;Andras&quot;,&quot;last_name&quot;:&quot;Kotschy&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6745-6764&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00023&quot;},&quot;abstract&quot;:&quot;The kinase DYRK1A is an attractive target for drug discovery programs due to its implication in multiple diseases. Through a fragment screen, we identified a simple biaryl compound that is bound to the DYRK1A ATP site with very high efficiency, although with limited selectivity. Structure-guided optimization cycles enabled us to convert this fragment hit into potent and selective DYRK1A inhibitors. Exploiting the structural differences in DYRK1A and its close homologue DYRK2, we were able to fine-tune the selectivity of our inhibitors. Our best compounds potently inhibited DYRK1A in the cell culture and in vivo and demonstrated drug-like properties. The inhibition of DYRK1A in vivo translated into dose-dependent tumor growth inhibition in a model of ovarian carcinoma.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00023&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00023" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00023&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00023" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00023&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00023" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00023&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00023&amp;href=/doi/10.1021/acs.jmedchem.1c00023" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00023" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00023" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00023%26sid%3Dliteratum%253Aachs%26pmid%3D33975430%26genre%3Darticle%26aulast%3DWeber%26date%3D2021%26atitle%3DStructure-Guided%2BDiscovery%2Bof%2BPotent%2Band%2BSelective%2BDYRK1A%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D10%26spage%3D6745%26epage%3D6764%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292288" title="X-rays">X-rays</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/jmcmar.2021.64.issue-10/20210527/jmcmar.2021.64.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The kinase DYRK1A is an attractive target for drug discovery programs due to its implication in multiple diseases. Through a fragment screen, we identified a simple biaryl compound that is bound to the DYRK1A ATP site with very high efficiency, although with limited selectivity. Structure-guided optimization cycles enabled us to convert this fragment hit into potent and selective DYRK1A inhibitors. Exploiting the structural differences in DYRK1A and its close homologue DYRK2, we were able to fine-tune the selectivity of our inhibitors. Our best compounds potently inhibited DYRK1A in the cell culture and <i>in vivo</i> and demonstrated drug-like properties. The inhibition of DYRK1A <i>in vivo</i> translated into dose-dependent tumor growth inhibition in a model of ovarian carcinoma.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">DYRK1A (dual-specificity tyrosine-phosphorylation-regulated kinase 1A) belongs to the CMGC family of protein kinases and is essential for maintaining the normal development and function of the brain, phosphorylating several proteins and thereby regulating their functions.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> DYRK1A has also been implicated in the pathogenesis of one of the most frequent genetic disorders, Downâs syndrome,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and recent evidence has also implicated DYRK1A in the pathology of neurodegenerative disorders such as Alzheimerâs disease<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and Parkinsonâs disease.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> DYRK1A is also involved in the regenerative pathways relevant to human insulin-producing pancreatic Î²-cells,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and its implication in tumorigenesis and cell survival has also been reported.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The natural product harmine was identified as a selective and potent inhibitor of DYRK1A.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In spite of the inherent liabilities of harmine, including the potent inhibition of MAO-A linked with hallucinogenic effects<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and poor metabolic stability, the most potent DYRK1A inhibitors reported so far are typically based on this scaffold,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> although some new chemotypes were also identified recently.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Although the MAO-A inhibition of Î²-carbolines could be eliminated,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> the identification of novel selective DYRK1A inhibitor chemotypes with drug-like properties remains highly desirable.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The accompanying paper describes the screening of a fragment collection by NMR spectroscopy followed by orthogonal validation to identify a number of fragments that bind to DYRK1A with high ligand efficiency (LE), including <b>1</b> with a LE of 0.59. The crystal structure of <b>1</b> in complex with the DYRK1A kinase domain (hereafter termed Dyrk1a) (PDB:<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7A4W">7A4W</a>), reported in the preceding article, showed (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) that compound <b>1</b> completely filled the buried part of this site with a combination of apolar and polar contacts. In particular, hydrogen bonds between the hinge region of the protein (Leu241) and the methoxy group of <b>1</b>, as well as between the aminopyrimidine and the side chain of Lys188 and Glu203 (a.k.a. âsalt-bridge regionâ, also involving Asp307, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C). The observed interactions were highly reminiscent of those seen in harmineâs bound structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR">3ANR</a>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). Because harmine (<b>2</b>) is known to be an efficient and selective inhibitor of DYRK1A, <b>1</b> was selected as the starting point for fragment elaboration. In addition, from the outset, molecular modeling highlighted the distinctive hinge conformation of Dyrk1a at the backbone carbonyl of Leu241 and how it could be used to design ligand selectivity for DYRK1A over a number of other kinases, via direct contacts with the backbone carbonyl of Leu241. The methoxy of <b>1</b> offered such contact. How this structural insight was used to gain selectivity over other kinases is illustrated below. It is important to note at this point that all DYRK1A inhibitors exhibit a very similar effect on DYRK1B (for details, see Table S1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Supporting Information</a>) due to the very high homology of these two proteins in their kinase domain.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural characterization of fragment <b>1</b> bound to Dyrk1a, as determined by X-ray crystallography (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7A4W">7A4W</a>). (A) Overall view of the structure, with <b>1</b> shown in green (space filling) and the ATP site of Dyrk1a as the molecular surface. (B) Overlay of Dyrk1a-bound harmine (orange, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR">3ANR</a>) onto <b>1</b> (green) highlighting the hinge region in magenta and salt-bridge region in blue. (C) Specific interactions between <b>1</b> and Dyrk1a showing selected hydrogen atoms (added with software MOE<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>). Black dotted lines depict hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first set of compounds (<b>3</b>â<b>6</b>) were aimed at establishing the minimum necessary elements for efficient binding. In agreement with the X-ray structure, chemical modifications that conserved the hydrogen acceptor moieties in the correct geometric arrangements led only to small variations in the affinity. Changing the diaminopyrimidine moiety to aminopyridine (<b>3</b>) led to a minor improvement, while modification to methylpyridine (<b>4</b>) slightly decreased the affinity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The X-ray structure of <b>3</b> in complex with Dyrk1a (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) confirmed the conservation of the binding mode of <b>1</b>; however, <b>3</b> binds with dual occupancy, its amine being 50% buried toward Glu203 or 50% flipped toward the solvent. Thus, neither orientation of the amine is overwhelmingly preferred. In the buried orientation, the replacement of this amine with methyl removes the hydrogen bond to Glu203, consistent with the decreased affinity of <b>4</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structures of Dyrk1a complexes of compounds derived by the early elaboration of fragment <b>1.</b> Only selected structural elements and hydrogen atoms are shown. Hydrogen bonds of interest are depicted with black dotted lines. (A) <b>3</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ2">7AJ2</a>) showing double occupancy, with its amine buried (green) or pointing toward the solvent (magenta). (B) Overlay of <b>1</b> (green) and <b>5</b> (orange, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ4">7AJ4</a>). (C) Overlay of <b>10</b> (orange sticks, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ5">7AJ5</a>) and <b>25</b> (green ball and stick, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ8">7AJ8</a>). The amine of <b>25</b> points toward Glu203. (D) <b>16</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ7">7AJ7</a>) with the imidazole methyl substituent offering a vector for growth toward the glycine loop (blue) and the opening of the ATP binding site including Asn244 and Asn292. (E) <b>28</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJA">7AJA</a>) highlighting the desolvation of polar groups (red arrow) and a water molecule trapped between <b>28</b> and Glu203. (F) <b>32</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJM">7AJM</a>). It is unclear if the desolvation of the cationic amine by Phe170 is compensated by cationâÏ interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Dyrk1a Inhibition with Our Starting Fragment (<b>1</b>), Harmine (<b>2</b>), and Early Fragment-Derived Compounds (<b>3â6</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0008.gif" alt="" id="GRAPHIC-d7e557-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">DYRK1A IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">158</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">126</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">MeO</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">670</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">218</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Measured in the DYRK1A FRET assay.</p></div></div></div><div class="NLM_p">It has been reported that chlorine attached to an aromatic ring can interact efficiently with the hinge region of Dyrk1a.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Indeed, the change of the hinge binder methoxy group to chlorine with the methoxy group moved vicinal to chlorine (<b>5</b>) led only to a minor deterioration. The X-ray structure of the <b>5</b>âDyrk1a complex (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B) confirmed that the hinge binding occurs via the chlorine, accommodated by the above-mentioned unusual orientation of the hinge carbonyl of Leu241. The X-ray data for <b>5</b> cannot exclude two orientations for its amine; however, signs of this equilibrium were weaker with <b>5</b> than with <b>3</b>; thus, the amino group of <b>5</b> was conservatively modeled with single occupancy pointing toward the protein. Removing the electron-donating substituents from both aromatic rings (<b>6</b>) on the other hand led to a significant drop in the affinity.</div><div class="NLM_p">The overlaid X-ray structures of <b>1</b> and <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) suggested that cyclization linking the attachment points of the chlorine and methoxy should be tolerated. The cyclization of the methoxy group to a benzofuran through a single (<b>7</b>) or double bond (<b>8</b>) led to a marked increase in its affinity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), consistent with conformational restriction compared to <b>1</b>. The replacement of the pyrimidine ring by pyridine (<b>9</b>,<b>10</b>) further improved binding to DYRK1A. This might be attributed to the increased electron density of the pyridine nitrogen which hydrogen bonds Lys188. The benzofuran derivatives (<b>8</b> and <b>10</b>) and their dihydro analogues (<b>7</b> and <b>9</b>, respectively) showed similar affinity. Moving from benzofuran <b>10</b> to the benzothiophene analogue (<b>11</b>) resulted in a marked decrease of affinity, reflecting the poorer acceptor properties of sulfur. The introduction of nitrogen into the five-membered ring (benzoxazole <b>12</b>) slightly decreased the affinity while the same manipulation on the benzene ring (furo[3,2-<i>b</i>]pyridine <b>13</b>) was well tolerated. In the next set of compounds, the hinge binder oxygen was deliberately replaced by nitrogen because nitrogen tends to be the better hydrogen bond acceptor in oxazoles.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Indeed, oxazole <b>14</b> showed a 2-fold improvement over its analogue <b>12</b>. The replacement of the oxygen of <b>14</b> by sulfur was beneficial; the thiazole derivative <b>15</b> registering a single-digit nanomolar affinity. Unfortunately, the sulfur of <b>15</b> blocked further growth at this position, but the corresponding imidazoles do not have this limitation. The imidazole ring (<b>16</b>) was about as efficient as the respective oxazole (<b>14</b>), while the introduction of an additional nitrogen atom, resulting in the imidazo[4,5-<i>b</i>]pyridine derivative <b>17</b> was tolerated. The X-ray structure of the complexes with Dyrk1a of <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) and <b>16</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D) confirmed that the cyclization as well as the swap of the hinge binder atom closely maintain the initial binding mode.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. DYRK1A Inhibition of Diaminopyridines and Pyrimidines Carrying a Bicyclic Hinge Binder Motif (<b>7â24</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0009.gif" alt="" id="GRAPHIC-d7e809-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center">bond</th><th class="colsep0 rowsep0" align="center" char=".">DYRKA IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">single</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">double</td><td class="colsep0 rowsep0" align="char" char=".">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">single</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">double</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">137</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"><i>N</i>-Me</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"><i>N</i>-Me</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">single</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">CâO</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">double</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Measured in the DYRK1A FRET assay.</p></div></div></div><div class="NLM_p">We also assessed the effect of introducing nitrogen into the bridgehead position. The imidazo[1,2-<i>a</i>]pyridine (<b>18</b>)-, [1,2,4]triazolo[2,3-<i>a</i>]pyridine (<b>19</b>)-, and pyrazolo[1,5-<i>a</i>]pyrimidine (<b>20</b>)-substituted diaminopyridine derivatives all showed high affinities towards DYRK1A in the same range as the other bicyclic compounds. Finally, we tested if further variation in the moiety contacting the hinge could be sterically accommodated by expanding the five-membered ring to six-membered. The benzodioxane derivative <b>22</b> matched the affinity of its dihydrobenzofuran analogue (<b>9</b>). Changing the acceptor moiety to the less electron-rich chromenone analogue (<b>23</b>) led to a perceptible drop of affinity due probably to electronic effects, while the quinoline derivative <b>24</b> was as efficient as benzodioxane <b>22</b>. In summary, we took advantage of the distinctive hinge of Dyrk1a to develop a large variety of bicyclic hinge binder motifs, which were well accommodated and offer a broad range of options. This variety was facilitated because there is no constraint to the hydrogen bond of the hinge backbone carbonyl of Leu241 in Dyrk1a, given its comparatively unusual orientation. The main requirement was an efficient heteroatom to accept a hydrogen bond from the hinge amide nitrogen of Leu241. These observations were important for the progression of the project because the chemical space of ATP-competitive kinase inhibitors is quite crowded, and the structural diversity of the identified bicyclic inhibitors helped escape from areas that were already covered by prior art.</div><div class="NLM_p">The bound structure of <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) is consistent with its particularly highly efficient binding (LE 0.63) because the above-described hinge binding was combined with additional interactions with the salt-bridge region. The hydrogen bond between the pyridine nitrogen and Lys188 was conserved from fragment <b>1</b> to more elaborated molecules. The amino group on the pyridine point toward the protein hydrogen bond glutamate-203, while the amino group that points toward the solvent is in the proximity of Asp307. Thus, this region involves multiple polar interactions, including water, combined with protein sidechain shifts when comparing X-ray structures. It was therefore challenging to establish precise structureâactivity relationships for the salt-bridge region because small changes in the geometry of polar contacts have large effects on the resulting energies. However, to address the contribution of these interactions, we undertook the systematic variation of the pyridine ring substitution pattern (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), using <b>10</b> as a reference for comparisons. The omission of one of the amino groups (<b>25</b>) led to a minor decrease in affinity (IC<sub>50</sub> increased to 19 nM from 14 nM) while removing the second amino group (<b>26</b>) resulted in a marked loss of affinity (320 nM). Thus, at least one of the two amino groups strengthens binding. Indeed, in the absence of both amines, there would be either a trapped water molecule or a void between the compound and Glu203. This interpretation is supported by the Dyrk1a bound X-ray structure of <b>25</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C), where the amino group points toward the protein, hydrogen-bonding Glu203. The polar nature of the interactions involving the amines was confirmed when the replacement of one amine by a methyl group (<b>27</b>) dropped the affinity to 77 nM. Deleterious effects were also observed upon the alkylation of one of the amines, although simple methylation in <b>29</b> maintained a binding affinity similar to that of <b>10</b> and <b>25</b>. Larger alkyl substituents are exposed to the solvent but still have to form specific interactions with the protein surface. The piperazinyl analogue <b>28</b> showed a marked drop in affinity and ligand efficiency, which may reflect desolvation because the X-ray structure of its bound complex suggests that the piperazine ring is in contact with the side chain of Asn292 but without forming a hydrogen bond (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E). In addition, the deletion of both plain amino groups in <b>28</b> resulted in a water molecule trapped between <b>28</b> and glutamate-203, which is likely to be entropically unfavorable.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. DYRK1A Inhibition of Pyridine-Substituted Benzofurans (<b>25â32</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0010.gif" alt="" id="GRAPHIC-d7e1175-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">320</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">piperazinyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">3560</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">MeOCH<sub>2</sub>CH<sub>2</sub>â</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">2-(3â²-thienyl)ethyl</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">189</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub>NHCH<sub>2</sub>COâ</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">168</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Measured in the DYRK1A FRET assay.</p></div></div></div><div class="NLM_p">Thus, the next set of compounds kept one unsubstituted amine and explored the substitution of the second amino group of the diaminopyridine moiety (<b>29</b>â<b>32</b>). A simple methylation (<b>29</b>) resulted in a minor decrease of affinity that translated to a drop of ligand efficiency to 0.59. Representative examples for the introduction of a polar acceptor (<b>30</b>) or an electron-rich aromatic group (<b>31</b>) led to a 10- to 100-fold drop of affinity. Finally, the acylation of the amino group converting it to a different H-bond donor (<b>32</b>) was also detrimental despite the conservation of the hydrogen bond with the salt bridge, as well as the formation of water-mediated hydrogen bonds with Asn292 and Asp307 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F).</div><div class="NLM_p">At this stage of the program, small molecule <b>10</b> was our lead DYRK1A inhibitor. It was not only bound to DYRK1A potently and efficiently (IC<sub>50</sub> = 14 nM, LE = 0.63) but was also translated into the potent inhibition of DYRK1A autophosphorylation on Ser520 with an IC<sub>50</sub> of 500 nM (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). <i>cis</i>-Autophosphorylation of DYRK1A on Ser520 results in protein 14-3-3Î² stimulating the catalytic activity of the kinase and serves as a useful biomarker of intracellular DYRK1A inhibition.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, there were some issues with this compoundâs selectivity. For example, compound <b>10</b> was also a high affinity binder to the undesired target CDK9 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), not a surprise considering the structural similarity between the ATP-binding sites of Dyrk1a and CDK9 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). As suggested by modeling analysis, a minor structural modification, the introduction of a methyl group into the 2-position of the benzofuran (<b>33</b>) drastically decreased the affinity for CDK9 while <b>33</b> remained a 41 nM binder of DYRK1A and maintained some cellular activity. This selectivity can be rationalized by overlaying the Dyrk1a-bound X-ray structures of <b>10</b> and <b>33</b>, with an X-ray structure of human CDK9 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH">3BLH</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The crystal structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH">3BLH</a> was solved at sufficient crystallographic resolution (2.48 Ã) and its unbound ATP site presents the intrinsically preferred conformation of its backbone hinge, which is consistent with other X-ray structures of CDK9 (e.g., <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLQ">3BLQ</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR">3BLR</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>). <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B shows the hinge region of the aligned X-ray structures with Dyrk1a in gray and CDK9 in magenta. The two kinases differ in the orientation of the backbone carbonyl groups of hinge residues Leu241 (Dyrk1a) and Cys106 (CDK9), which confer the desired selectivity to our inhibitors. The methyl substituent of the benzofuran ring of <b>33</b> (green structure) clashes sterically with the carbonyl oxygen of CDK9 (short CÂ·Â·Â·O distance), while the carbonyl of Dyrk1a avoids that clash due to its orientation being somewhat perpendicular to the added methyl. To further test this interpretation, we also prepared <b>34</b>, the 2-chloro-analogue of <b>10</b>. Although the replacement of hydrogen with a bulkier chlorine substituent led to some decrease of affinity toward DYRK1A, this compound still maintained a 50-fold selectivity against CDK9.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural basis for the design of compounds selective for DYRK1A over CDK9. Black dotted lines denote hydrogen bonds. (A) Alignment the ATP-binding sites of Dyrk1a bound to <b>10</b> (green) and unliganded CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH">3BLH</a>). Residues within 5 Ã of <b>10</b> are shown for both proteins; differing residue pairs (Dyrk1a residues labeled) are in red and same residue types are in gray. (B) Overlay of CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH">3BLH</a>) onto Dyrk1a bound to <b>10</b> (gold sticks) or <b>33</b> (green ball and sticks, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJS">7AJS</a>). Only the hinge backbone of Dyrk1a (grey) and CDK9 (magenta) is shown. The red oval highlights the clash between the methyl group of <b>33</b> and the hinge backbone carbonyl Cys106 in CDK9. (C) Overlay of Dyrk1a bound to <b>33</b> (green sticks) and <b>38</b> (brown ball and sticks, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJV">7AJV</a>). The butyl substituent at position 2 crosses the path of the protein chain (gray ribbon) into the solvent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. DYRK1A, CDK9 Inhibition, and Cellular Inhibition of DYRK1A Autophosphorylation of Compounds <b>10</b>,<b>33â38</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0011.gif" alt="" id="GRAPHIC-d7e1460-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CDK9 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">pSer520 IC<sub>50</sub> U2OS (nM)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="left">>10,000</td><td class="colsep0 rowsep0" align="left">1800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="left">5430</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">1257</td><td class="colsep0 rowsep0" align="left">250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Bu</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="left">1244</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Bu</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">>10,000</td><td class="colsep0 rowsep0" align="left">153</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">Bu</td><td class="colsep0 rowsep0" align="left">Bu</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">128</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Measured in the DYRK1A FRET assay.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Measured in the CDK9 FRET assay.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Measured in the inhibition of the DYRK1A pSer520 autophosphorylation assay in U2OS cells.</p></div></div></div><div class="NLM_p">In anticipation of the future challenges, we decided to move away from the benzofuran core and focus on the imidazo[4,5-<i>b</i>]pyridine ring system, which seemed superior with respect to synthetic tractability, metabolic stability, and freedom to operate. The methylated analogue <b>35</b> showed high affinity toward DYRK1A while being over 100-fold less potent on CDK9. This compound was also quite potent in the cellular autophosphorylation inhibition assay registering at 250 nM. Further synthetic modifications, such as the replacement of the methyl group in the 1-position by a butyl group (<b>36</b>) was well tolerated. This latter compound also showed a considerable improvement in the cellular assay. Thus, to assess if a similar increase of the apolar character at the 2-position of the five-membered ring can be accommodated by the Dyrk1a hinge, we prepared and tested the 2-ethyl (<b>37</b>) and 2-butyl (<b>38</b>) analogues. These compounds maintained high affinity for DYRK1A, high selectivity versus CDK9, and a potent inhibition of DYRK1A autophosphorylation in the cellular setting, consolidating our choice of the imidazopyridine core for future optimization. We obtained the X-ray structure of <b>38</b> in its Dyrk1a bound complex (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Comparing it with the structure of the <b>33</b>-Dyrk1a complex shows that the cores are closely overlaid, and the flexible butyl chain can avoid clashing into the Dyrk1a hinge region. Such a substituent is largely solvent exposed, which might be used to modulate physicochemical properties but offers fewer opportunities for further potency gains than elaboration at position 1 of the five-membered ring.</div><div class="NLM_p">Having a series of potent and selective DYRK1A inhibitors in hand, subsequent optimization focused on the improvement of the cellular activity of the compounds. Compound <b>36</b> suggested that growing the substituent in the 1-position while maintaining a methyl group in position-2 could result in more potent compounds in cells (100 vs 250 nM for <b>35</b>). The addition of a small branched alkyl group, such as <i>tert</i>-butyl (<b>39</b>), cyclopropyl (<b>40</b>), or cyclopentyl (<b>41</b>), maintained the on-target affinity (7â11 nM) and showed cellular activities in the 80â228 nM range (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The selectivity versus CDK9 has dropped for <b>41</b> compared to the other compounds. The introduction of a polar end group on a flexible chain (<b>42</b>) was also well-tolerated affinity-wise but the cellular activity decreased to 280 nM. The lipophilic cyclohexylethyl end group (<b>43</b>) restored activity but again with a drop in CDK9 selectivity. The introduction of the less flexible 4-fluorobenzyl substituent (<b>44</b>) led to a marked deterioration of the on-target affinity along with a sharp decrease of cellular activity. When we increased the flexibility by removing the aromatic end group by 2 (<b>45</b>) or 3 atoms (<b>46</b>), we generated highly potent DYRK1A inhibitors with affinities at 3.0 and 1.0 nM, respectively. The cellular activity of <b>45</b> was in the usual range at 226 nM, while <b>46</b> showed the highest activity registered so far at 35 nM. We have also synthesized some fluoroalkylated analogues of <b>35</b>. The difluoroethyl compound (<b>47</b>) showed very high affinity and cellular activity (3.0 and 34 nM, respectively) that was even further improved by the trifluoroethyl substitution. This compound (<b>48</b>) registered at 2.0 and 28 nM in the affinity and cellular assays, respectively. Finally, the addition of two more methylene groups into the linker (<b>49</b>) led to a slight drop in affinity and activity compared to <b>48</b> (6.0 vs 2.0 nM affinity, and 47 vs 28 nM activity). The cellular target hitting of <b>40</b> and <b>48</b> was also confirmed in a nanoBRET assay (for details see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. DYRK1A, DYRK2, and CDK9 Inhibition and Cellular Inhibition of DYRK1A Autophosphorylation of Compounds <b>39â50</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0012.gif" alt="" id="GRAPHIC-d7e1722-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">DYRK2 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">CDK9 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">pSer520 IC<sub>50</sub> U2OS (nM)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left"><i>t</i>-Bu</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">1837</td><td class="colsep0 rowsep0" align="char" char=".">228</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">cyclopropyl</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">2149</td><td class="colsep0 rowsep0" align="char" char=".">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">cyclopentyl</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">314</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">MeO(CH<sub>2</sub>)<sub>3</sub>â</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">3027</td><td class="colsep0 rowsep0" align="char" char=".">280</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">cyclohexylethyl</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">470</td><td class="colsep0 rowsep0" align="char" char=".">110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">4-fluorobenzyl</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">134</td><td class="colsep0 rowsep0" align="char" char=".">4575</td><td class="colsep0 rowsep0" align="char" char=".">3000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">2-(2â²-thienyl)ethyl</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">1952</td><td class="colsep0 rowsep0" align="char" char=".">226</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">2-PhO-ethyl</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">1019</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">CF<sub>2</sub>HCH<sub>2</sub>â</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">5692</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub>CH<sub>2</sub>â</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">5700</td><td class="colsep0 rowsep0" align="char" char=".">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>â</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1407</td><td class="colsep0 rowsep0" align="char" char=".">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">8835</td><td class="colsep0 rowsep0" align="char" char=".">1650</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Measured in the DYRK1A FRET assay.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Measured in the DYRK2 FRET assay.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Measured in the CDK9 FRET assay.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Measured in the inhibition of the DYRK1A pSer520 autophosphorylation assay in U2OS cells.</p></div></div></div><div class="NLM_p">We systematically determined the affinity of our DYRK1A inhibitors <b>39</b>â<b>49</b> toward DYRK2. It was not clear if the downstream effects of DYRK2 inhibition are antagonistic or synergistic with the biological consequences of DYRK1A inhibition, so generating compounds of different selectivities could be useful to probe the biology of these targets. Before addressing DYRK2 selectivity, the compounds showed high affinity for DYRK2 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), consistent with the DYRK2 sequence and X-ray structures being very similar to those of Dyrk1a in the ATP site, as demonstrated by the X-ray structures of Dyrk1a and the kinase domain of DYRK2 (hereafter Dyrk2) complexed with a benzofuran derivative <b>50</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Within the ATP site, Val222, Met240 (hinge), and Val306 in Dyrk1a are changed to Ile285, Leu303, and Ile367 in Dyrk2 (isoform 1 residue numbering), respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Despite two valines in the Dyrk1a ATP site being changed to bulkier isoleucines in Dyrk2, compound <b>50</b> and the isosteric imidazo[4,5-<i>b</i>]pyridine ring systems, are accommodated unhindered in Dyrk2. The corresponding two additional methyl groups in Dyrk2 do not occlude the binding volume of the imidazo-pyridine or benzofuran cores, instead maybe increasing favorable van der Waals contacts between the compound core and Dyrk2. Thus, gaining selectivity over DYRK2 with the present chemotype was challenging. However, compounds with an aromatic end group (<b>44</b>â<b>46</b>) linked to the imidazole position 1 seemed to have a mild preference for DYRK1A over DYRK2, in particular <b>46</b> (9.0 vs 1.0 nM). An overlay of X-ray structures of Dyrk2 and <b>46</b> complexed to Dyrk1a (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJW">7AJW</a>) gave some insights into this emerging selectivity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). The 2-PhO-ethyl side chain of <b>46</b> sits alongside the imidazo-pyridine core, which largely removes this apolar substituent from water. This orientation of the side chain is also stabilized by van der Waals contacts with the compound core and the protein, in particular regarding the end phenyl. One edge of this phenyl is tucked under the glycine loop (residues 165â173 in Dyrk1a), while the opposite edge donates a C-H hydrogen bond to Asn292 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B) and, importantly, contacts the side chain of Val306 (Ile367 in Dyrk2). This shape complementarity between the phenyl of <b>46</b> and Dyrk1a would be disrupted when facing the additional methyl of Ile367 in Dyrk2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), likely contributing to the poorer affinity for DYRK2.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Use of X-ray structures for the design of Dyrk1a inhibitors selective over Dyrk2. Black and green dotted lines depict hydrogen bonds and van der Waals contacts, respectively. (A) Overlay of <b>50</b> bound to Dyrk1a (green, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKL">7AKL</a>) and Dyrk2 (magenta, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKF">7AKF</a>). (B) Overlay of <b>46</b> (green, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJW">7AJW</a>) and <b>53</b> (orange, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AK2">7AK2</a>) bound to Dyrk1a. (C) Overlay of <b>56</b> (green, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKB">7AKB</a>) and <b>58</b> (orange, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKE">7AKE</a>) bound to Dyrk1a. (D) Overlay of <b>58</b> bound to Dyrk1a (green) and Dyrk2 (magenta, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKH">7AKH</a>). The glycine loop is shown in blue ribbons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on this insight, it was hypothesized that rigidifying the linker may help confine the phenyl to its Dyrk1a-bound orientation, reinforcing a clash with Ile367 in Dyrk2, leading to increased selectivity. Thus, a methyl substituent was introduced in the middle of the linker chain, affording the enantiomers <i>R</i>-methyl (<b>51</b>) and <i>S</i>-methyl (<b>52</b>). In DYRK1A, both compounds showed the same affinity of 8.0 nM while their DYRK2 affinity differed by a factor of 2 (46 vs 22 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The absolute configuration of the stereocenter in <b>51</b> (and <b>54</b> below) was elucidated by the X-ray structure of its Dyrk1a complex. Overlaying the bound structures of <b>46</b> and <b>51</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJY">7AJY</a>) showed that the aromatic rings occupy the same space in Dyrk1a despite an altered conformation of the aliphatic linker. Unfortunately, both <b>51</b> and <b>52</b> lost in terms of affinity and cellular activity when compared to <b>46</b>. We also prepared the pyridine analogues without (<b>53</b>) or with (<b>54</b>,<b>55</b>) the methyl substituent in the linker, and X-ray structures of <b>53</b> and <b>54</b> were obtained (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKA">7AKA</a>). An overlay of the X-ray structures of <b>46</b> and <b>53</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B. Compared to <b>46</b>, the potency of <b>53</b> with respect to the different targets dropped, possibly due to the desolvation of pyridine. Indeed, the pyridine of Dyrk1a-bound <b>53</b> and <b>54</b> adopts essentially the same position and interactions as those of the phenyl of <b>46</b> and <b>51</b>, contacting the (â¼4 Ã) Val306 targeted for selectivity. This is consistent with the affinities of <b>53</b> and <b>54</b> for DYRK1A being equivalent to that of <b>51</b>, â¼7 nM. The selectivity against DYRK2 was between 6- and 17-fold for <b>53</b>â<b>55</b>, consistent with the approach targeting the Val306/Ile367 pair. Interestingly, the affinity toward DYRK2 degraded more with the methylated linkers of <b>54</b> (116 nM) and <b>55</b> (117 nM) than with the plain linker of <b>53</b> (34 nM), maybe the reduced linker flexibility lessens the ability to adapt to DYRK2. However, the present linkers remain flexible with several torsions able to adjust the conformation when binding to DYRK2. Increased selectivity would require substituents which cannot reorientate to alleviate a clash with Ile367. Overall, there was evidence that a substituent reaching the Val306/Ile367 pair can impart some DYRK1A/DYRK2 selectivity.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. DYRK1A, DYRK2, and CDK9 Inhibition and Cellular Inhibition of DYRK1A Autophosphorylation by Compounds <b>51â58</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0013.gif" alt="" id="GRAPHIC-d7e2224-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">DYRK2 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">CDK9 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">pSer520 IC<sub>50</sub> U2OS (nM)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left"><i>R</i>-Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left"><i>S</i>-Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="left">881</td><td class="colsep0 rowsep0" align="left">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"><i>S</i>-Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">116</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">131</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"><i>R</i>-Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="left">>3000</td><td class="colsep0 rowsep0" align="left">>300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="left">289</td><td class="colsep0 rowsep0" align="left">32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="left">222</td><td class="colsep0 rowsep0" align="left">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"><i>R</i>-Me</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">195</td><td class="colsep0 rowsep0" align="left">467</td><td class="colsep0 rowsep0" align="left">44</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Measured in the DYRK1A FRET assay.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Measured in the DYRK2 FRET assay.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Measured in the CDK9 FRET assay.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Measured in the inhibition of the DYRK1A pSer520 autophosphorylation assay in U2OS cells.</p></div></div></div><div class="NLM_p">Building on the above approach, a natural progression was to increase the size of the aryl moiety reaching the Val306/Ile367 pair, to increase the steric repulsion with Ile367. The X-ray structures of <b>53</b> and <b>54</b> suggested that a small apolar substituent at position 6 of the pyridine may strengthen the contacts with the glycine loop, further anchoring the pyridine in a position that clashes with Ile367 in Dyrk2. Thus, we introduced a halogen into the 6-position of the pyridine ring of <b>53</b>. The addition of a bromine (<b>56</b>) or chlorine (<b>57</b>) was well tolerated by DYRK1A giving 2.0 nM-ar or 3.0 nM-ar inhibitors, respectively. Reassuringly the cellular activities of <b>56</b> and <b>57</b> were among the best observed at 32 and 26 nM, respectively. The X-ray structure of <b>56</b> confirmed that its bromine is nested under the glycine loop, with favorable apolar contacts to Val173 and Phe170 of Dyrk1a (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). The bigger halogen substituent (<b>56</b>) decreased the affinity toward DYRK2 (52 vs 34 nM) but not the chlorine (33 vs 34 nM). Still, both compounds increased the DYRK1A/DYRK2 selectivity with respect to <b>53</b> (26-fold and 11-fold vs 5.7-fold). Finally, we tested if the methyl substitution of the linker would further add to the selectivity gained with the halogenated pyridine. Compound <b>58</b>, which combines these two features showed a 39-fold selectivity, the highest observed in this series, and both its affinity for DYRK1A at 5.0 nM and its cellular activity at 44 nM were respectable. We also obtained the X-ray structure of <b>58</b> with both Dyrk1a and Dyrk2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). With both proteins, the pyridine is anchored to the glycine loop via the bromine, but the pyridine is clearly shifted in Dyrk2 to avoid a clash with Ile367; this shift in turn disrupts a number of contacts, including the C-H hydrogen bond to the side chain of Asn353 in Dyrk2. Overall, we obtained a collection of compounds with high affinity for DYRK1A, good cellular potency, and covering a range of selectivity toward Dyrk2.</div><div class="NLM_p">The selectivity profile of <b>40</b> for the inhibition of other protein kinases was characterized in a DiscoverX KINOMEscan assay which measured the percentage activity remaining for each of 442 kinases (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Table S1</a>). From the kinases that showed a dose-dependent inhibition between 10 nM and 1 Î¼M of <b>40,</b> only two kinases were inhibited to less than 10% activity at the lower dose, DYRK1A (9.2%) and DYRK2 (1.6%) and only 8 other kinases to less than 75% activity, most notably DYRK1B (20%) CLK1 (48%), CLK2 (40%), CLK4 (52%), CSNK1G1 (69%), HIPK1 (72%), and RPS6KA4 (61%). We also determined the affinity of <b>40</b> and <b>48</b> toward closely related kinases in a binding assay. The measured <i>t</i> values for <b>40</b> were 0.76 nM for DYRK1B, 4.7 nM for CLK1, 5.7 nM for CLK2, and 3.2 nM for CLK4. <b>48</b> bound to the same targets with affinities of 0.12 nM (DYRK1B), 3.2 nM (CLK1), 2.2 nM (CLK2), and 5.7 nM (CLK4), respectively. Leu244 in CLK1 adopts a similar conformation to the equivalent to Leu241 in DYRK1A (see the Supporting Information in ref <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>), providing some explanation for the observed selectivity, which is a feature seen for other DYRK1A inhibitors.<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> It is interesting to note that efficient inhibitors of CLK1 carrying a similar combination of a bicyclic hinge binder and monocyclic salt-bridge binder motif were reported recently.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> At 1 Î¼M compound, 37 kinases were inhibited to less than 50% activity. It is also worth mentioning that none of the studied 37 receptor targets was affected more than 40% at 10 Î¼M concentration of <b>40</b>. In the patch-clamp model, <b>40</b> induced a 52% decrease of hERG activity at 10 Î¼M.</div><div class="NLM_p">In order to ensure the rapid generation of our DYRK1A inhibitors, we needed to establish a collection of robust and scalable synthetic routes that would ideally allow for the late-stage introduction of the differentiating elements. Our early DYRK1A inhibitors (<b>3</b>â<b>6</b>) were prepared from commercially available building blocks through the formation of the biaryl link in a Suzuki coupling. As we wanted to explore the bicyclic hinge binder element and the substitution pattern on the diaminopyridine moiety (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, <b>7</b>â<b>35</b>, <b>50</b>), the Suzuki coupling remained the key construction step but some of the coupling reagents needed to be prepared, and in certain cases the Suzuki coupling was also followed by the modification of the pyridine ringâs substituents (Z = CH).</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Strategies Applied in the Preparation of Our DYRK1A Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After the identification of the imidazo[4,5-<i>b</i>]pyridine hinge binder motif, the variation of the R<sup>1</sup> and R<sup>2</sup> substituents was achieved in an amidine formationâcyclization sequence (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The key intermediate tetra-substituted bipyridyl compound was prepared via the formerly established Suzuki approach. The R<sup>2</sup> substituent was introduced in a conventional acylation, while the activation of the amide function enabled us to use primary amines to install the R<sup>1</sup> group. The palladium-catalyzed cyclization of the amidine and protecting group removal completed the sequence to give <b>36</b>â<b>49</b>, <b>51</b>, and <b>52</b>. This synthetic route was used also to prepare the common intermediate leading to <b>54</b>â<b>58</b>. Aromatic nucleophilic substitution with 2-halopyridines, followed by protecting group removal furnished the desired selective DYRK1A inhibitors. The developed synthetic routes were sufficiently robust to furnish building blocks and final products on the multigram scale needed for <i>in vivo</i> studies and detailed characterization.</div><div class="NLM_p">To evaluate the inhibition of DYRK1A <i>in vivo</i>, we selected compound <b>40</b>, which had favorable <i>in vitro</i> ADME properties including the complete predicted oral absorption, moderate to good microsomal stability, and a high unbound (free) fraction in plasma (for details see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Supporting Information</a>). The <i>in vivo</i> PK characterization of <b>40</b> showed a good <i>in vitro: in vivo</i> correlation with high plasma clearance (226 mL/min/kg) and an oral bioavailability of 39% at 3 mg/kg that showed an over proportional increase with the dose (for details see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Supporting Information</a>). To determine whether the <i>in vitro</i> functional effect could be recapitulated <i>in vivo</i>, mice bearing RS4;11 tumors were treated with different doses of <b>40</b>. Following the oral administration of 3.125, 6.25, 12.5, or 25 mg/kg of <b>40</b>, the tumors were harvested after 2 or 6 h and the change in the level of DYRK1A phosphorylated on Ser520 was determined by the western blot. We observed a dose-dependent inhibition of DYRK1A autophosphorylation at both timepoints with the effect appearing more pronounced after 2 h (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). It should also be emphasized that at the highest dose of 25 mg/kg, the effect was maintained after 6 h. In a similar experiment, we evaluated <b>46</b> and <b>48</b> at the 6.25 mg/kg dose. Both compounds led to a sustained decrease of phosphorylated DYRK1A levels with <b>46</b> being slightly less active than <b>40</b> giving 59 and 25% inhibition of DYRK1A phosphorylation at the 2 and 6 h time points compared to 77 and 25% observed for <b>40</b>. Compound <b>48</b>, on the other hand, demonstrated a very strong and sustained inhibition of pDYRK1A (93% after 2 h and 95% after 6 h, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) superior to that of <b>40</b> and <b>46</b>, which might reflect a combination of its increased cellular activity and stability.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>In Vivo</i> Inhibition of DYRK1A Autophosphorylation by Compounds <b>40</b>, <b>46</b>, and <b>48</b> (<i>n</i> = 3)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">pDYRK1A (S520) inhibition (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">xenograft</th><th class="colsep0 rowsep0" align="center" char=".">dose (mpk, p.o.)</th><th class="colsep0 rowsep0" align="center" char=".">2Â h</th><th class="colsep0 rowsep0" align="center" char=".">6Â h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="char" char=".">3.125</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="char" char=".">84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="char" char=".">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="char" char=".">59</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">RS4;11</td><td class="colsep0 rowsep0" align="char" char=".">6.25</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="char" char=".">4.687</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="char" char=".">9.375</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="char" char=".">18.75</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="char" char=".">37.5</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">80</td><td class="colsep0 rowsep0" align="char" char=".">92</td></tr></tbody></table></div></div><div class="NLM_p">We evaluated the antiproliferative activity of our DYRK1A inhibitors <b>40</b> and <b>48</b> against a range of human cancer cell lines. These cell lines exhibited little sensitivity to DYRK1A inhibition in 2D culture. However, when growing in 3D culture in soft agar as spheroids, their sensitivity to DYRK1A inhibition increased considerably (for the detailed graphs see the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Supporting Information</a>). In three cell lines (ovarian cancer cell line A2780, neuroblastoma cell line SK-N-MC, and cervical cancer cell line C33-A) in 2D culture, all compounds demonstrated IC<sub>50</sub>s around 1 Î¼M, with no differentiation between the two compounds (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). In 3D culture, a clear difference in cellular activity between <b>40</b> and <b>48</b> was observed with the latter compound being more potent against all cell lines, and the observed cellular IC<sub>50</sub>s correlated nicely with the cellular pDYRK1A inhibition activities observed in the U2OS cell line (90 nM for <b>40</b> and 28 nM for <b>48</b>). Although one can hypothesize that the efficient inhibition of DYRK1B, CLK1, CLK2, and CLK4 might play an active role in these biological processes, the explanation of the different sensitivity of a given cell line in the 2D and 3D culture requires further experimentation.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Effect of DYRK1A Inhibitors <b>40</b> and <b>48</b> on the Viability of Selected Cancer Cell Lines in 2D and 3D Cultures</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">2D viability (MTT assay) IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">3D viability (soft agar assay) IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">pSer520 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">A2780</th><th class="colsep0 rowsep0" align="center" char=".">SK-N-MC</th><th class="colsep0 rowsep0" align="center" char=".">C-33A</th><th class="colsep0 rowsep0" align="center" char=".">A2780</th><th class="colsep0 rowsep0" align="center" char=".">SK-N-MC</th><th class="colsep0 rowsep0" align="center" char=".">C-33A</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">1539</td><td class="colsep0 rowsep0" align="char" char=".">958</td><td class="colsep0 rowsep0" align="char" char=".">1022</td><td class="colsep0 rowsep0" align="char" char=".">126</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">157</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">1099</td><td class="colsep0 rowsep0" align="char" char=".">1281</td><td class="colsep0 rowsep0" align="char" char=".">1154</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">21</td></tr></tbody></table></div></div><div class="NLM_p">Encouraged by these results, we grafted A2780 cells subcutaneously into mice to evaluate levels of DYRK1A phosphorylation on Ser520 by the western blot at 2 or 6 h post-treatment. Analysis of the data revealed dose- and time-dependent inhibitions of pDYRK1A similar to that observed in the RS4;11 cell line <i>in vivo</i>. At the lowest dose of 4.7 mg/kg, we observed a transient inhibition of pDYRK1A (S520) at 2 h but with complete recovery by 6 h (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Increasing the dose to 37.5 mg/kg led to the almost complete inhibition of DYRK1A autophosphorylation at both 2 (82% inhibition) and 6 h (95% inhibition) that was retained but not increased upon at 75 mg/kg. We measured the plasma and tumor concentrations of <b>40</b> at the different doses and time points and established that tumors were well exposed. At doses of 18.75 mg/kg and above, the tumor concentration of <b>40</b> was greater than the measured cellular pDYRK1A (S520) IC<sub>50</sub> for at least 6 h (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Supporting Information</a>), demonstrating a clear correlation between tumor exposure and PD response.</div><div class="NLM_p">Finally, we determined the antitumor activity of <b>40</b> in a dose-dependent efficacy study in A2780-xenografted mice. Animals were treated with different doses of <b>40</b> daily for 2 weeks. At the lower doses of 4.75â9.5 mg/kg, we observed no effect on tumor growth (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). For the dose of 18.75 mg/kg, at which the PD response was more robust, we observed some inhibition of tumor growth (TGI 55%, <i>P</i> < 0.01). Increasing the dose to 37.5 and 75 mg/kg increased the antitumor activity of <b>40</b>, resulting in an almost complete tumor stasis while on treatment (TGI 63 and 92%, <i>P</i> < 0.001). Increased toxicity was observed at the higher doses with a mean body weight changes of â9.7 and â16.3% at 37.5 and 75 mg/kg doses, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">Figure S1</a>). The 75 mg/kg dose was also the maximal tolerated dose in female Balb/C nude mice. The body weight changes were transient and recovered rapidly on the cessation of treatment. The antitumor effects of <b>40</b> on A270 tumors appeared cytostatic as upon stopping dosing, the tumors rapidly regrew with similar kinetics to the untreated controls. These results suggest that DYRK1A inhibitors, at least in this ovarian model, exert their antitumor activity through inhibiting tumor growth and might not be efficient as single agents to induce tumor regressions. Further work is needed to understand if this effect on tumor growth might play an effective role in combination therapy.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Tumor volume changes in mice xenografted with A2780 cells on treatment with <b>40</b>. BALB/C nude mice bearing established A2780 xenografted tumors were dosed BID with the indicated amounts of <b>40</b> for 14 days (black triangles). Tumor volume was determined as described in the Experimental section.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Summary of <i>In Vivo</i> Responses in A2780-Xenografted Mice Treated with <b>40</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">doseÂ 40 (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">T/C (%) @ D14</th><th class="colsep0 rowsep0" align="center" char=".">TGI (%) @ D14</th><th class="colsep0 rowsep0" align="center"><i>P</i></th><th class="colsep0 rowsep0" align="center" char=".">MBWC (%) @ D14</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">+4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.75</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="left">ns</td><td class="colsep0 rowsep0" align="char" char=".">â1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9.5</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="left">ns</td><td class="colsep0 rowsep0" align="char" char=".">â8.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">18.75</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="left"><0.01</td><td class="colsep0 rowsep0" align="char" char=".">â10.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">37.5</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="char" char=".">â9.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">75.0</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="char" char=".">â16.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">T/C, tumor/control; TGI, tumor growth inhibition; MBWC, mean-body-weight change.</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54213" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54213" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from a fragment hit identified by NMR spectroscopy, we conducted a structure-guided drug discovery program that led to the identification of potent and selective DYRK1A inhibitors. By exploiting the unique orientation of the backbone CâO group of Leu241 in the hinge region in DYRK1A, we identified a reliable way to confer selectivity on our inhibitors against the majority of other kinases by placing a small substituent in the proximity of this moiety. We were also able to fine-tune the selectivity of our DYRK1A inhibitors against the closely related DYRK2 kinase by targeting the sequence differences in the two kinase ATP pockets. Our developed compounds also have the desired properties to probe the <i>in vitro</i> and <i>in vivo</i> biology of DYRK1A inhibition. They are potent inhibitors of DYRK1A in the cellular setting, which was also recapitulated <i>in vivo</i>. Interestingly, we observed a significant difference between the sensitivity of cancer cell lines to our inhibitors in 2D and 3D models. The good <i>in vivo</i> PK properties of our inhibitors enabled us to translate their <i>in vitro</i> cell killing into tumor growth inhibition in the xenografted mice model potentially opening the way to new therapeutic strategies in oncology and Downâs syndrome.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> TR-FRET Assay</h3><div class="NLM_p last">A TR-FRET assay was used to measure the activity of the protein kinases DYRK1A, DYRK2, and CDK9. The assay was performed on a TECAN Evo robotic platform. Compound at 5% DMSO was added to reaction buffer (50 mM Hepes pH 7.4, 1 mM EGTA, 10 mM MgCl<sub>2</sub>, 2 mM DTT, and 0.01% Tween20) containing 20 ng/Î¼L DYRK1A kinase (Carna Biosciences #04-130), 100 Î¼M Ulight-MBP substrate (PerkinElmer #TRF109L) and 10 Î¼M ATP co-substrate (Sigma-Aldrich #A2383) and incubated for 40 min at room temperature. The kinase reaction was stopped by adding 10 mM EDTA (Sigma-Aldrich #E7889) and 1 nM Anti-phospho-MBP antibody (PerkinElmer #TRF0201L) and incubated for 1 h minimum at room temperature. Plates were read on a multimode reader (PerkinElmer Envision 2400) with an excitation wavelength of 337 nm and emission wavelengths of 620 nm for the donor and 665 nm for the acceptor. A similar format was used for other TR-FRET kinase inhibition assays.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> DYRK1A (pS520) Cell Assay</h3><div class="NLM_p last">U2OS cells (ATCC) were transiently transfected with a plasmid expressing full length wild-type DYRK1A (pcDNA3.1). After 5 h, compounds were added and cells were incubated for a further 5 h. Cells were lysed and equal amounts of protein were separated by SDS-PAGE and transferred to the PVDF membrane. Membranes were probed for pS520 DYRK1A (custom rabbit-polyclonal antibody immunized with the synthetic peptide SNSGRARpSDPTHQHR, Eurogentec; 1:500 in 5% BSA-TBST), detected with anti-rabbit IgG-HRP (7074, CST; 1:3000), and then quantified on an ECL camera (BioRad). Membranes were subsequently stripped and reprobed with a total anti-DYRK1A antibody (H0000-1859, Abnova; 1:1000 in 5% BSA-TBST) and quantified as above.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 2D and 3D Cell Viability Assays</h3><div class="NLM_p last">For 2D viability assays, A2780, C-33A, and SK-N-MC cells (ATCC) were seeded in 96-well plates and supplemented 48 h later with serial dilutions of compounds. After 120 h incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma) was added to each well. After 4 h, the formazan metabolite was solubilized in DMSO and cell viability was estimated by the measurement of optical density at 540 nm. For 3D vitality assays, 2000 (A2780), 6000 (C-33A), or 25,000 (SK-<i>N</i>-MC) cells were seeded in Agarose type VII (Sigma A-4018) and cultured 7, 11, or 14 days, respectively. Vital colonies were then stained overnight with MTT. Colonies were counted using a light microscope and image analysis software (AxioVision, Zeiss). IC<sub>50</sub> values for the inhibition of cell viability, migration, or colony formation were calculated from doseâresponse curves (XLfit).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Animal Studies</h3><div class="NLM_p">Female BALB/C nu/nu mice were purchased from Charles River Laboratories. Xenograft studies were undertaken by Onco<i>design</i> S.A., Dijon, France in accordance with âPrincipe dâÃ©thique de lâexpÃ©rimentation animale, Directive no 86/609â, France.</div><div class="NLM_p">Tumors were induced subcutaneously by injecting 1 Ã 10<sup>7</sup> of RS4;11 or A2780 cells (ATCC) in 200 Î¼L of RPMI 1640 into the right flank of the female <i>nu/nu</i> mice and allowed to reach a target volume of 150 mm<sup>3</sup>. On day 0 of the study, tumors were randomized into treatment groups before compound administration (<i>n</i> = 8â10 for efficacy studies and <i>n</i> = 3 for pharmacodynamic studies).</div><div class="NLM_p">Compound <b>40</b> was formulated in PEG300/Ethanol/water (4/1/5, v/v) and administered by oral gavage twice daily for 14 days. Tumor size was measured twice weekly with electronic calipers and tumor volume calculated according to the formula ((width Ã width) Ã length)/2. Body weight was measured daily for the first 14 days then twice weekly thereafter. T/C (%) = (Median tumor volume of treated group at D14/Median tumor volume of the control group at D14) Ã 100. TGI (%) = 1 â ((T<sub>14</sub>/T<sub>0</sub>)/(C<sub>D14</sub>/C<sub>0</sub>))/1 â (C<sub>0</sub>/C<sub>14</sub>) Ã 100, where T<sub>14</sub> and T<sub>0</sub> equals the median tumor volume of the treated group at day 14 and day 1, respectively, and C<sub>14</sub> and C<sub>0</sub> equals the median tumor volume of the control group at day 14 and day 1, respectively.</div><div class="NLM_p last">For the assessment of the Ser520 phosphorylation of DYRK1A, tumors were excised at 2 and 6 h post-treatment and lysed in RIPA buffer containing protease and phosphatase inhibitor cocktails (Roche). Western blotting for the phosphorylation of anti P-(S520)DYRK1A (Rabbit Polyclonal, Eurogentec) was performed using standard techniques. Blots were scanned using a Bio-Rad GS-800 calibrated densitometer, quantitative analysis of western blots was performed using TotalLab software (Amersham), and % inhibition was calculated with respect to the control values.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Synthetic Remarks</h3><div class="NLM_p">All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from commercial sources and used without further drying.</div><div class="NLM_p">The reactions were monitored using LCMS and GCMS instruments. Analytical LCâMS: Agilent HP1200 LC with Agilent 6140 quadrupole MS, operating in positive or negative ion electrospray ionization mode. Molecular weight scan range was 100â1350 <i>m</i>/<i>z</i>. Parallel UV detection was done at 210 and 254 nm. Samples were supplied as a 1 mM solution in MeCN or in THF/water (1:1) with 5 Î¼L loop injection. LCMS analyses were performed on two instruments, one of which was operated with basic, and the other with acidic eluents.</div><div class="NLM_p">Basic LCMS: Gemini-NX, 3 Î¼m, C18, 50 mm Ã 3.00 mm i.d. column at 23 Â°C, at a flow rate of 1 mL min<sup>â1</sup> using 5 mM aq. NH<sub>4</sub>HCO<sub>3</sub> solution and MeCN as eluents.</div><div class="NLM_p">Acidic LCMS: ZORBAX Eclipse XDB-C18, 1.8 Î¼m, 50 mm Ã 4.6 mm i.d. column at 40 Â°C, at a flow rate of 1 mL min<sup>â1</sup> using water and MeCN as eluents, both containing 0.02 V/V % formic acid.</div><div class="NLM_p">Combination gas chromatography and low-resolution mass spectrometry were performed on an Agilent 6850 gas chromatograph and Agilent 5975C mass spectrometer using 15 m Ã 0.25 mm column with 0.25 Î¼m HP-5MS coating and helium as the carrier gas. Ion source: EI<sup>+</sup>, 70 eV, 230 Â°C, quadrupole: 150 Â°C, interface: 300 Â°C.</div><div class="NLM_p">Flash chromatography was performed on a ISCO CombiFlash Rf 200i with pre-packed silica-gel cartridges (Redi<i>SepR</i><sub>f</sub> Gold High Performance).</div><div class="NLM_p">Preparative HPLC purifications were performed on a Gemini-NX 10 Î¼m C18, 250 mm Ã 50 mm i.d. columns running at a flow rate of 118 mL min<sup>â1</sup> with UV diode array detection (210â400 nm).</div><div class="NLM_p"><sup>1</sup>H NMR and proton-decoupled <sup>13</sup>C NMR measurements were performed on Bruker Avance III 500 MHz and Bruker Avance III 400 MHz spectrometers, using DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> as the solvent. <sup>1</sup>H and <sup>13</sup>C NMR data are in the form of delta values, given in parts per million (ppm), using the residual peak of the solvent as the internal standard (DMSO-<i>d</i><sub>6</sub>: 2.50 ppm (<sup>1</sup>H)/39.5 ppm (<sup>13</sup>C); CDCl<sub>3</sub>: 7.26 ppm (<sup>1</sup>H)/77.0 ppm (<sup>13</sup>C)). Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), q (quartet), sp (septet), m (multiplet), br s (broad singlet), dd (doublet of doublets), td (triplet of doublets), and qd (quartet of doublets). In some cases, two sets of signals appear in the spectra due to hindered rotation.</div><div class="NLM_p">HRMS were determined on a Shimadzu IT-TOF, ion source temperature 200 Â°C, ESI +/â, ionization voltage: (Â±)4.5 kV. Mass resolution min. 10,000.</div><div class="NLM_p last">All obtained products had an LC purity above 96% that was corroborated by their <sup>1</sup>H and <sup>13</sup>C NMR spectra unless specifically mentioned otherwise.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Reagent Synthesis and General Procedures</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl <i>N</i>-[6-(<i>tert</i>-Butoxycarbonylamino)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]carbamate (<b>R1</b>)</h4><div class="NLM_p">To 109.7 g of (4-bromo-6-<i>tert</i>-butoxycarbonylamino-pyridin-2-yl)-carbamic acid <i>tert</i>-butyl ester<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (283 mmol), 107.7 g of bis(pinacolato)diboron (424 mmol), 0.29 g of Pd(OAc)<sub>2</sub> (1.27 mmol), 0.70 g of 1,1â²-bis(diphenylphosphino)ferrocene (1.27 mmol), and 83.2 g of KOAc (848 mmol) were added to 1100 mL of previously degassed 1,4-dioxane, and the mixture was stirred at 80 Â°C under an argon atmosphere until no further conversion was observed. Then, the reaction mixture was filtered; the solid was washed with dioxane. 5.5 g of charcoal was added to the filtrate, and it was stirred for 2 min at the reflux temperature. The mixture was filtered, washed with warm 1,4-dioxane, and the volatiles were evaporated under reduced pressure. The residue was crystallized from <i>tert</i>-butyl-methyl-ether to give 92 g (75%) of <b>R1</b> as a white crystalline solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>-<i>d</i><sub><i>6</i></sub>): Î´ ppm 8.16 (br s, 2H), 7.92 (s, 2H), 1.54 (s, 18H), 1.34 (s, 12H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>-<i>d</i><sub><i>6</i></sub>): Î´ ppm 153.1, 150.9, 111.9, 84.7, 80.0, 49.2, 28.4, 27.3, 25.1.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>tert-</i>Butyl <i>N</i>-[6-(<i>tert</i>-Butoxycarbonylamino)-4-[6-chloro-5-(acetylamino)-2-pyridyl]-2-pyridyl]carbamate (<b>R2</b>)</h4><div id="sec4_6_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> Step A: <i>N</i>-(6-Bromo-2-chloro-3-pyridyl)acetamide</h5><div class="NLM_p">To 31.4 g of 6-bromo-2-chloro-pyridin-3-amine (151.3 mmol) was dissolved in 200 mL of glacial acetic acid, then 15 mL of acetic anhydride (158.9 mmol) was added to this solution dropwise, and the reaction mixture was stirred at room temperature until no further conversion was observed. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc and the organic phase was washed with 10% aqueous K<sub>2</sub>CO<sub>3</sub> and brine. Following drying over Na<sub>2</sub>SO<sub>4</sub> removal of the solvents under reduced pressure gave 35.5 g (94%) of <i>N-</i>(6-bromo-2-chloro-3-pyridyl)acetamide.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.75 (s, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.66 (d, <i>J</i> = 8.5 Hz, 1H), 2.12 (s, 3H); HPLC-MS: (M â H)<sup>â</sup>: 247.0; 249.0.</div></div><div id="sec4_6_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Step B: <i>tert</i>-Butyl <i>N</i>-[6-(<i>tert</i>-Butoxycarbonylamino)-4-[6-chloro-5-(acetylamino)-2-pyridyl]-2-pyridyl]carbamate</h5><div class="NLM_p">To 13.1 g of <i>N-</i>(6-bromo-2-chloro-3-pyridyl)acetamide (52.5 mmol), 24.0 g of <b>R1</b> (55.1 mmol) and 33.4 g of K<sub>3</sub>PO<sub>4</sub> (157.3 mmol) were dissolved in 250 mL of 1,2-dimethoxyethane-water 4:1, then 0.304 g of tetrakis(triphenylphosphine)palladium(0) (0.26 mmol) was added, and the mixture was heated under nitrogen at 90 Â°C until no further conversion was observed. Then, the mixture was diluted with 250 mL of water and extracted with EtOAc (3 Ã 400 mL). The organic layer was washed with brine (1 Ã 800 mL), dried over MgSO<sub>4</sub>, the volatiles were removed under reduced pressure, and the residue was recrystallized from EtOAc to obtain 18.2 g (73%) of <i>tert</i>-butyl <i>N-</i>[6-(<i>tert</i>-butoxycarbonylamino)-4-[6-chloro-5-(acetylamino)-2-pyridyl]-2-pyridyl]carbamate.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.80 (s, 1H), 9.51 (s, 2H), 8.40 (d, 1H), 8.00 (s, 2H), 7.92 (d, <i>J</i> = 8.4 Hz, 1H), 2.18 (s, 3H), 1.49 (s, 18H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 169.7, 153.2, 152.1, 150.1, 147.8, 142.6, 134.7, 132.9, 120.9, 104.4, 80.2, 28.5, 24.1.</div></div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert-</i>Butyl <i>N</i>-[6-(<i>tert</i>-Butoxycarbonylamino)-4-[3-(2-hydroxyethyl)-2-methyl-imidazo[4,5-<i>b</i>]pyridin-5-yl]-2-pyridyl]carbamate (<b>R3</b>)</h4><div id="sec4_6_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Step A: <i>N</i>-(6-Bromo-2-fluoro-3-pyridyl)acetamide</h5><div class="NLM_p">To 17.0 g of 6-bromo-2-fluoro-pyridin-3-amine (89.0 mmol) was dissolved in 100 mL of acetic acid, then 8.82 mL of acetic anhydride (93.5 mmol) was added, and the reaction mixture was stirred at room temperature until no further conversion was detected. The reaction mixture was concentrated under reduced pressure, the remaining solid was dissolved in DCM. The DCM solution was extracted with 10% potassium carbonate solution then with brine. The organic layer was dried over MgSO<sub>4</sub> then the solvent was removed under reduced pressure to give 18.2 g (88%) of <i>N</i>-(6-bromo-2-fluoro-3-pyridyl)acetamide.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 10.04 (s, 1H), 8.35â8.52 (m, 1H), 7.58 (d, <i>J</i> = 8.25 Hz, 1H), 2.11 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 169.9, 152.5, 135.7, 129.4, 126.5, 121.9, 24.0; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>7</sub>H<sub>6</sub>N<sub>2</sub>OFBr [M + H]<sup>+</sup>: 232.9720; found, 232.9729.</div></div><div id="sec4_6_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Step B: 2-(5-Bromo-2-methyl-imidazo[4,5-<i>b</i>]pyridin-3-yl)ethanol</h5><div class="NLM_p">The mixture of 6.00 g of <i>N</i>-(6-bromo-2-fluoro-3-pyridyl)acetamide (25.7 mmol), 3.15 g of 2-aminoethanol (51.5 mmol), and 5 mL of <i>N</i>,<i>N</i>-diethylethanamine were stirred at 50 Â°C until no further conversion was observed then the solvent was removed under reduced pressure, then 150 mL of acetic acid was added, and the mixture was heated under reflux conditions until full conversion was observed (approximately 4 days). The reaction mixture was cooled down to room temperature then 250 mL of water was added followed by the extraction of the water phase with diethyl ether (3 Ã 250 mL) and EtOAc (2 Ã 250 mL). The combined organic layers were extracted with brine, then they were dried over MgSO<sub>4</sub>. Solvents were removed in vacuum to give 5.3 g of 2-(5-bromo-2-methyl-imidazo[4,5-<i>b</i>]pyridin-3-yl)ethanol as a crude product, which was used in the next step without further purification.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.87 (d, <i>J</i> = 8.2 Hz, 1H), 7.37 (d, <i>J</i> = 8.2 Hz, 1H), 4.95 (t, <i>J</i> = 5.5 Hz, 1H), 4.23 (t, <i>J</i> = 5.5 Hz, 2H), 3.71 (q, <i>J</i> = 5.5 Hz, 2H), 2.58 (s, 3H); HPLC-MS: (M + H)<sup>+</sup>: 256.0.</div></div><div id="sec4_6_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Step C: <i>tert</i>-Butyl <i>N</i>-[6-(<i>tert</i>-Butoxycarbonylamino)-4-[3-(2-hydroxyethyl)-2-methyl-imidazo[4,5-b]pyridin-5-yl]-2-pyridyl]carbamate</h5><div class="NLM_p last">To 5.32 g of 2-(5-bromo-2-methyl-imidazo[4,5-<i>b</i>]pyridin-3-yl)ethanol (20.9 mmol), 10.01 g of <b>R1</b> (23.0 mmol), 0.469 g of Pd(OAc)<sub>2</sub> (0.1 mmol), 1.50 g of PBuAd<sub>2</sub> (4.18 mmol), and 13.31 g of K<sub>3</sub>PO<sub>4</sub> (62.7 mmol) were suspended in 100 mL of DME, and the mixture was stirred under nitrogen at 105 Â°C until no further conversion was observed. 500 mL of water was added, then the mixture was extracted with EtOAc (3 Ã 250 mL) and with brine. The organic layer was dried over MgSO<sub>4</sub>, then volatiles were removed in vacuum to give 10.1 g of <i>tert</i>-butyl <i>N-</i>[6-(<i>tert</i>-butoxycarbonylamino)-4-[3-(2-hydroxyethyl)-2-methyl-imidazo[4,5<i>-b</i>]pyridin-5-yl]-2-pyridyl]carbamate as the crude product, which was used in the next steps without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.34 (s, 2H), 8.03 (m, 3H), 7.68 (d, <i>J</i> = 8.3 Hz, 1H), 4.98 (t, <i>J</i> = 5.4 Hz, 1H), 4.33 (t, <i>J</i> = 5.4 Hz, 2H), 3.81 (q, <i>J</i> = 5.4 Hz, 2H), 2.63 (s, 3H), 1.49 (s, 18H); HPLC-MS: (M + H)<sup>+</sup>: 485.2.</div></div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>tert</i>-Butyl <i>N-</i>[6-(<i>tert</i>-Butoxycarbonylamino)-4-[3-(2-hydroxypropyl)-2-methyl-imidazo[4,5-<i>b</i>]pyridin-5-yl]-2-pyridyl]carbamate (<b>R4</b>)</h4><div id="sec4_6_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Step A: 1-(5-Bromo-2-methyl-imidazo[4,5-<i>b</i>]pyridin-3-yl)propan-2-ol</h5><div class="NLM_p">The mixture of 12.0 g of <i>N</i>-(6-bromo-2-fluoro-3-pyridyl)acetamide (51.5 mmol), 9.15 g of 1-aminopropan-2-ol (113.3 mmol), and 14 mL of triethylamine was stirred at 60 Â°C until no further conversion was observed. The solvent and excess amine were removed under reduced pressure.</div><div class="NLM_p">The remained solid was dissolved in 300 mL of acetic acid and the solution was heated at 130 Â°C until no further conversion was observed. The solvent was removed under reduced pressure. The residue was taken up the mixture of 200 mL of methanol and 40 mL of water. 9.6 g of LiOH*H<sub>2</sub>O (230 mmol) was added and the mixture was stirred at ambient temperature until no further conversion was observed, then it was poured into water. The precipitate was filtered off, washed with water, and dried to give 10.7 g of (77%) of 1-(5-bromo-2-methyl-imidazo[4,5-<i>b</i>]pyridin-3-yl)propan-2-ol.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.87 (d, <i>J</i> = 8.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.1 Hz, 1H), 4.97 (d, <i>J</i> = 4.3 Hz, 1H), 4.19â3.94 (m, 3H), 2.57 (s, 3H), 1.21 (d, <i>J</i> = 5.9 Hz, 3H); HPLC-MS: (M + H)<sup>+</sup>: 270.0.</div></div><div id="sec4_6_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Step B: <i>tert</i>-Butyl <i>N</i>-[6-(<i>tert</i>-Butoxycarbonylamino)-4-[3-(2-hydroxypropyl)-2-methyl-imidazo[4,5-b]pyridin-5-yl]-2-pyridyl]carbamate</h5><div class="NLM_p">To 5.38 g of 1-(5-bromo-2-methyl-imidazo[4,5-<i>b</i>]pyridin-3-yl)propan-2-ol (20 mmol), 8.70 g of <b>R1</b> (20 mmol), 0.449 g of palladium acetate (2.0 mmol), 1.43 g of triphenylphosphine (4.0 mmol), and 12.70 g of K<sub>3</sub>PO<sub>4</sub> the (60 mmol) were suspended in 133 mL of DME, and the mixture was stirred under argon at 110 Â°C until no further conversion was observed. The volatiles were removed under reduced pressure, the remained solid was dissolved in 700 mL of EtOAc which was extracted with 3 Ã 300 mL of water. The organic phase was washed with brine then it was dried over MgSO<sub>4</sub>. The evaporation of EtOAc under reduced pressure gave the crude product, which was purified by flash chromatography using DCM and methanolic ammonia as eluents. 4.9 g (49%) of <i>tert</i>-butyl <i>N-</i>[6-(<i>tert</i>-butoxycarbonylamino)-4-[3-(2-hydroxypropyl)-2-methyl-imidazo[4,5<i>-b</i>]pyridin-5-yl]-2-pyridyl]carbamate was obtained as a white solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.41 (s, 2H), 8.10 (s, 2H), 8.03 (d, <i>J</i> = 8.3 Hz, 1H), 7.70 (d, <i>J</i> = 8.3 Hz, 1H), 5.03 (d, <i>J</i> = 4.9 Hz, 1H), 4.28 (dd, <i>J</i> = 13.7, 3.5 Hz, 1H), 4.18 (m, 1H), 4.10 (dd, <i>J</i> = 13.6, 7.8 Hz, 1H), 2.64 (s, 3H), 1.50 (s, 18H), 1.19 (d, <i>J</i> = 6.2 Hz, 3H); HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>35</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 499.2591; found, 499.2646.</div></div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedure IâSuzuki Coupling and Deprotection</h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step A</h4><div class="NLM_p last">1 equiv of the appropriate halide derivative, 1â1.2 equiv of <b>R1</b> and 3 equiv of K<sub>2</sub>CO<sub>3</sub> were dissolved in 1,2-dimethoxyethane-water 7:1 (8 mL/mmol), then 0.05 equiv of palladium acetate and 0.1 equiv of <sup><i>n</i></sup>BuPAd<sub>2</sub> were added, and the mixture was heated at 100 Â°C under nitrogen in a microwave reactor until no further conversion was observed. <i>Celite</i> was added to the reaction mixture and the volatiles were evaporated under reduced pressure. The solid residue was purified by flash chromatography on silica gel using DCM and methanolic ammonia as eluents.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step B</h4><div class="NLM_p last">The product obtained in step A was stirred in a mixture of DCM (5 mL/mmol) and TFA (5 mL/mmol) until no further conversion was observed. The volatiles were evaporated under reduced pressure, the solid residue was dissolved in the ammonia solution (7 N in methanol, 20 mL/mmol), and the volatiles were evaporated under reduced pressure again. The crude product was purified by preparative reversed phase chromatography using 5 mM aqueous NH<sub>4</sub>HCO<sub>3</sub> solution and MeCN as eluents.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure IIâAmidine Formation, Ring Closure, and Deprotection</h3><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step A</h4><div class="NLM_p last">1.0 equiv of the appropriate amide and 5.0 equiv of 2,6-lutidine were dissolved in dry DCM (10 mL/mmol of the amide). The DCM solution was cooled to 0 Â°C under nitrogen and DCM solution of 5.0 equiv of nonafluorobutanesulfonic anhydride (1.5 M) was added dropwise. The reaction mixture was allowed to warm up to room temperature over 1 h then 5 equiv of the appropriate amine was added in one portion, and the mixture was stirred until no further conversion was observed. The DCM mixture was washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated under reduced pressure, and purified by flash chromatography using DCM and methanolic ammonia as eluents to give the amidine intermediate.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Step B</h4><div class="NLM_p last">To 1 equiv of the amidine intermediate from step A was dissolved in DME (6.5 mL/mmol). 0.2 equiv of Pd(OAc)<sub>2</sub>, 0.4 equiv of PBuAd<sub>2</sub>, and 2 equiv of K<sub>3</sub>PO<sub>4</sub> were added, and the reaction mixture was stirred under nitrogen at 115 Â°C in a microwave reactor until no further conversion was observed. The reaction mixture was concentrated under reduced pressure and purified by flash chromatography using DCM and methanolic ammonia as eluents to yield the appropriate Boc-protected example.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step C</h4><div class="NLM_p last">Starting from the product of step B, the final product was obtained following the deprotection protocol described in <a class="ref internalNav" href="#sec4_7" aria-label="General Procedure I Step B">General Procedure I Step B</a>.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Procedure IIIâNucleophilic Substitution and Deprotection</h3><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step A</h4><div class="NLM_p last">To the solution of 1 equiv of <b>R3</b> or <b>R4</b> in dry DMF (4.0 mL/mmol) under nitrogen 3 equiv of sodium hydride was added, and the resulting mixture was stirred at 0 Â°C for 15 min. Following the addition of 2 equiv of the appropriate aryl halide, the mixture was stirred at 50 Â°C for 5 h. If the formation of the expected product was not observed by HPLC-MS at this point, the reaction temperature was raised to 120 Â°C and stirring continued until no further conversion was observed. After cooling water was added to the reaction mixture and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, and solvent was removed under reduced pressure. The crude product was purified by flash chromatography using DCM and MeOH as eluents to give the Boc-protected example.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Step B</h4><div class="NLM_p last">Starting from the product of step A, the final product was obtained following the deprotection protocol described in <a class="ref internalNav" href="#sec4_7" aria-label="General Procedure I Step B">General Procedure I Step B</a>.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> General Procedure IVâSuzuki Coupling</h3><div class="NLM_p last">1 equiv of 4-bromopyridine-2,6-diamine, 1â1.5 equiv of the appropriate boronic acid or ester, and 3 equiv of K<sub>2</sub>CO<sub>3</sub> were dissolved in 1,2-dimethoxyethaneâwater 4:1 (5 mL/mmol). Then, 5 mol % of palladium acetate and 10 mol % of <sup><i>n</i></sup>BuPAd<sub>2</sub> were added, and the mixture was heated at 100 Â°C under nitrogen in a microwave reactor until no further conversion was observed. <i>Celite</i> was added to the reaction mixture and the volatiles were evaporated under reduced pressure. The solid residue was purified by flash chromatography on silica gel using DCM and methanolic ammonia as eluents.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Examples in the Paper</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-(4-Methoxyphenyl)pyrimidin-2,6-diamine (<b>1</b>)</h4><div class="NLM_p last">Prepared following published procedures.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(4-Methoxyphenyl)pyridin-2-amine (<b>3</b>)</h4><div class="NLM_p">To 0.173 g of 4-bromopyridine-2-amine (1.0 mmol), 0.304 g of (4-methoxyphenyl)boronic acid (2.0 mmol). and 0.420 g of K<sub>2</sub>CO<sub>3</sub> (3.0 mmol) in 15 mL of 1,2-dimethoxyethane and 3.75 mL of water was added 0.116 g of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 mmol) and heated at 100 Â°C under nitrogen in a microwave reactor until no further conversion was observed. The crude product was purified by flash chromatography on silica gel using heptane and EtOAc as eluents, to give 0.121 g (60%) of <b>3</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.92 (d, <i>J</i> = 5.5 Hz, 1H), 7.59 (m, 2H), 7.03 (m, 2H), 6.76 (dd, <i>J</i> = 5.5, 1.6 Hz, 1H), 6.67 (d, <i>J</i> = 1.0 Hz, 1H), 5.97 (s, 2H), 3.8 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.7, 160.3, 148.4, 148.3, 130.9, 128.1, 114.9, 110.2, 104.8, 55.7; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>13</sub>N<sub>2</sub>O [M + H]<sup>+</sup>: 201.1022; found, 201.1022.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 4-(4-Methoxyphenyl)-2-methyl-pyridine (<b>4</b>)</h4><div class="NLM_p">To 0.172 g of 4-bromo-2-methyl-pyridine (1.0 mmol), 0.304 g of (4-methoxyphenyl)boronic acid (2.0 mmol), and 0.420 g of K<sub>2</sub>CO<sub>3</sub> (3.0 mmol) in 20 mL of 1,2-dimethoxyethane and 5 mL of water 0.230 g of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.2 mmol) was added, and the mixture was heated at 100 Â°C under nitrogen in a microwave reactor until no further conversion was observed. The crude product was purified by flash chromatography on silica gel using heptane and EtOAc as eluents, to give 0.150 g (75%) of <b>4</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.43 (d, <i>J</i> = 5.4 Hz, 1H), 7.74 (d, <i>J</i> = 9.0 Hz, 2H), 7.52 (s, 1H), 7.44 (d, <i>J</i> = 5.3 Hz, 1H), 7.05 (d, <i>J</i> = 8.6 Hz, 2H), 3.81 (s, 3H), 2.50 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.6, 158.9, 149.9, 147.2, 129.9, 128.5, 120.2, 118.2, 115.0, 55.7, 24.6; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>14</sub>NO [M + H]<sup>+</sup> 200.1070; found, 200.1069.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-(4-Chloro-3-methoxy-phenyl)pyridin-2-amine (<b>5</b>)</h4><div class="NLM_p">To 0.173 g of 4-bromopyridine-2-amine (1.0 mmol), 0.224 g of (4-chloro-3-methoxy-phenyl)boronic acid (1.2 mmol), and 0.420 g of K<sub>2</sub>CO<sub>3</sub> (3.0 mmol) in 15 mL of 1,2-dimethoxyethane and 3.75 mL of water 0.116 g of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 mmol) was added, and the mixture was heated at 100 Â°C under nitrogen in a microwave reactor until no further conversion was observed. The crude product was purified by preparative HPLC (C18) using H<sub>2</sub>O (0.1% TFA) and MeCN as eluents, to give 0.104 g (44%) of <b>5</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.98 (d, <i>J</i> = 5.5 Hz, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.33 (d, <i>J</i> = 1.9 Hz, 1H), 7.21 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.83 (dd, <i>J</i> = 5.4, 1.6 Hz, 1H), 6.72 (d, <i>J</i> = 0.9 Hz, 1H), 6.05 (br, 2H), 3.94 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.7, 155.2, 148.7, 147.9, 139.3, 130.8, 122.0, 119.9, 111.2, 110.6, 105.7, 56.6; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>OCl [M + H]<sup>+</sup> 235.0633; found, 235.0614.</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-(4-Chlorophenyl)-2-methyl-pyridine (<b>6</b>)</h4><div class="NLM_p">To 0.250 g of 4-bromo-2-methyl-pyridine (1.45 mmol), 0.272 g of (4-chlorophenyl)boronic acid (1.74 mmol), and 0.600 g of K<sub>2</sub>CO<sub>3</sub> (4.35 mmol) in 10 mL of 1,2-dimethoxyethane and 2.5 mL of water 0.116 g of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.10 mmol) was added, and the mixture was heated at 100 Â°C under nitrogen in a microwave reactor until no further conversion was observed. The crude product was purified by flash chromatography on silica gel using heptane and EtOAc as eluents, to give 0.157 g (53%) of <b>6</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.50 (d, <i>J</i> = 5.2 Hz, 1H), 7.82 (d, <i>J</i> = 8.7 Hz, 2H), 7.59 (d, <i>J</i> = 1.2 Hz, 1H), 7.57 (d, <i>J</i> = 8.7 Hz, 2H), 7.50 (dd, <i>J</i> = 5.1, 1.9 Hz, 1H), 2.53 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.2, 150.1, 146.4, 136.7, 134.5, 129.6, 129.1, 120.8, 118.7, 24.6; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>11</sub>NCl [M + H]<sup>+</sup> 204.0575; found, 204.0585.</div></div><div id="sec4_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 6-(2,3-Dihydro-benzofuran-5-yl)-pyrimidine-2,4-diamine (<b>7</b>)</h4><div class="NLM_p">To 0.145 g of 6-chloropyrimidine-2,4-diamine (1.0 mmol), 0.270 g of benzofuran-5-ylboronic acid (1.1 mmol), and 0.414 g of K<sub>2</sub>CO<sub>3</sub> (3.0 mmol) in 5 mL of 1,2-dimethoxyethane and 1 mL of water 0.072 g of <sup><i>n</i></sup>BuPAd<sub>2</sub> (0.2 mmol) and 0.022 g of Pd(OAc)<sub>2</sub> (0.1 mmol) was added, and the mixture was heated at 130 Â°C under nitrogen in a microwave reactor until no further conversion was observed. The crude product was purified by preparative HPLC (C18) using H<sub>2</sub>O (0.1% TFA) and MeCN as eluents, to give 0.075 g (33%) of <b>7</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.79 (d, <i>J</i> = 1.1 Hz, 1H), 7.66 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 6.79 (d, <i>J</i> = 8.4 Hz, 1H), 6.23 (s, 2H), 6.11 (s, 1H), 5.86 (s, 2H), 4.57 (t, <i>J</i> = 8.7 Hz, 2H), 3.21 (t, <i>J</i> = 8.7 Hz, 2H) ppm; <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 165.6, 164.0, 162.6, 161.4, 131.2, 128.0, 126.8, 123.6, 109.0, 89.8, 71.8, 29.3; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>13</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 229.1014; found, 229.1087.</div></div><div id="sec4_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 6-Benzofuran-5-yl-pyrimidine-2,4-diamine Trifluoroacetic Acid (1:1) Salt (<b>8</b>)</h4><div class="NLM_p">To 0.145 g of 6-chloropyrimidine-2,4-diamine (1.0 mmol), 0.244 g of 2,3-dihydrobenzofuran-5-ylboronic acid (1.0 mmol), and 0.415 g of K<sub>2</sub>CO<sub>3</sub> (3.0 mmol) in 15 mL of 1,2-dimethoxyethane and 3.75 mL of water 0.116 g of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1 mmol) was added, and the mixture was heated at 100 Â°C under nitrogen in a microwave reactor until no further conversion was observed. The crude product was purified by preparative HPLC (C18) using H<sub>2</sub>O (0.1% TFA) and MeCN as eluents, to give 0.128 g (57%) of <b>8</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 12.24 (br s, 1H), 8.17 (br s, 2H), 8.17 (d, <i>J</i> = 2.2 Hz, 1H), 8.08 (d, <i>J</i> = 1.8 Hz, 1H), 7.85 (dm, 1H), 7.67 (dd, <i>J</i> = 8.7, 1.8 Hz, 1H), 7.51 (vbr s, 2H), 7.13 (dd, <i>J</i> = 2.2, 0.9 Hz, 1H), 6.34 (s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 165.6, 156.7, 156.3, 148.5, 128.4, 126.5, 123.7, 120.8, 112.8, 107.6, 94.6; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>11</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 227.0927; found, 227.0917.</div></div><div id="sec4_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-(2,3-Dihydro-benzofuran-5-yl)-pyridine-2,6-diamine (<b>9</b>)</h4><div class="NLM_p">Starting from 0.100 g of 4-bromopyridine-2,6-diamine (0.53 mmol) and 0.196 g 2-(2,3-dihydrobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.79 mmol) as the appropriate boronic ester, following General procedure IV, 0.100 g (83%) of <b>9</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.38 (d, <i>J</i> = 1.4 Hz, 1H), 7.25 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 6.80 (d, <i>J</i> = 8.2 Hz, 1H), 5.84 (s, 2H), 5.39 (s, 4H), 4.55 (t, <i>J</i> = 8.7 Hz, 2H), 3.21 (t, <i>J</i> = 8.7 Hz, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.4, 159.7, 150.3, 132.5, 128.4, 126.4, 123.4, 109.4, 93.4, 71.7, 29.4; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>14</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 228.1131; found, 228.1122.</div></div><div id="sec4_11_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-(Benzofuran-5-yl)pyridine-2,6-diamine (<b>10</b>)</h4><div class="NLM_p">0.188 g of 4-bromopyridine-2,6-diamine (1 mmol), 162 mg of benzofuran-5-ylboronic acid (1.0 mmol), 0.115 g of tetrakis(triphenylphosphine)palladium(0) (0.1 mmol), and 0.350 g of K<sub>2</sub>CO<sub>3</sub> (2.5 mmol) were suspended in the mixture 7.5 mL of DME and 1.8 mL of water, the mixture was stirred under nitrogen at 100 Â°C in a microwave reactor until no further conversion was observed. The crude product was purified by flash column chromatography using DCM and methanolic ammonia as eluents to give 0.110 g (49%) of <b>10</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.03 (d, <i>J</i> = 2.3 Hz, 1H), 7.78 (dm, <i>J</i> = 1.9 Hz, 1H), 7.64 (dm, <i>J</i> = 8.6 Hz, 1H), 7.45 (dd, <i>J</i> = 8.6, 1.9 Hz, 1H), 7.01 (dd, <i>J</i> = 2.3, 0.9 Hz, 1H), 5.92 (s, 2H), 5.46 (s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 154.7, 150.6, 147.1, 135.5, 128.1, 119.3, 111.9, 107.5, 94.1; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>12</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 226.0975; found, 226.0956.</div></div><div id="sec4_11_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-Benzo[<i>b</i>]thiophen-5-yl-pyridine-2,6-diamine (<b>11</b>)</h4><div class="NLM_p">Starting from 0.100 g of 4-bromopyridine-2,6-diamine (0.53 mmol) and 277 mg of 2-(benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.07 mmol) as the appropriate boronic ester following general procedure IV, 0.105 g (80%) of <b>11</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.05 (d, <i>J</i> = 8.4 Hz, 1H), 8.03 (d, <i>J</i> = 1.4 Hz, 1H), 7.80 (d, <i>J</i> = 5.4 Hz, 1H), 7.53 (d, <i>J</i> = 5.7 Hz, 1H), 7.51 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 5.98 (s, 2H), 5.53 (s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.7, 150.5, 140.5, 139.4, 136.6, 128.7, 124.8, 123.4, 123.2, 121.5, 94.0; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>12</sub>N<sub>3</sub>S [M + H]<sup>+</sup> 242.0746; found, 242.0743.</div></div><div id="sec4_11_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-(1,3-Benzoxazol-5-yl)pyridine-2,6-diamine (<b>12</b>)</h4><div class="NLM_p">0.188 g of 4-bromopyridine-2,6-diamine (1.0 mmol), 0.490 g of 1,3-benzoxazol-5-ylboronic acid (2.0 mmol), 0.115 g of tetrakis(triphenylphosphine)palladium(0) (0.1 mmol), and 0.414 g of K<sub>2</sub>CO<sub>3</sub> (3.0 mmol) were suspended in the mixture of 7.5 mL of DME and 1.8 mL of water, and the mixture was stirred under nitrogen at 100 Â°C in a microwave reactor until no further conversion was observed. Solvents were removed under reduced pressure, and the crude product was purified by flash chromatography using DCM and methanolic ammonia as eluents to give 0.100 g (44%) of <b>12</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.79 (s, 1H), 7.87 (d, <i>J</i> = 1.7 Hz, 1H), 7.82 (d, <i>J</i> = 8.5 Hz, 1H), 7.58 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 5.94 (s, 2H), 5.49 (s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.9, 155.4, 150.0, 149.8, 140.7, 137.5, 124.7, 117.9, 111.8, 94.2; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 227.0927; found, 227.0915.</div></div><div id="sec4_11_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-Furo[3,2-<i>b</i>]pyridin-5-yl-pyridine-2,6-diamine (<b>13</b>)</h4><div class="NLM_p">Starting from 0.522 g of <b>R1</b> (1.2 mmol) and 0.154 g of 5-chloro-furo[3,2-<i>b</i>]pyridine (1.0 mmol) following general procedure I, 0.096 g (42%) of <b>13</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.35 (d, <i>J</i> = 2.3 Hz, 1H), 8.09 (dd, <i>J</i> = 8.7, 1.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.7 Hz, 1H), 7.17 (dd, <i>J</i> = 2.3, 1.0 Hz, 1H), 6.35 (s, 2H), 5.51 (s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.9, 153.0, 151.5, 148.9, 147.5, 147.3, 119.6, 116.8, 108.4, 93.8; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>11</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 227.0850; found, 227.0923.</div></div><div id="sec4_11_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 4-Benzooxazol-6-yl-pyridine-2,6-diamine (<b>14</b>)</h4><div class="NLM_p">Starting from 0.188 g of 4-bromopyridine-2,6-diamine (1.0 mmol) and 0.245 g of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzoxazole (1.0 mmol) following general procedure IV, 0.078 g (34%) of <b>14</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.79 (s, 1H), 7.87 (d, <i>J</i> = 1.7 Hz, 1H), 7.85 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 5.95 (s, 2H), 5.52 (s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.9, 155.3, 150.4, 149.9, 140.1, 138.4, 123.7, 120.6, 109.2, 94.2; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>11</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 227.0927; found, 227.0921.</div></div><div id="sec4_11_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-Benzothiazol-6-yl-pyridine-2,6-diamine (<b>15</b>)</h4><div class="NLM_p">Starting from 0.435 g of <b>R1</b> (1.0 mmol) and 0.215 g of 6-bromo-1,3-benzothiazole (1.0 mmol) following general procedure I, 0.067 g (28%) of <b>15</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.41 (s, 1H), 8.32 (d, <i>J</i> = 1.6 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.67 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 5.97 (s, 2H), 5.52 (br s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.9, 157.3, 153.4, 149.8, 137.8, 134.8, 125.3, 123.6, 120.5, 94.1; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>11</sub>N<sub>4</sub>S [M + H]<sup>+</sup> 243.0626; found, 243.0694.</div></div><div id="sec4_11_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-(1-Methylbenzimidazol-5-yl)pyridine-2,6-diamine (<b>16</b>)</h4><div class="NLM_p">0.188 g of 4-bromopyridine-2,6-diamine (1.0 mmol), 0.352 g of (3-methylbenzimidazol-5-yl)boronic acid (2.0 mmol), 0.072 g of CataCXium (0.2 mmol), 0.0224 g of palladium (II) acetate (0.1 mmol), and 0.414 g of K<sub>2</sub>CO<sub>3</sub> (3.0 mmol) were suspended in the mixture of 4 mL of DME and 2 mL of water, and the mixture was stirred under nitrogen at 100 Â°C in a microwave reactor until no further conversion was observed. The crude product was purified by flash chromatography using DCM and methanolic ammonia as eluents to give 0.078 g (33%) of <b>16</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.21 (s, 1H), 7.70 (d, <i>J</i> = 1.5 Hz, 1H), 7.67 (d, <i>J</i> = 8.5 Hz, 1H), 7.38 (dd, <i>J</i> = 8.5 Hz, 1.5 Hz, 1H), 5.99 (s, 2H), 5.47 (s, 4H), 3.87 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.7, 151.1, 145.9, 143.9, 135.4, 134.8, 120.7, 119.8, 108.3, 94.2, 31.2; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>13</sub>N<sub>5</sub> [M + H]<sup>+</sup> 240.1244; found, 240.1233.</div></div><div id="sec4_11_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-(3-Methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)-pyridine-2,6-diamine (<b>17</b>)</h4><div class="NLM_p">Starting from 0.289 g <b>R1</b> (0.9 mmol) and 0.159 g of 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[4,5-<i>b</i>]pyridine (0.75 mmol) following general procedure I, 0.100 g (55%) <b>17</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.45 (s, 1H), 8.11 (d, <i>J</i> = 8.3 Hz, 1H), 7.62 (d, <i>J</i> = 8.3 Hz, 1H), 6.37 (s, 2H), 5.51 (s, 4H), 3.87 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.9, 150.9, 149.0, 147.6, 147.1, 135.1, 128.1, 115.4, 93.8, 29.9; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>13</sub>N<sub>6</sub> [M + H]<sup>+</sup> 241.1122; found, 241.1195.</div></div><div id="sec4_11_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-(Imidazo[1,2-<i>a</i>]pyridin-6-yl)-pyridine-2,6-diamine (<b>18</b>)</h4><div class="NLM_p">Starting from 0.435 g of <b>R1</b> (1.0 mmol) and 0.197 g of 6-bromoimidazo[1,2-<i>a</i>]pyridine (1.0 mmol) following general procedure I, 0.028 g (12%) of <b>18</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.85 (br s, 1H), 8.02 (br s, 1H), 7.64 (d, <i>J</i> = 9.4 Hz, 1H), 7.62 (d, <i>J</i> = 1.2 Hz, 1H), 7.39 (dd, <i>J</i> = 9.4, 1.8 Hz, 1H), 6.00 (br s, 4H), 5.98 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 157.6, 144.4, 134.1, 125.0, 124.3, 124.1, 117.3, 114.4, 93.3; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>12</sub>N<sub>5</sub> [M + H]<sup>+</sup> 226.1021; found, 226.1094.</div></div><div id="sec4_11_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-([1,2,4]Triazolo[1,5-<i>a</i>]pyridin-6-yl)pyridine-2,6-diamine (<b>19</b>)</h4><div class="NLM_p">Starting from 0.130 g of <b>R1</b> (0.30 mmol) and 0.060 g of 6-bromo [1,2,4]triazolo [1,5-<i>a</i>] pyridine (0.30 mmol) following general procedure I, 0.031 g (46%) of <b>19</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.07 (dd, <i>J</i> = 2.24, 0.9 Hz, 1H), 8.54 (s, 1H), 7.91 (dm, 1H), 7.80 (dd, <i>J</i> = 9.1, 1.8 Hz, 1H), 5.96 (s, 2H), 5.57 (s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.0, 154.9, 150.0, 145.7, 129.9, 127.6, 126.4, 116.6, 93.7; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>11</sub>N<sub>6</sub> [M + H]<sup>+</sup> 226.0967; found, 227.1033.</div></div><div id="sec4_11_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-(Pyrazolo[1,5-<i>a</i>]pyrimidin-5-yl)-pyridine-2,6-diamine (<b>20</b>)</h4><div class="NLM_p">Starting from 0.435 g of <b>R1</b> (1.0 mmol) and 0.198 g of 5-bromopyrazolo[1,5-<i>a</i>]pyrimidine (1.0 mmol) following general procedure I, 0.044 g (19%) of <b>20</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.14 (dd, <i>J</i> = 7.4, 0.5 Hz, 1H), 8.24 (d, <i>J</i> = 2.3 Hz, 1H), 7.29 (d, <i>J</i> = 7.5 Hz, 1H), 6.74 (dd, <i>J</i> = 2.4, 0.6 Hz, 1H), 6.38 (s, 2H), 5.64 (br s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.2, 155.4, 148.1, 146.4, 145.9, 136.6, 105.8, 96.9, 93.5; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>11</sub>N<sub>6</sub> [M + H]<sup>+</sup> 226.0967; found, 227.1033.</div></div><div id="sec4_11_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-(3-Methyl-benzo[<i>c</i>]isoxazol-5-yl)-pyridine-2,6-diamine (<b>21</b>)</h4><div class="NLM_p">Starting from 0.113 g of <b>R1</b> (0.26 mmol) and 0.050 g of 5-bromo-3-methyl-3aH-2,1-benzoxazole following general procedure I, 0.010 g (16%) of <b>21</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.85 (br s, 1H), 7.60 (d, <i>J</i> = 9.4 Hz, 1H), 7.51 (dd, <i>J</i> = 9.3, 1.5 Hz, 1H), 5.93 (s, 2H), 5.49 (br s, 4H), 2.86 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 168.1, 159.9, 156.6, 149.4, 134.6, 131.7, 117.9, 116.0, 115.1, 93.6, 12.2; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>13</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 241.1011; found, 241.1080.</div></div><div id="sec4_11_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine-2,6-diamine (<b>22</b>)</h4><div class="NLM_p">Starting from 0.188 g of 4-bromopyridine-2,6-diamine (1.0 mmol) and 0.216 g of 2,3-dihydro-1,4-benzodioxin-6-ylboronic acid (1.2 mmol) following general procedure IV, 0.165 g (68%) of <b>22</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 6.99 (dd, <i>J</i> = 8.2 Hz, 2.2 Hz, 1H), 6.97 (d, <i>J</i> = 2.2 Hz, 1H), 6.90 (d, <i>J</i> = 8.2 Hz, 1H), 5.84 (s, 2H), 5.39 (s, 4H), 4.26 (s, 4H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.6, 149.6, 144.0, 133.3, 119.4, 117.7, 115.0, 93.4, 64.6; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 244.1080; found, 244.1094.</div></div><div id="sec4_11_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 6-(2,6-Diamino-4-pyridyl)chromen-4-one (<b>23</b>)</h4><div class="NLM_p">Starting from 0.188 g of 4-bromopyridine-2,6-diamine (1.0 mmol) and 0.327 g of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)chromen-4-one (1.2 mmol) as the appropriate boronic ester and following general procedure IV, 0.150 g (59%) of <b>23</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.33 (d, <i>J</i> = 6.0 Hz, 1H), 8.16 (d, <i>J</i> = 2.4 Hz, 1H), 7.94 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.73 (d, <i>J</i> = 8.8 Hz, 1H), 6.39 (d, <i>J</i> = 6.0 Hz, 1H), 5.99 (s, 2H), 5.56 (s, 4H); <sup>13</sup>C NMR (125 MHz DMSO-<i>d</i><sub>6</sub>): Î´ ppm 176.8, 160.1, 157.6, 156.3, 148.2, 137.1, 132.4, 124.8, 122.2, 119.7, 112.7; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 254.0924; found, 254.0932.</div></div><div id="sec4_11_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 4-(6-Quinolyl)pyridine-2,6-diamine (<b>24</b>)</h4><div class="NLM_p">Starting from 0.188 g of 4-bromopyridine-2,6-diamine (1.0 mmol) and 0.306 g of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (1.2 mmol) following general procedure IV, 0.160 g <b>24</b> (68%) was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.91 (dd, <i>J</i> = 4.2, 1.6 Hz, 1H), 8.44 (dm, <i>J</i> = 8.4 Hz, 1H), 8.14 (d, <i>J</i> = 1.8 Hz, 1H), 8.08 (d, <i>J</i> = 8.8 Hz, 1H), 7.91 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 7.56 (dd, <i>J</i> = 8.4, 4.2 Hz, 1H), 6.05 (s, 2H), 5.55 (br s, 4H); <sup>13</sup>C NMR (125 MHz DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.9, 151.2, 149.5, 148.0, 138.1, 136.8, 129.8, 128.4, 125.6, 125.5, 122.3, 94.1; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>13</sub>N<sub>4</sub> [M + H]<sup>+</sup> 237.1135; found, 237.1143.</div></div><div id="sec4_11_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 4-(Benzofuran-5-yl)pyridin-2-amine (<b>25</b>)</h4><div class="NLM_p">Starting from 0.173 g of 4-bromopyridin-2-amine (1.0 mmol) and 0.193 g of benzofuran-5-ylboronic acid (1.2 mmol) following general procedure IV, 0.091 g (43%) of <b>25</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.06 (d, <i>J</i> = 2.1 Hz, 1H), 7.96 (d, <i>J</i> = 5.3 Hz, 1H), 7.92 (d, <i>J</i> = 1.5 Hz, 1H), 7.69 (d, <i>J</i> = 8.7 Hz, 1H), 7.57 (dd, <i>J</i> = 8.6, 1.9 Hz, 1H), 7.03 (d, <i>J</i> = 2.0 Hz, 1H), 6.82 (dd, <i>J</i> = 5.4, 1.6 Hz, 1H), 6.74 (d, <i>J</i> = 0.9 Hz, 1H), 6.01 (br s, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.7, 155.0, 149.2, 148.6, 147.4, 134.1, 128.4, 123.6, 119.8, 112.2, 110.9, 107.5, 105.8; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>11</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 211.0866; found, 211.0864.</div></div><div id="sec4_11_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-(Benzofuran-5-yl)pyridine (<b>26</b>)</h4><div class="NLM_p">0.400 g of 5-bromobenzofuran (2.0 mmol), 0.458 g of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (2.0 mmol), 0.072 g of CataCXium (0.2 mmol), 0.0224 g of palladium (II) acetate (0.05 mmol), and 0.832 g of K<sub>2</sub>CO<sub>3</sub> (6.0 mmol) were suspended in the mixture of 5 mL of DME and 2.5 mL of water, and the mixture was stirred under nitrogen at 90 Â°C until no further conversion was observed. The crude product was purified by flash column chromatography using DCM and methanolic ammonia as eluents to give 0.036 g (18%) of 4-(benzofuran-5-yl)pyridine <b>26</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.63 (m, 2H), 8.11 (t, <i>J</i> = 1.3 Hz, 1H), 8.09 (d, <i>J</i> = 2.2 Hz, 1H), 7.75 (m, 4H), 7.05 (d, <i>J</i> = 2.2 Hz, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 155.3, 150.6, 147.9, 147.6, 132.8, 128.6, 123.9, 122.0, 120.4, 112.5, 107.6; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>9</sub>NO [M + H]<sup>+</sup> 196.0757; found, 196.0760.</div></div><div id="sec4_11_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4-(Benzofuran-5-yl)-6-methyl-pyridin-2-amine (<b>27</b>)</h4><div id="sec4_11_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Step A: 4-(Benzofuran-5-yl)-6-methyl-pyridin-2-ol</h5><div class="NLM_p">1.40 g of 4-bromo-6-methyl-pyridin-2-ol (7.45 mmol), 2.07 g of 2-(benzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8.50 mmol), 0.501 g of CataCXium (1.40 mmol), 0.157 g of palladium (II) acetate (0.70 mmol), and 3.08 g of K<sub>2</sub>CO<sub>3</sub> (22.0 mmol) were suspended in the mixture of 30 mL of DME and 15 mL of water. The mixture was stirred under nitrogen at 100 Â°C in a microwave reactor until no further conversion was observed. The precipitate was filtered off, washed with water, and dried in vacuum to give 1.67 g of (quant.) of 4-(benzofuran-5-yl)-6-methyl-pyridin-2-ol.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 11.6 (br s 1H), 8.06 (d, <i>J</i> = 2.1 Hz, 1H), 7.97 (d, <i>J</i> = 1.7 Hz, 1H), 7.67 (d, <i>J</i> = 1.8 Hz, 1H), 7.61 (dd, <i>J</i> = 8.7, 1.85 Hz, 1H), 7.01 (dd, <i>J</i> = 2.2, 0.9 Hz, 1H), 6.45â6.35 (br m, 2H), 2.23 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 163.8, 155.2, 152.7, 147.5, 146.1, 133.2, 128.3, 123.7, 120.2, 113.1, 112.1, 107.5, 104.0, 19.2; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>11</sub>NO<sub>2</sub> [M + H]<sup>+</sup> 226.0863; found, 226.0852.</div></div><div id="sec4_11_26_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step B: 4-(Benzofuran-5-yl)-2-chloro-6-methyl-pyridine</h5><div class="NLM_p">1.67 g of 4-(benzofuran-5-yl)-6-methyl-pyridin-2-ol (7.45 mmol) was dissolved in 5 mL of POCl<sub>3</sub> under nitrogen. The reaction mixture was stirred at 140 Â°C until no further conversion was observed. Excess of POCl<sub>3</sub> was distilled off, the remaining material was poured into ice water, stirred, and the solid was filtered off and was washed with 0.1 M NaHCO<sub>3</sub> solution, then with water. The crude product was purified by flash column chromatography using DCM as the eluent to give 0.600 g (36%) of 4-(benzofuran-5-yl)-2-chloro-6-methyl-pyridine.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.13 (d, <i>J</i> = 1.4 Hz, 1H), 8.09 (d, <i>J</i> = 2.1 Hz, 1H), 7.75 (dd, <i>J</i> = 8.6 Hz, 1.8 Hz, 1H), 7.72 (dm, <i>J</i> = 8.6 Hz, 1H), 7.65 (s, 1H), 7.65 (s, 1H), 7.03 (d, <i>J</i> = 2.0 Hz, 1H), 2.51 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.0, 155.5, 151.8, 150.7, 147.7, 131.6, 128.5, 124.4, 120.8, 120.7, 119.0, 112.4, 107.5, 24.1; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>10</sub>NOCl [M + H]<sup>+</sup> 244.0524; found, 244.0530.</div></div><div id="sec4_11_26_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step C: 4-(Benzofuran-5-yl)-6-methyl-pyridin-2-amine (<b>27</b>)</h5><div class="NLM_p">0.121 g of 4-(benzofuran-5-yl)-2-chloro-6-methyl-pyridine (0.5 mmol) and 0.126 g of diphenylmethaneimine (0.7 mmol) was dissolved in toluene (15 mL) then 0.046 g of Pd<sub>2(</sub>dba)<sub>3</sub> (0.05 mmol), 0.031 g of BINAP (0.05 mmol), and 0.058 g of sodium <i>tert</i>-butylate (0.6 mmol) were added. The reaction mixture was stirred in a microwave reactor at 100 Â°C until no further conversion was observed. The solvent was removed in vacuum, the remaining solid was dissolved in the mixture of 5 mL of MeOH and 3 mL of 1 M hydrochloric acid. The reaction mixture was stirred until no further conversion was observed. The solvent was removed in vacuum then the crude product was purified by flash chromatography using DCM and methanolic ammonia as eluents to give 0.052 g of (48%) of (4-(benzofuran-5-yl)-6-methyl-pyridin-2-amine.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.04 (d, <i>J</i> = 2.17 Hz, 1H), 7.89 (d, <i>J</i> = 1.65 Hz, 1H), 7.67 (d, <i>J</i> = 8.65 Hz, 1H), 7.55 (dd, <i>J</i> = 8.65, 1.83 Hz, 1H), 7.02 (d, <i>J</i> = 2.17 Hz, 1H), 6.69 (br s, 1H), 6.53 (br s, 1H), 5.86 (b rs, 2H), 2.3 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.3, 157.0, 154.9, 149.5, 147.3, 134.4, 128.2, 123.6, 119.7, 110.0, 112.1, 107.5, 102.9, 24.3; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>12</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 225.096; found, 225.1033.</div></div></div><div id="sec4_11_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 1-[4-(Benzofuran-5-yl)-2-pyridyl]piperazine (<b>28</b>)</h4><div class="NLM_p">0.196 g of 6-bromobenzofuran (1.00 mmol), 0.281 g of 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]piperazine (0.75 mmol), 0.203 g of tetrakis(triphenylphosphine)palladium(0) (0.20 mmol), and 0.400 g of K<sub>2</sub>CO<sub>3</sub> (3.00 mmol) were suspended in the mixture of 4.5 mL of DME and 1.5 mL of water. The mixture was stirred under nitrogen at 100 Â°C in a microwave reactor until no further conversion was observed. The solvent was removed in vacuum, and the remaining mixture was purified by flash chromatography using DCM and methanolic ammonia as eluents to give 0.030 g (11%) of <b>28</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.15 (d, <i>J</i> = 5.2 Hz, 1H), 8.06 (d, <i>J</i> = 2.1 Hz, 1H), 8.04 (br s, 1H), 7.69 (s, 2H), 7.03 (br s, 1H), 7.02 (d, <i>J</i> = 2.1 Hz, 1H), 6.95 (dm, <i>J</i> = 5.2 Hz, 1H), 3.49 (m, 4H), 2.8 (m, 4H), 2.47 (br s, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 160.6, 155.1, 149.6, 148.5, 147.4, 134.2, 128.3, 124.0, 120.2, 112.1, 111.7, 107.5, 104.9, 46.4, 45.9; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 280.1444; found, 280.1427.</div></div><div id="sec4_11_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 4-(Benzofuran-5-yl)-<i>N</i>6-methyl-pyridine-2,6-diamine (<b>29</b>)</h4><div class="NLM_p">0.500 g of <b>10</b> (2.22 mmol) was stirred in 1.7 mL of formic acid (4.44 mmol) at 70 Â°C in the presence of 0.180 g of zinc oxide (2.22 mmol) until no further conversion was observed. A mixture of the mono- and diformylated products was formed in a 4:1 ratio. The reaction mixture was evaporated directly onto <i>Celite</i> and purified by flash chromatography using DCM and methanolic ammonia as eluents to give 0.280 g of a mixture of the two products. The mixture was dissolved in 5 mL of abs. THF, and the resulting solution was added dropwise to the suspension of 0.156 g of LiAlH<sub>4</sub> (4.12 mmol) in 15 mL of abs. THF. The resulting mixture was stirred until no further conversion was observed. The excess of LiAlH<sub>4</sub> was decomposed with careful subsequent addition of 0.156 mL of H<sub>2</sub>O, 0.312 mL of 2 M NaOH, and finally 0.312 mL of H<sub>2</sub>O. The inorganics were removed by filtration, and the filtrate was evaporated onto <i>Celite.</i> The crude product was purified by flash chromatography using DCM and methanolic ammonia as eluents to give 0.050 g (30%) of 29 as a white solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.03 (d, <i>J</i> = 2.2 Hz, 1H), 7.82 (d, <i>J</i> = 1.8 Hz, 1H), 7.65 (dm, <i>J</i> = 8.6 Hz, 1H), 7.49 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.02 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 6.03 (br q, 1 H), 5.94 (d, <i>J</i> = 1.0 Hz, 1 H), 5.88 (d, <i>J</i> = 1.0 Hz, 1 H), 5.59 (br s, 2 H), 2.75 (d, 3 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.7, 159.4, 154.8, 150.7, 147.2, 135.4, 128.1, 123.5, 119.4111.9, 107.5, 93.8, 92.8, 28.9; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>14</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 240.1131; found, 240.1121.</div></div><div id="sec4_11_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 4-Benzofuran-5-yl-<i>N</i>-(3-methoxy-propyl)-pyridine-2,6-diamine Hydrochloride (<b>30</b>)</h4><div id="sec4_11_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step A: <i>N</i>-[6-Amino-4-(benzofuran-5-yl)-2-pyridyl]-3-methoxy-propanamide</h5><div class="NLM_p">The solution of 0.200 g of <b>10</b> (0.88 mmol) and 0.680 mL of TEA (4.42 mmol) in 40 mL of THF was cooled to â78 Â°C. To the resulting mixture, 0.120 g of 3-methoxypropanoyl chloride (0.97 mmol) dissolved in 10 mL of THF was added dropwise. The reaction mixture was left to warm to room temperature. It was evaporated directly onto <i>Celite</i>, and then it was purified by flash chromatography using DIPE and EtOAc as eluents to give 0.130 g (46%) of <i>N</i>-[6-amino-4-(benzofuran-5-yl)-2-pyridyl]-3-methoxy-propanamide as a white solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 12.52 (s, 1H), 8.10 (d, <i>J</i> = 2.2 Hz, 1H), 7.97 (d, <i>J</i> = 1.6 Hz, 1H), 7.83â7.76 (m, 2H), 7.74 (d, <i>J</i> = 8.6, 2H), 7.59 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.44 (br s, 1H), 7.05 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 6.21 (d, <i>J</i> = 16.0 Hz, 2H), 5.86 (s, 2H), 3.43 (t, <i>J</i> = 6.0 Hz, 2H), 3.40â3.35 (m, 2H), 3.25 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 170.4, 159.4, 155.0, 151.6, 151.1, 147.4, 134.6, 128.4, 123.6, 119.7, 112.2, 107.6, 101.7, 100.0, 68.6, 58.4, 37.1; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 312.1342; found, 312.1343.</div></div><div id="sec4_11_29_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Step B: 4-Benzofuran-5-yl-<i>N</i>-(3-methoxy-propyl)-pyridine-2,6-diamine Hydrochloride (<b>30</b>)</h5><div class="NLM_p">The solution of the product of step A in 5 mL of <i>abs.</i> THF was added to the suspension of 0.055 g of LiAlH<sub>4</sub> (1.44 mmol) in 35 mL of abs. THF. The resulting mixture was stirred until no further conversion was observed. The excess of LiAlH<sub>4</sub> was decomposed with careful subsequent addition of 0.055 mL of H<sub>2</sub>O, 0.110 mL of 2 M NaOH, and finally 0.110 mL of H<sub>2</sub>O. The inorganics were removed by filtration, and the filtrate was evaporated onto <i>Celite.</i> The crude product was purified by flash chromatography using DCM and methanolic ammonia as eluents. The product was taken up in the solution of HCl in Et<sub>2</sub>O, then the precipitate was collected by filtration to give 0.095 g (60%) of <b>30</b> as a white powder.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 12.53 (s, 1H), 8.10 (d, <i>J</i> = 2.2 Hz, 1H), 7.98 (d, <i>J</i> = 1.7 Hz, 1H), 7.79 (br, 1H), 7.74 (dm, 1H), 7.59 (dd, <i>J</i> = 8.7, 1.8 Hz, 1H), 7.45 (br, 2H), 7.07 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 6.23 (d, <i>J</i> = 0.9 Hz, 1H), 6.20 (d, <i>J</i> = 1.2 Hz, 1H), 3.43 (t, <i>J</i> = 6.1 Hz, 2H), 3.38 (m, 2H), 3.25 (s, 3H), 1.83 (m, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 156.1, 155.7, 152.9, 151.5, 147.8, 132.7, 128.4, 123.8, 120.4, 112.4, 107.6, 93.3, 92.1, 69.6, 58.5, 39.4, 28.9; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 298.1485; found, 298.1558.</div></div></div><div id="sec4_11_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 4-Benzofuran-5-yl-<i>N</i>-(2-thiophen-3-yl-ethyl)-pyridine-2,6-diamine Hydrochloride (<b>31</b>)</h4><div id="sec4_11_30_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Step A: <i>N</i>-[6-Amino-4-(benzofuran-5-yl)-2-pyridyl]-2-(3-thienyl)acetamide</h5><div class="NLM_p last">The mixture of 0.139 g of (3-thienyl)acetic acid (0.97 mmol), 10 mL of abs. THF, 0.090 mL of (0.135 g, 0.97 mmol) oxalyl chloride, and a drop of DMF was stirred at room temperature for 20 min, then it was cooled to â78 Â°C. Also, added dropwise to the â78 Â°C solution of 0.200 g of <b>10</b> (0.88 mmol) and 0.680 mL of TEA (4.42 mmol) in 40 mL of THF. The reaction mixture was left to warm to room temperature and evaporated directly on to <i>Celite</i>. The solid was purified by flash chromatography using DIPE and EtOAc as eluents to give 0.209 g of (67%) of <i>N</i>-[6-amino-4-(benzofuran-5-yl)-2-pyridyl]-2-(3-thienyl)acetamide as a white solid.</div></div><div id="sec4_11_30_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Step B: 4-Benzofuran-5-yl-<i>N</i>-(2-thiophen-3-yl-ethyl)-pyridine-2,6-diamine Hydrochloride (<b>31</b>)</h5><div class="NLM_p">The solution of the product of step A (0.137 g, 0.39 mmol) in 5 mL of abs. THF was added dropwise to the suspension of 75 mg of LiAH<sub>4</sub> (1.44 mmol) in 35 mL of THF. The resulting mixture was stirred until no further conversion was observed. The excess of LiAlH<sub>4</sub> was decomposed with the careful subsequent addition of 0.075 mL of H<sub>2</sub>O, 0.150 mL of 2 M NaOH, and finally 0.150 mL of H<sub>2</sub>O. The inorganics were removed by filtration, and the filtrate was evaporated onto <i>Celite.</i> The crude product was purified by flash chromatography using DCM and methanolic ammonia as eluents. The product was taken up in the solution of HCl in Et<sub>2</sub>O, then the precipitate was collected by filtration to give 0.075 g (62%) of <b>31</b> as a white powder.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 12.66 (br s, 1H), 8.10 (d, <i>J</i> = 2.1 Hz, 1H), 7.97 (d, <i>J</i> = 1.7 Hz, 1H), 7.85 (br s, 1H), 7.74 (d, <i>J</i> = 8.6 Hz, 1H), 7.59 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 7.52 (br s, 2H), 7.49 (dd, <i>J</i> = 4.9, 3.0 Hz, 1H), 7.36 (br d, <i>J</i> = 2.3 Hz, 1H), 7.15 (dd, <i>J</i> = 4.9, 1.0 Hz, 1H), 7.07 (dd, <i>J</i> = 2.2, 0.8 Hz, 1H), 6.25 (s, 1H), 6.20 (s, 1H), 3.62 (m, 2H), 2.93 (t, <i>J</i> = 7.2 Hz, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 156.1, 155.7, 152.9, 151.4, 147.8, 139.4, 132.7, 129.1, 128.4, 126.5, 123.8, 122.4, 120.5, 112.4, 107.6, 93.4, 92.2, 42.9, 29.5; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>OS [M + H]<sup>+</sup> 336.1101; found, 336.1174.</div></div></div><div id="sec4_11_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>N</i>-[6-Amino-4-(benzofuran-5-yl)-2-pyridyl]-2-(methylamino)acetamide (<b>32</b>)</h4><div class="NLM_p">The solution of 0.225 g <b>10</b> (1.0 mmol) and 0.278 mL of TEA (2.0 mmol) in 8 mL of THF was cooled to â50 Â°C. 0.157 g of 2-bromoacetyl chloride (0.083 mL, 1.0 mmol) dissolved in 2 mL of THF was added dropwise to the resulting mixture. After 10 min of stirring, 5 mL of methyl amine (10.0 mmol, 2 M in THF) was added, and the reaction mixture was left to warm up to room temperature, where it was stirred until no further conversion was observed. The reaction mixture was evaporated directly onto <i>Celite</i>, and then, it was purified by flash chromatography using DCM and methanolic ammonia as eluents to give 0.197 g (66%) of <b>32</b> as a white powder.</div><div class="NLM_p last">1H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.68 (br s, 1H), 8.06 (d, <i>J</i> = 2.2 Hz, 1H), 7.86 (d, <i>J</i> = 1.8 Hz, 1 H), 7.70 (d, <i>J</i> = 8.4 Hz, 1 H), 7.61 (br s, 1 H), 7.52 (dd, <i>J</i> = 8.6, 1.8 Hz, 1 H), 7.06 (dd, <i>J</i> = 2.2, 0.9 Hz, 1 H), 6.47 (d, <i>J</i> = 1.4 Hz, 1 H), 6.01 (s, 2 H), 3.23 (s, 2 H), 2.93 (br s, 2 H), 2.33 (s, 3 H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 170.7, 159.7, 155.0, 151.4, 150.7, 147.4, 134.6, 128.4, 123.6, 119.7, 112.2, 107.6, 101.9, 99.1, 55.1, 36.5; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 297.1346; found, 297.1338.</div></div><div id="sec4_11_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 4-(2-Methyl-benzofuran-5-yl)-pyridine-2,6-diamine Trifluoroacetic Acid (1:1) Salt (<b>33</b>)</h4><div class="NLM_p">The mixture of 0.211 g of 5-bromo-2-methylbenzofuran (1.0 mmol), 0.279 g of bis-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.1 mmol), 0.0225 g of palladium acetate (0.1 mmol), 0.072 g of PBuAd<sub>2</sub> (0.2 mmol), and 0.553 g of K<sub>2</sub>CO<sub>3</sub> (4.0 mmol) in 5 mL of DME and 1 mL of H2O was stirred under argon for 30 min 0.170 g of 4-bromopyridin-2,6-diamine (0.90 mmol) was added to the mixture, and the stirring was continued for 1 h. The reaction mixture was evaporated directly onto <i>Celite</i>, and then, it was purified by flash chromatography of a reverse phase silica column using 0.1% TFA and MeCN as eluents to give 0.080 g (37%) of <b>33</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 12.68 (br s, 1H), 7.77 (dm, 1H), 7.62 (dm, 1H), 7.26 (br s, 4H), 7.44 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 6.68 (m, 1H), 6.18 (s, 2H), 2.47 (d, <i>J</i> = 0.8 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 157.5, 156.6, 155.5, 152.6, 132.3, 130.1, 122.5, 119.1, 111.7, 103.6, 93.5, 14.2; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>14</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 240.1131; found, 240.1123.</div></div><div id="sec4_11_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 4-(2-Chloro-benzofuran-5-yl)-pyridine-2,6-diamine Trifluoroacetic Acid (1:1.3) Salt (<b>34</b>)</h4><div class="NLM_p">The mixture of 0.232 g of 5-bromo-2-chlorobenzofuran (1.0 mmol), 0.279 g of bis-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.1 mmol), 0.0225 g of palladium acetate (0.1 mmol), 0.072 g of PBuAd<sub>2</sub> (0.2 mmol), and 0.553 g of K<sub>2</sub>CO<sub>3</sub> (4.0 mmol) in 5 mL of DME and 1 mL of H2O was stirred under argon for 30 min. 0.170 g of 4-bromopyridin-2,6-diamine (0.90 mmol) was added to the mixture and the stirring was continued for 1 h. The reaction mixture was evaporated directly onto <i>Celite</i>, and then, it was purified by flash chromatography of a reverse phase silica column using 0.1% TFA and MeCN as eluents to give 0.019 g (7%) of <b>34</b>.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 12.33 (br s, 1H), 7.84 (dm, 1H), 7.75 (dm, 1H), 7.56 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 7.23 (br s, 4H), 7.15 (d, <i>J</i> = 0.8 Hz, 1H), 6.16 (s, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 156.0, 154.8, 152.7, 141.9, 133.6, 129.1, 123.9, 119.5, 112.2, 104.7, 93.6; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>OCl [M + H]<sup>+</sup> 260.0585; found, 260.0587.</div></div><div id="sec4_11_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 4-(2,3-Dimethyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>35</b>)</h4><div class="NLM_p">Starting from 0.500 g of <b>R1</b> (1.15 mmol) and 0.190 g of 6-chloro-2,3-dimethyl-imidazo[4,5<i>-b</i>]pyridine (1.05 mmol) following general procedure I, 0.047 g (18%) of <b>35</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.96 (d, <i>J</i> = 8.3 Hz, 1H), 7.57 (d, <i>J</i> = 8.3 Hz, 1H), 6.40 (s, 2H), 5.63 (br s, 4H), 3.79 (s, 3H), 2.59 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.1, 155.3, 149.1, 148.6, 134.8, 126.4, 115.1, 93.7, 28.5, 14.5; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>15</sub>N<sub>6</sub> [M + H]<sup>+</sup> 255.1289; found, 255.1361.</div></div><div id="sec4_11_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 4-(2-Methyl-3-butyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>36</b>)</h4><div class="NLM_p">Starting from 0.143 g of <b>R2</b> (0.3 mmol) and 0.219 g of butylamine (0.297 mL, 3 mmol) following general procedure II, 0.019 g (21%) of <b>36</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.95 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 6.34 (s, 2H), 5.48 (br s, 4H), 4.27 (t, 2H), 2.6 (s, 3H), 1.79 (quint, 2H), 1.31 (m, 2H), 092 (t, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 154.6, 149.6, 149.2, 148.4, 134.6, 126.5, 115.1, 93.7, 41.9, 31.6, 20.0, 14.7, 14.1; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for, C<sub>16</sub>H<sub>21</sub>N<sub>6</sub> [M + H]<sup>+</sup> 297.1769; found, 297.1842.</div></div><div id="sec4_11_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 4-(2-Ethyl-3-butyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>37</b>)</h4><div id="sec4_11_36_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> Step A: <i>N</i>-(6-Bromo-2-chloro-3-pyridyl)propanamide</h5><div class="NLM_p">3.00 g of 6-bromo-2-chloro-pyridin-3-amine (14.5 mmol) and 2.20 mL of triethylamine (15.9 mmol) were dissolved in 60 mL of DCM. The solution was cooled to 0 Â°C and 1.40 mL of propanoyl chloride (15.9 mmol) was added dropwise over 30 min. On the completion of the addition, the reaction mixture was allowed to warm up to room temperature where it was stirred until no further conversion was observed. The reaction mixture was diluted with EtOAc and washed with water. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography using DCM as the eluent to give 3.55 g (93%) of <i>N-</i>(6-bromo-2-chloro-3-pyridyl)propanamide.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.67 (s, 1H), 8.16 (d, <i>J</i> = 8.2 Hz, 1H), 7.64 (d, <i>J</i> = 8.4 Hz, 1H), 2.43 (q, <i>J</i> = 15.0, 7.5 Hz 2H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); HPLC-MS: (M â H)<sup>â</sup>: 261.0; 263.0.</div></div><div id="sec4_11_36_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Step B: <i>tert</i>-Butyl <i>N</i>-[6-(<i>tert</i>-butoxycarbonylamino)-4-[6-chloro-5-(propanoylamino)-2-pyridyl]-2-pyridyl]carbamate</h5><div class="NLM_p">Starting from 3.53 g of <i>N-</i>(6-bromo-2-chloro-3-pyridyl)propanamide (13.4 mmol), following step B of <b>R2</b>, 5.70 g of <i>tert-</i>butyl <i>N</i>-[6-(<i>tert</i>-butoxycarbonylamino)-4-[6-chloro-5-(propanoylamino)-2-pyridyl]-2-pyridyl]carbamate (87%) was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.68 (s, 1H), 9.45 (s, 2H), 8.40 (d, <i>J</i> = 8.5 Hz, 1H), 8.00 (s, 2H), 7.91 (d, <i>J</i> = 8.4 Hz, 1H), 2.48 (q, <i>J</i> = 13.0, 7.5 Hz 2H), 1.49 (s, 18H), 1.11 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 173.4, 153.1, 152.1, 150.0, 147.8, 142.6, 134.6, 132.9, 120.9, 104.4, 80.2, 29.5, 28.5, 9.9; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub>Cl [M + H]<sup>+</sup> 492.1935; found, 492.2005.</div></div><div id="sec4_11_36_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> Step C: 4-(3-Butyl-2-ethyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>37</b>)</h5><div class="NLM_p">Starting from 0.49 g of <i>tert</i>-butyl <i>N</i>-[6-(<i>tert</i>-butoxycarbonylamino)-4-[6-chloro-5-(propanoylamino)-2-pyridyl]-2-pyridyl]carbamate (1.0 mmol) and 0.50 mL of butylamine (5.0 mmol) as the appropriate amine following general procedure II, 0.085 g (22%) of <b>37</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 7.98 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 6.35 (s, 2H), 5.47 (br s, 4H), 4.27 (t, <i>J</i> = 7.2 Hz, 2H), 2.95 (q, <i>J</i> = 14.9, 7.3 Hz 2H), 1.79 (m, 2H), 1.37 (t, <i>J</i> = 7.4 Hz, 3H), 1.32 (m, 2H), 0.93 (t, <i>J</i> = 7.3 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.5, 158.5, 149.5, 148.4, 134.4, 126.5, 115.0, 93.6, 41.6, 31.7, 20.9, 19.9, 14.0, 11.5; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>23</sub>N<sub>6</sub> [M + H]<sup>+</sup> 311.1906; found, 311.1982.</div></div></div><div id="sec4_11_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 4-(2,3-Dibutyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>38</b>)</h4><div id="sec4_11_37_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> Step A: <i>N</i>-(6-Bromo-2-chloro-3-pyridyl)pentanamide</h5><div class="NLM_p">To 3.00 g of 6-bromo-2-chloro-pyridin-3-amine (14.5 mmol) and 2.4 mL of triethylamine (17.4 mmol) were dissolved in 60 mL of DCM. The solution was cooled to 0 Â°C and 2.1 mL of pentanoyl chloride (17.4 mmol) was added dropwise over 30 min. On the completion of the addition, the reaction mixture was allowed to warm up to room temperature, where it was stirred until no further conversion was observed. The reaction mixture was diluted with EtOAc and washed with water. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography using DCM as the eluent to give 3.59 g (85%) of <i>N-</i>(6-bromo-2-chloro-3-pyridyl)pentanamide.</div><div class="NLM_p last">HPLC-MS: (M â H)<sup>â</sup> = 289.0; 291.0.</div></div><div id="sec4_11_37_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> Step B: <i>tert</i>-Butyl <i>N</i>-[6-(<i>tert</i>-butoxycarbonylamino)-4-[6-chloro-5-(pentanoylamino)-2-pyridyl]-2-pyridyl]carbamate</h5><div class="NLM_p">Starting from <i>N-</i>(6-bromo-2-chloro-3-pyridyl)pentanamide following step B of <b>R2</b>, 4.35 g of <i>tert</i>-butyl <i>N</i>-[6-(<i>tert-</i>butoxycarbonylamino)-4-[6-chloro-5-(pentanoylamino)-2-pyridyl]-2-pyridyl]carbamate (72%) was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.70 (s, 1H), 9.45 (s, 2H), 8.37 (d, <i>J</i> = 8.4 Hz, 1H), 8.00 (s, 2H), 7.91 (d, <i>J</i> = 8.3 Hz, 1H), 2.47 (t, <i>J</i> = 7.5 Hz, 2H), 1.6 (m, 2H), 1.49 (s, 18H), 1.36 (m, 2H), 0.91 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 172.7, 153.1, 152.1, 150.2, 147.8, 142.9, 134.8, 132.9, 120.9, 104.4, 80.2, 36.0, 28.5, 27.6, 22.2, 14.2; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>35</sub>N<sub>5</sub>O<sub>5</sub>Cl [M + H]<sup>+</sup> 520.2248; found, 520.2312.</div></div><div id="sec4_11_37_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Step C: 4-(2,3-Dibutyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>38</b>)</h5><div class="NLM_p">Starting from 0.52 g of <i>tert</i>-butyl <i>N</i>-[6-(<i>tert</i>-butoxycarbonylamino)-4-[6-chloro-5-(pentanoylamino)-2-pyridyl]-2-pyridyl]carbamate (1.0 mmol) and 0.5 mL of butylamine (5.0 mmol) following general procedure II, 0.075 g (22%) of <b>38</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 6.34 (s, 2H), 5.48 (s, 4H), 4.27 (t, <i>J</i> = 7.1 Hz, 2H), 2.91 (t, <i>J</i> = 7.5 Hz, 2H), 1.82 (m, 2H), 1.79 (m, 2H), 1.44 (m, 2H), 1.31 (m, 2H), 0.95 (t, <i>J</i> = 7.3 Hz, 3H), 0.92 (t, <i>J</i> = 7.3 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 157.7, 149.7, 149.3, 148.4, 134.6, 126.6, 115.2, 93.7, 41.8, 31.8, 29.2, 27.1, 22.4, 20.0, 14.3, 14.1; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>28</sub>N<sub>6</sub> [M + H]<sup>+</sup> 339.2219; found, 339.2289.</div></div></div><div id="sec4_11_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 4-(3-<i>tert</i>-Butyl-2-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>39</b>)</h4><div class="NLM_p">Starting from 0.30 g of <b>R2</b> (0.63 mmol) and 0.33 mL of <i>tert</i>-butylamine (0.23 g, 3.2 mmol) following general procedure II, 0.077 g (51%) of <b>39</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.90 (d, <i>J</i> = 8.3 Hz, 1H), 7.53 (d, <i>J</i> = 8.3 Hz, 1H), 6.32 (s, 1H), 5.49 (br s, 4H), 2.77 (s, 3H), 1.92 (s, 9H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 154.5, 149.6, 149.5, 148.7, 134.8, 126.3, 114.7, 93.6, 59.8, 30.3, 20.6; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: Principal peak: 240.1125 [M + H-C<sub>4</sub>H<sub>8</sub>]<sup>+</sup>. Fragment ion formula: C<sub>12</sub>H<sub>12</sub>N<sub>6</sub> no molecular ion was detected due to extensive fragmentation.</div></div><div id="sec4_11_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 4-(3-Cyclopropyl-2-methyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>40</b>)</h4><div class="NLM_p">Starting from 1.50 g of <b>R2</b> (3.14 mmol) and 1.1 mL of cyclopropylamine (0.896 g, 15.7 mmol) following general procedure II, 0.205 g (23%) of <b>40</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.92 (d, <i>J</i> = 8.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.3 Hz, 1H), 6.35 (s, 2H), 5.49 (br s, 4H), 3.36 (m, 1H), 2.64 (s, 3H), 1.26 (m, 2H), 1.20 (m, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 156.9, 149.6, 149.3, 134.4, 126.5, 115.0, 93.7, 24.5, 15.5, 6.9; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub> [M + H]<sup>+</sup> 281.1436; found, 281.1518.</div></div><div id="sec4_11_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 4-(3-Cyclopentyl-2-methyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>41</b>)</h4><div class="NLM_p">Starting from 0.47 g of <b>R1</b> (1.07 mmol) and 0.23 g of 6-chloro-3-cyclopentyl-2-methyl-imidazo[4,5<i>-b</i>]pyridine (0.98 mmol) following general procedure I, 0.106 g (35%) of <b>41</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.93 (d, <i>J</i> = 8.3 Hz, 1H), 7.53 (d, <i>J</i> = 8.3 Hz, 1H), 6.32 (s, 2H), 5.48 (br s, 4H), 4.91 (quint, <i>J</i> = 8.3 Hz, 1H), 2.62 (s, 3H), 2.42 (m, 2H), 2.11 (m, 2H), 2.08 (m, 2H), 1.72 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 154.8, 149.4, 149.1, 148.1, 135.0, 126.5, 114.8, 93.7, 56.2, 30.6, 25.3, 15.4; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub> [M + H]<sup>+</sup> 309.1749; found, 309.1821.</div></div><div id="sec4_11_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 4-[3-(3-Methoxypropyl)-2-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>42</b>)</h4><div class="NLM_p">Starting from 0.239 g of <b>R2</b> (0.50 mmol) and 0.222 g of 3-methoxypropan-1-amine (0.255 mL, 2.5 mmol) following general procedure II, 0.047 g (31%) of <b>42</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.95 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 6.33 (s, 2H), 5.48 (br s, 4H), 4.31 (t, <i>J</i> = 7.0 Hz, 2H), 3.31 (t, <i>J</i> = 6.0 Hz, 2H), 3.22 (s, 3H), 2.59 (s, 3H), 2.07 (m, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 154.8, 149.7, 149.2, 148.4, 134.7, 126.5, 115.2, 93.7, 69.3, 58.3, 39.7, 29.3, 14.5; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 313.1688; found, 313.1761.</div></div><div id="sec4_11_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 4-[3-(2-Cyclohexylethyl)-2-methyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>43</b>)</h4><div class="NLM_p">Starting from 0.30 g of <b>R2</b> (0.63 mmol) and 0.401 g of (2-aminoethyl)-cyclohexane (3.2 mmol) following general procedure II, 0.053 g (24%) of <b>43</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.95 (d, <i>J</i> = 8.2 Hz, 1H), 7.55 (d, <i>J</i> = 8.2 Hz, 1H), 6.34 (s, 2H), 5.47 (br s, 4H), 4.29 (t, <i>J</i> = 7.4 Hz, 2H), 2.59 (s, 3H), 1.83 (d, <i>J</i> = 12.8 Hz, 2H), 1.67 (m, 5H), 1.23 (m, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 159.8, 154.5, 149.6, 149.2, 148.3, 134.6, 126.5, 115.1, 93.7, 40.0, 37.1, 35.2, 33.0, 26.5, 26.1, 14.6; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>27</sub>N<sub>6</sub> [M + H]<sup>+</sup> 351.2219; found, 351.2273.</div></div><div id="sec4_11_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 4-[3-(4-Fluorobenzyl)-2-methyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>44</b>)</h4><div id="sec4_11_43_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Step A: 6-Chloro-<i>N</i>-[(4-fluorophenyl)methyl]-3-nitro-pyridin-2-amine</h5><div class="NLM_p">0.94 g of 4-fluoro-benzylamine (7.5 mmol) was added dropwise to the mixture of 1.0 g of 2,6-dichloro-3-nitro-pyridine (5.39 mmol) and 1.86 g of K<sub>2</sub>CO<sub>3</sub> (13.5 mmol) in 25 mL of dry DCE, and the reaction mixture was stirred at ambient temperature until no further conversion was observed. The reaction mixture was diluted with DCM and washed with water. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography using heptane and EtOAc as the eluent to give 1.10 g (74%) of 6-chloro-<i>N</i>-[(4-fluorophenyl)methyl]-3-nitro-pyridin-2-amine.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 9.2 (s, 1H), 8.4 (d, <i>J</i> = 8.5 Hz, 1H), 7.4 (m, 2H), 7.13 (m, 2H), 6.79 (d, <i>J</i> = 8.5 Hz, 1H), 4.68 (s, 2H), 3.28 (d, <i>J</i> = 9.4 Hz, 3H); HPLC-MS: (M + H)<sup>+</sup>: 282.</div></div><div id="sec4_11_43_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> Step B: 6-Chloro-N2-[(4-fluorophenyl)methyl]pyridine-2,3-diamine</h5><div class="NLM_p last">A mixture of 0.52 g of 6-chloro-<i>N</i>-[(4-fluorophenyl)methyl]-3-nitro-pyridin-2-amine (1.85 mmol) and 0.040 g of Pt/C (0.19 mmol) in 30 mL of MeOH was stirred under 1 bar of hydrogen until no further conversion was observed. The reaction mixture was filtered through <i>Celite</i> and concentrated under reduced pressure to give 0.450 g (97%) of 6-chloro-<i>N</i>2-[(4-fluorophenyl)methyl]pyridine-2,3-diamine, which was used without any further purification. HPLC-MS: (M + H)<sup>+</sup>: 253.</div></div><div id="sec4_11_43_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> Step C: 5-Chloro-3-[(4-fluorophenyl)methyl]-2-methyl-imidazo[4,5-<i>b</i>]pyridine</h5><div class="NLM_p">The mixture of 0.10 g of 6-chloro-<i>N</i>2-[(4-fluorophenyl)methyl]pyridine-2,3-diamine (0.41 mmol) and 0.405 mL of 1 M HCl in Et<sub>2</sub>O (0.41 mmol) in 4 mL of acetic acid was heated in a MW tube at 160 Â°C until no further conversion was observed. After cooling to ambient temperature <i>Celite</i> was added to the reaction mixture, and the volatiles were evaporated under reduced pressure. The solid residue was purified by flash chromatography on silica gel using DCM and MeOH as eluents to give 0.146 g (44%) of 5-chloro-3-[(4-fluorophenyl)methyl]-2-methyl-imidazo[4,5-<i>b</i>]pyridine.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.04 (d, <i>J</i> = 8.2 Hz, 1H), 7.32 (d, <i>J</i> = 8.2 Hz, 1H), 7.25 (m, 2H), 7.18 (m, 2H), 5.45 (s, 2H), 2.51 (s, 3H); HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>12</sub>N<sub>3</sub>FCl [M + H]<sup>+</sup>: 276.0698; found, 276.0697.</div></div><div id="sec4_11_43_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Step D: 4-[3-(4â²-Fluorobenzyl)-2-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>44</b>)</h5><div class="NLM_p">Starting from 0.42 g of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-<i>N</i>2,<i>N</i>6-ditrityl-pyridine-2,6-diamine (0.58 mmol) and 0.14 g of 5-chloro-3-[(4-fluorophenyl)methyl]-2-methylimidazo[4,5-<i>b</i>]pyridine (0.51 mmol) following general procedure I, 0.064 g (36%) of <b>44</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.01 (d, <i>J</i> = 8.3 Hz, 1H), 7.61 (d, <i>J</i> = 8.3 Hz, 1H), 7.34 (m, 2H), 7.19 (m, 2H), 6.36 (s, 2H), 5.52 (s, 2H), 5.49 (s, 4H), 2.52 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 162.0, 159.9, 154.5, 150.0, 149.0, 148.3, 134.6, 133.5, 129.9, 126.9, 116.2, 115.5, 93.6, 44.4, 14.8; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>18</sub>N<sub>6</sub>F [M + H]<sup>+</sup> 348.1499; found, 348.1565.</div></div></div><div id="sec4_11_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 4-{3-[2-(Furan-2-yl)ethyl]-2-methyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl}pyridine-2,6-diamine (<b>45</b>)</h4><div class="NLM_p">Starting from 0.30 g of <b>R2</b> (0.63 mmol) and using 2-(2-furyl)ethanamine as the appropriate amine following general procedure II, 0.025 g (12%) of <b>45</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (dd, <i>J</i> = 2.0, 0.7 Hz, 1H), 6.34 (s, 2H), 6.33 (dd, <i>J</i> = 3.2, 1.9 Hz, 1H), 6.04 (d, <i>J</i> = 3.2 Hz, 1H), 5.49 (br s, 4H), 4.49 (t, <i>J</i> = 6.7 Hz, 2H), 3.20 (t, <i>J</i> = 6.7 Hz, 2H), 2.32 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 154.7, 152.2, 149.8, 149.2, 148.1, 142.6, 134.7, 126.5, 115.3, 111.1, 107.6, 93.7, 41.4, 27.9, 14.0; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>19</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 335.1545; found, 335.1618.</div></div><div id="sec4_11_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 4-[2-Methyl-3-(2-phenoxyethyl)-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>46</b>)</h4><div class="NLM_p">Starting from 0.60 g of <b>R2</b> (1.26 mmol) and using 2-phenoxyethanamine as the appropriate amine following general procedure II, 0.108 g (30%) of <b>46</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.56 (d, <i>J</i> = 8.3 Hz, 1H), 7.25 (t, <i>J</i> = 7.9 Hz, 1H), 6.91 (m, 3H), 6.34 (s, 2H), 5.48 (br s, 4H), 4.66 (t, <i>J</i> = 5.4 Hz, 2H), 4.39 (t, <i>J</i> = 5.4 Hz, 2H), 2.67 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 158.3, 155.4, 149.9, 149.2, 148.2, 134.7, 130.0, 126.7, 121.4, 115.5, 114.8, 93.8, 65.9, 42.0, 14.8; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>21</sub>N<sub>6</sub>O [M + H]<sup>+</sup>: 361.1699; found, 361.1774.</div></div><div id="sec4_11_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 4-[3-(2,2-Difluoroethyl)-2-methyl-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>47</b>)</h4><div class="NLM_p">Starting from 0.50 g of <b>R2</b> (1.05 mmol) and using 2,2-difluoroethanamine as the appropriate amine following general procedure II, 0.090 g (28%) of <b>47</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.01 (d, <i>J</i> = 8.3 Hz, 1H), 7.60 (d, <i>J</i> = 8.3 Hz, 1H), 6.53 (tt, <i>J</i> = 54.6, 3.4 Hz, 1H), 6.34 (s, 2H), 5.49 (s, 4H), 4.78 (td, <i>J</i> = 15.5, 3.3 Hz, 2H), 2.62 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 155.0, 150.2, 149.0, 148.5, 134.5, 126.9, 115.8, 114.3, 93.7, 44.0, 14.6; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>15</sub>N<sub>6</sub>F<sub>2</sub> [M + H]<sup>+</sup> 305.1321; found, 305.1318.</div></div><div id="sec4_11_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 4-[2-Methyl-3-(2,2,2-trifluoroethyl)-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>48</b>)</h4><div class="NLM_p">Starting from 1.50 g of <b>R2</b> (3.14 mmol) and using 2,2,2-trifluoroethylamine as the appropriate amine following general procedure II, 0.318 g (31%) of <b>48</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 8.04 (d, <i>J</i> = 8.3 Hz, 1H), 7.63 (d, <i>J</i> = 8.3 Hz, 1H), 6.34 (s, 2H), 5.51 (br s, 4H), 5.24 (q, <i>J</i> = 9.3 Hz, 2H), 2.64 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.9, 154.9, 150.6, 148.8, 148.2, 134.4, 127.3, 124.4, 116.3, 93.7, 43.0, 14.5; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>14</sub>N<sub>6</sub>F<sub>3</sub> [M + H]<sup>+</sup> 323.1165; found, 323.1238.</div></div><div id="sec4_11_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 4-[2-Methyl-3-(4,4,4-trifluorobutyl)-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl]pyridine-2,6-diamine (<b>49</b>)</h4><div class="NLM_p">Starting from 0.30 g of <b>R2</b> and using 4,4,4-trifluorobutan-1-amine as the appropriate amine following general procedure II, 0.077 g (35%) <b>49</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.56 (d, <i>J</i> = 8.3 Hz, 1H), 6.34 (s, 1H), 5.45 (br s, 4H), 4.35 (t, <i>J</i> = 7.4 Hz, 2H), 2.61 (s, 3H), 2.36 (m, 2H), 2.07 (quint, <i>J</i> = 7.4 Hz, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 154.7, 149.8, 149.2, 148.3, 134.7, 90.7, 127.9, 126.6, 115.4, 41.1, 30.6, 22.3, 14.6; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>18</sub>N<sub>6</sub>F<sub>3</sub> [M + H]<sup>+</sup> 351.1467; found, 351.1533.</div></div><div id="sec4_11_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> 4-[2,3-Dimethyl-benzofuran-5-yl]pyridine-2,6-diamine (<b>50</b>)</h4><div class="NLM_p">Starting from 0.435 g of <b>R1</b> (1.00 mmol) and using 0.337 g of 5-bromo-2,3-dimethyl-benzofuran (1.50 mmol) as the appropriate halide following general procedure I, 0.084 g (33%) of <b>50</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.59 (d, <i>J</i> = 1.7 Hz, 1H), 7.47 (d, <i>J</i> = 8.5 Hz, 1H), 7.36 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 5.95 (s, 2H), 5.44 (br s, 4H), 2.39 (br s, 3H), 2.16 (m, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 153.7, 151.8, 150.8, 134.7, 130.8, 122.2, 116.7, 110.9, 110.2, 94.1, 12.1, 8.0; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>16</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 254.1215; found, 254.1287.</div></div><div id="sec4_11_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 4-{2-Methyl-3-[(2<i>R</i>)-2-phenoxypropyl]-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl}pyridine-2,6-diamine (<b>51</b>) and 4-{2-Methyl-3-[(2<i>S</i>)-2-phenoxypropyl]-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl}pyridine-2,6-diamine (<b>52</b>)</h4><div class="NLM_p">Starting from 1.20 g of <b>R2</b> (2.52 mmol) and using 2-phenoxypropan-1-amine as the appropriate amine following general procedure II, a mixture of <b>52</b> and <b>51</b> was obtained. The enantiomers were separated on a CHIRALCEL OK column using MeOH+0.1% DEA as an eluent to obtain 0.164 g (17%) of <b>51</b> as the first eluting enantiomer and 0.166 g of (18%) <b>52</b> as the enantiomer eluting second.</div><div class="NLM_p"><b>51</b>: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.54 (d, <i>J</i> = 8.3 Hz, 1H), 7.20 (m, 2H), 6.87 (m, 2H), 6.86 (m, 1H), 6.35 (s, 2H), 5.49 (s, 4H), 4.97 (m, 1H), 4.52 (dd, <i>J</i> = 14.4, 7.1 Hz, 1H), 4.48 (dd, <i>J</i> = 14.5, 4.8 Hz, 1H), 2.65 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 157.5, 155.3, 149.9, 149.3, 148.5, 134.5, 130.1, 126.6, 121.3, 115.7, 115.5, 93.9, 72.2, 47.1, 18.2, 15.0; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>23</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 375.1851; found, 375.1924; ee > 99.8%.</div><div class="NLM_p last"><b>52</b>: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.54 (d, <i>J</i> = 8.3 Hz, 1H), 7.20 (m, 2H), 6.87 (m, 2H), 6.86 (m, 1H), 6.35 (s, 2H), 5.49 (s, 4H), 4.97 (m, 1H), 4.52 (dd, <i>J</i> = 14.4, 7.1 Hz, 1H), 4.48 (dd, <i>J</i> = 14.5, 4.8 Hz, 1H), 2.65 (s, 3H), 1.35 (d, <i>J</i> = 6.1 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 159.8, 157.5, 155.3, 149.9, 149.3, 148.5, 134.5, 130.1, 126.6, 121.3, 115.7, 115.5, 93.9, 72.2, 47.1, 18.2, 15.0; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>23</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 375.1850; found, 375.1922; ee > 99.8%.</div></div><div id="sec4_11_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 4-{2-Methyl-3-[2-(pyridin-2-yloxy)ethyl]-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl}pyridine-2,6-diamine (<b>53</b>)</h4><div class="NLM_p">Starting from 0.48 g of <b>R3</b> (1.0 mmol) and using 2-fluoropyridine as the appropriate aryl halide following general procedure III, 0.223 g (61%) of <b>53</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 11.95 (br s, 1H), 8.09 (dm, 1H), 7.95 (d, <i>J</i> = 8.3 Hz, 1H), 7.66 (m, 1H), 7.56 (d, <i>J</i> = 8.3 Hz, 1H), 6.95 (m, 1H), 6.75 (dm, 1H), 6.33 (s, 2H), 5.49 (s, 4H), 4.69 (m, 2H), 4.67 (m, 2H), 2.61 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 163.0, 159.8, 155.2, 149.8, 149.2, 148.3, 147.2, 139.9, 134.7, 126.6, 117.9, 115.4, 111.2, 93.7, 63.7, 41.9, 14.7; HRMS (TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>20</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 362.1651; found, 362.1731.</div></div><div id="sec4_11_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 4-{2-Methyl-3-[(2<i>R</i>)-2-(pyridin-2-yloxy)propyl]-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl}pyridine-2,6-diamine (54) and 4-{2-Methyl-3-[(2<i>S</i>)-2-(pyridin-2-yloxy)propyl]-3<i>H</i>-imidazo[4,5<i>-b</i>]pyridin-5-yl}pyridine-2,6-diamine (<b>55</b>)</h4><div class="NLM_p">Starting from 0.41 g of <b>R4</b> (1.5 mmol) and using 2-fluoropyridine as the appropriate aryl halide following general procedure III, a mixture of <b>54</b> and <b>55</b> was obtained. The enantiomers were separated on CHIRALCEL OK column using 50:50 heptane/EtOH +0.05% DEA as the eluent to give 0.085 g (15%) of <b>55</b> as the first eluting enantiomer, and 0.082 g (15%) of <b>54</b> as the enantiomer eluting second.</div><div class="NLM_p"><b>54:</b><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.97 (dm, 1H), 7.90 (d, <i>J</i> = 8.2 Hz, 1H), 7.61 (m, 1H), 7.53 (d, <i>J</i> = 8.3 Hz, 1H), 6.87 (m, 1H), 6.69 (dm, 1H), 6.36 (s, 2H), 5.65 (m, 1H), 5.50 (br s, 4H), 4.53 (d, <i>J</i> = 5.9 Hz, 2H), 2.65 (s, 3H), 1.39 (d, <i>J</i> = 6.3 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 162.7, 159.8, 155.2, 149.7, 149.2, 148.5, 147.1, 139.8, 134.5, 126.5, 117.6, 115.3, 111.3, 93.7, 69.9, 46.8, 18.3, 14.9; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>22</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 376.1880; found, 376.1867; ee > 99.8%.</div><div class="NLM_p last"><b>55</b>: <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.97 (dm, 1H), 7.90 (d, <i>J</i> = 8.2 Hz, 1H), 7.61 (m, 1H), 7.53 (d, <i>J</i> = 8.3 Hz, 1H), 6.87 (m, 1H), 6.69 (dm, 1H), 6.36 (s, 2H), 5.65 (m, 1H), 5.50 (br, 4H), 4.53 (d, <i>J</i> = 5.9 Hz, 2H), 2.65 (s, 3H), 1.39 (d, <i>J</i> = 6.3 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 162.7, 159.8, 155.2, 149.7, 149.2, 148.5, 147.1, 139.8, 134.5, 126.5, 117.6, 115.3, 111.3, 93.7, 69.9, 46.8, 18.3, 14.9; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>22</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 376.1880; found, 376.1872; ee > 99.8%.</div></div><div id="sec4_11_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 4-(3-{2-[(6-Bromopyridin-2-yl)oxy]ethyl}-2-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>56</b>)</h4><div class="NLM_p">Starting from 0.30 g of <b>R3</b> (0.6 mmol) and using 2-fluoro-6-bromopyridine as the appropriate aryl halide following general procedure III, 0.077 g (18%) of <b>56</b> was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.59(dd, <i>J</i> = 8.3, 7.4 Hz 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 7.17(d, <i>J</i> = 7.4 Hz 1H), 6.78 (d, <i>J</i> = 8.3 Hz, 1H), 6.33 (s, 2H), 5.47 (s, 4H), 4.66 (m, 2H), 4.67 (m, 2H), 2.63s(3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 162.7, 159.8, 155, 1, 149.8, 149.2, 148.3, 142.5, 138.0, 134.6, 126.6, 121.4, 115.4, 110, 1, 64.6, 41.6, 14.7; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>19</sub>N<sub>7</sub>OBr [M + H]<sup>+</sup> 440.0829; found, 440.0823.</div></div><div id="sec4_11_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 4-(3-{2-[(6-Chloropyridin-2-yl)oxy]ethyl}-2-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>57</b>)</h4><div class="NLM_p">Starting from 0.20 g of <b>R3</b> (0.4 mmol) and using 2-fluoro-6-chloropyridine as the appropriate aryl halide following general procedure III, 0.028 g <b>57</b> (17%) was obtained.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.94 (d, <i>J</i> = 8.3 Hz, 1H), 7.69 (dd, <i>J</i> = 7.6, 0.5 Hz, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 7.04 (dd, <i>J</i> = 7.6, 0.5 Hz, 1H), 6.75 (dd, <i>J</i> = 8.3, 0.5 Hz, 1H), 6.33 (s, 2H), 5.47 (s, 4H), 4.67 (m, 4H), 2.63 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 162.8, 159.8, 155.1, 149.8, 149.2, 148.3, 147.4, 142.7, 134.6, 126.6, 117.4, 115.4, 109.9, 93.7, 64.5, 41.8, 14.7; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>19</sub>N<sub>7</sub>ClO [M + H]<sup>+</sup> 396.1334; found, 396.1331.</div></div><div id="sec4_11_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 4-(3-{(2<i>R</i>)-2-[(6-Bromopyridin-2-yl)oxy]propyl}-2-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)pyridine-2,6-diamine (<b>58</b>)</h4><div class="NLM_p">To 0.41 g of <i>tert</i>-butyl <i>N-</i>[6-(<i>tert</i>-butoxycarbonylamino)-4-[3-(2-hydroxypropyl)-2-methyl-imidazo[4,5-<i>b</i>]pyridin-5-yl]-2-pyridyl]carbamate (0.8 mmol) was dissolved in 6 mL of DMF, then 0.098 g of sodium hydride (2.5 mmol) was added portionwise, then the reaction mixture was stirred at room temperature for 15 min followed by the addition of 0.43 g of 2-bromo-6-fluoropyridine (2.5 mmol). The reaction mixture was stirred at 50 Â°C until no further conversion was observed. 50 mL of EtOAc was added then the organic phase was washed with water (3 Ã 25 mL) and brine (1 Ã 25 mL). The organic phase was dried over MgSO<sub>4</sub>. The solvent was removed under reduced pressure to give an intermediate, which was purified by flash column chromatography using dichloromethane and methanolic ammonia as eluents. The obtained solid was dissolved in 2 mL of DCM, 2 mL of trifluoroacetic acid was added, and the mixture was stirred at room temperature until no further conversion was observed. Volatiles were removed under reduced pressure to give 0.17 g of racemic 4-(3-{2-[(6-bromopyridin-2-yl)oxy]propyl}-2-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)pyridine-2,6-diamine as a crude product. The separation of enantiomers by chiral HPLC on an AS-H column using heptane/EtOH (60:40) containing 0.1% Et<sub>2</sub>NH gave 0.083 g (44%) of <b>58</b> as the first eluting enantiomer.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 7.88 (d, <i>J</i> = 8.3 Hz, 1H), 7.52 (d, <i>J</i> = 8.3 Hz, 1H), 7.51 (t, <i>J</i> = 8.0 Hz, 1H), 7.07 (d, <i>J</i> = 7.5 Hz, 1H), 6.69 (d, <i>J</i> = 8.2 Hz, 1H), 6.36 (s, 2H), 5.60 (m, 1H), 5.48 (br s, 4H), 4.52 (d<i>, J</i> = 6.0 Hz, 2H), 2.65 (s, 3H), 1.41 (d, <i>J</i> = 6.3 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ ppm 162.3, 159.8, 155.0, 149.7, 149.2, 148.5, 142.4, 137.8, 134.5, 126.5, 121.0, 115.3, 110.1, 93.8, 70.8, 46.7, 18.2, 14.9; HRMS (IT-TOF, ESI) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>21</sub>BrN<sub>7</sub>lO [M + H]<sup>+</sup> 454.0985; found, 454.0970.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00023" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00023?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00023</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Description of data tables, structural determination details, LC chromatograms, and <sup>1</sup>H NMR spectra of key compounds, (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf">jm1c00023_si_001.pdf (7.28 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_002.csv">jm1c00023_si_002.csv (4.03 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The X-ray structures mentioned in this paper have been deposited in the PDB with the following codes. Dyrk1a: <b>3</b>: 7AJ2, <b>5</b>: 7AJ4, <b>10</b>: 7AJ5, <b>16</b>: 7AJ7; <b>25</b>: 7AJ8, <b>28</b>: 7AJA, <b>32</b>: 7AJM, <b>33</b>: 7AJS; <b>38</b>: 7AJV, <b>46</b>: 7AJW, <b>50</b>: 7AKL; <b>51</b>: 7AJY; <b>53</b>: 7AK2, <b>54</b>: 7AKA, <b>56</b>: 7AKB, <b>58</b>: 7AKE. Dyrk2: <b>50</b>: 7AKF; <b>58</b>: 7AKH. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.1c00023" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andras Kotschy</span> - <span class="hlFld-Affiliation affiliation">Servier
Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7675-3864" title="Orcid link">http://orcid.org/0000-0002-7675-3864</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#32535c564053411c595d4641515a4b72415740445b57401c515d5f"><span class="__cf_email__" data-cfemail="3d5c53594f5c4e135652494e5e55447d4e584f4b54584f135e5250">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Csaba Weber</span> - <span class="hlFld-Affiliation affiliation">Servier
Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melinda Sipos</span> - <span class="hlFld-Affiliation affiliation">Servier
Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Attila Paczal</span> - <span class="hlFld-Affiliation affiliation">Servier
Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Balazs Balint</span> - <span class="hlFld-Affiliation affiliation">Servier
Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</span>;Â 
    <span>Present Address:
                        PÃ¡kÃ¡sz u. 2., H-1031 Budapest, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vilibald Kun</span> - <span class="hlFld-Affiliation affiliation">Servier
Research Institute of Medicinal Chemistry, ZÃ¡hony u. 7., H-1031 Budapest, Hungary</span>;Â 
    <span>Present Address:
                        Ãlmos u 21., H-2461 TÃ¡rnok, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicolas Foloppe</span> - <span class="hlFld-Affiliation affiliation">Vernalis
(R&D) Ltd., Granta
Park, CB21 6GB Cambridge, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pawel Dokurno</span> - <span class="hlFld-Affiliation affiliation">Vernalis
(R&D) Ltd., Granta
Park, CB21 6GB Cambridge, U.K.</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7332-8889" title="Orcid link">http://orcid.org/0000-0002-7332-8889</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew J. Massey</span> - <span class="hlFld-Affiliation affiliation">Vernalis
(R&D) Ltd., Granta
Park, CB21 6GB Cambridge, U.K.</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0276-2573" title="Orcid link">http://orcid.org/0000-0002-0276-2573</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Lee Walmsley</span> - <span class="hlFld-Affiliation affiliation">Vernalis
(R&D) Ltd., Granta
Park, CB21 6GB Cambridge, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roderick E. Hubbard</span> - <span class="hlFld-Affiliation affiliation">Vernalis
(R&D) Ltd., Granta
Park, CB21 6GB Cambridge, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Murray</span> - <span class="hlFld-Affiliation affiliation">Vernalis
(R&D) Ltd., Granta
Park, CB21 6GB Cambridge, U.K.</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1007-8218" title="Orcid link">http://orcid.org/0000-0003-1007-8218</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Benwell</span> - <span class="hlFld-Affiliation affiliation">Vernalis
(R&D) Ltd., Granta
Park, CB21 6GB Cambridge, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Edmonds</span> - <span class="hlFld-Affiliation affiliation">Institut
de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Didier Demarles</span> - <span class="hlFld-Affiliation affiliation">Technologie
Servier, 27 Rue EugÃ¨ne
Vignat, 45000 Orleans, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alain Bruno</span> - <span class="hlFld-Affiliation affiliation">Institut
de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mike Burbridge</span> - <span class="hlFld-Affiliation affiliation">Institut
de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francisco Cruzalegui</span> - <span class="hlFld-Affiliation affiliation">Institut
de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</span>;Â 
    <span>Present Address:
                        Evotec (France) SAS, 195 Route dâEspagne, 31036 Toulouse Cedex, France</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all the authors. All the authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i123">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank co-workers at the Analytical Division of the Servier Research Institute of Medicinal Chemistry for providing detailed chemical analysis of the compounds.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">DYRK</td><td class="NLM_def"><p class="first last">dual specificity tyrosine-regulated kinase</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein databank</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved fluorescence energy transfer</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">CDK9</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 9</p></td></tr><tr><td class="NLM_term">CLK</td><td class="NLM_def"><p class="first last">CDC-like kinase</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go related gene</p></td></tr><tr><td class="NLM_term">HIPK2</td><td class="NLM_def"><p class="first last">Homeodomain-interacting protein kinase 2</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immunodeficiency</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 20 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eirmbter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejedor, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joost, H.-G.</span></span> <span> </span><span class="NLM_article-title">Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">25893</span>â <span class="NLM_lpage">25902</span>, <span class="refDoi">Â DOI: 10.1074/jbc.273.40.25893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1074%2Fjbc.273.40.25893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=9748265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADyaK1cXms1egt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=25893-25902&author=W.+Beckerauthor=Y.+Weberauthor=K.+Wetzelauthor=K.+Eirmbterauthor=F.+J.+Tejedorauthor=H.-G.+Joost&title=Sequence+characteristics%2C+subcellular+localization%2C+and+substrate+specificity+of+DYRK-related+kinases%2C+a+novel+family+of+dual+specificity+protein+kinases&doi=10.1074%2Fjbc.273.40.25893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases</span></div><div class="casAuthors">Becker, Walter; Weber, Yvonne; Wetzel, Kristiane; Eirmbter, Klaus; Tejedor, Francisco J.; Joost, Hans-Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">25893-25902</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DYRK1 is a dual specificity protein kinase presumably involved in brain development.  The kinase belongs to a new family of protein kinases comprising at least seven mammalian isoforms (DYRK1A, DYRK1B, DYRK1C, DYRK2, DYRK3, DYRK4A, and DYRK4B), the yeast homolog Yak1p, and the Drosophila kinase minibrain (MNB).  In rat tissues, DYRK1A is expressed ubiquitously, whereas transcripts for DYRK1B, DYRK2, DYRK3, and DYRK4 were detected predominantly in testes of adult but not prepuberal rats.  By fluorescence microscopy and subcellular fractionation, a green fluorescent protein (GFP) fusion protein of DYRK1A was found to accumulate in the nucleus of transfected COS-7 and HEK293 cells, whereas GFP-DYRK2 was predominantly detected in the cytoplasm.  DYRK1A exhibited a punctate pattern of GFP fluorescence inside the nucleus and was co-purified with the nuclear matrix.  Anal. of GFP-DYRK1A deletion constructs showed that the nuclear localization of DYRK1A was mediated by its nuclear targeting signal (amino acids 105-139) but that its characteristics subnuclear distribution depended on addnl. N-terminal elements (amino acids 1-104).  When expressed in Escherichia coli, DYRK1A, DYRK2, DYRK3, MNB, and Yak1p catalyzed their autophosphorylation on tyrosine residues.  The kinases differed in their substrate specificity in that DYRK2 and DYRK3, but not DYRK1A and MNB, catalyzed phosphorylation of histone H2B.  The heterogeneity of their subcellular localization and substrate specificity suggests that the kinases are involved in different cellular functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Q1vPoFEv4LVg90H21EOLACvtfcHk0lgp2NZgwrj48w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1egt7g%253D&md5=4b8029c26149c1ecb9d65baf50dd978d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.40.25893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.40.25893%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DW.%26aulast%3DWeber%26aufirst%3DY.%26aulast%3DWetzel%26aufirst%3DK.%26aulast%3DEirmbter%26aufirst%3DK.%26aulast%3DTejedor%26aufirst%3DF.%2BJ.%26aulast%3DJoost%26aufirst%3DH.-G.%26atitle%3DSequence%2520characteristics%252C%2520subcellular%2520localization%252C%2520and%2520substrate%2520specificity%2520of%2520DYRK-related%2520kinases%252C%2520a%2520novel%2520family%2520of%2520dual%2520specificity%2520protein%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D25893%26epage%3D25902%26doi%3D10.1074%2Fjbc.273.40.25893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E. M. C.</span></span> <span> </span><span class="NLM_article-title">Down syndrome--recent progress and future prospects</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">R75</span>â <span class="NLM_lpage">R83</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddp010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1093%2Fhmg%2Fddp010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=19297404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSnt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=R75-R83&author=F.+K.+Wisemanauthor=K.+A.+Alfordauthor=V.+L.+J.+Tybulewiczauthor=E.+M.+C.+Fisher&title=Down+syndrome%2D%2Drecent+progress+and+future+prospects&doi=10.1093%2Fhmg%2Fddp010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Down syndrome-recent progress and future prospects</span></div><div class="casAuthors">Wiseman, Frances K.; Alford, Kate A.; Tybulewicz, Victor L. J.; Fisher, Elizabeth M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">Rev. Iss. 1</span>),
    <span class="NLM_cas:pages">R75-R83</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Down syndrome (DS) is caused by trisomy of chromosome 21 (Hsa21) and is assocd. with a no. of deleterious phenotypes, including learning disability, heart defects, early-onset Alzheimer's disease and childhood leukemia.  Individuals with DS are affected by these phenotypes to a variable extent; understanding the cause of this variation is a key challenge.  Here, we review recent research progress in DS, both in patients and relevant animal models.  In particular, we highlight exciting advances in therapy to improve cognitive function in people with DS and the significant developments in understanding the gene content of Hsa21.  Moreover, we discuss future research directions in light of new technologies.  In particular, the use of chromosome engineering to generate new trisomic mouse models and large-scale studies of genotype-phenotype relationships in patients are likely to significantly contribute to the future understanding of DS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgWPB7T5JFA7Vg90H21EOLACvtfcHk0lgp2NZgwrj48w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSnt7w%253D&md5=8a17f1eb33786dda74d661dbc97b4844</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddp010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddp010%26sid%3Dliteratum%253Aachs%26aulast%3DWiseman%26aufirst%3DF.%2BK.%26aulast%3DAlford%26aufirst%3DK.%2BA.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26aulast%3DFisher%26aufirst%3DE.%2BM.%2BC.%26atitle%3DDown%2520syndrome--recent%2520progress%2520and%2520future%2520prospects%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2009%26volume%3D18%26spage%3DR75%26epage%3DR83%26doi%3D10.1093%2Fhmg%2Fddp010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mariano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralinaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, M.</span></span> <span> </span><span class="NLM_article-title">First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimerâs Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1198</span>â <span class="NLM_lpage">1202</span>, <span class="refDoi">Â DOI: 10.1021/cn5001815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5001815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1198-1202&author=M.+Marianoauthor=C.+Schmittauthor=P.+Miralinaghiauthor=M.+Cattoauthor=R.+W.+Hartmannauthor=A.+Carottiauthor=M.+Engel&title=First+Selective+Dual+Inhibitors+of+Tau+Phosphorylation+and+Beta-Amyloid+Aggregation%2C+Two+Major+Pathogenic+Mechanisms+in+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fcn5001815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer's Disease</span></div><div class="casAuthors">Mariano, Marica; Schmitt, Christian; Miralinaghi, Parisa; Catto, Marco; Hartmann, Rolf W.; Carotti, Angelo; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1198-1202</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In Alzheimer's disease (AD), multiple factors account for the accumulation of neurocellular changes, which may begin several years before symptoms appear.  The most important pathogenic brain changes that are contributing to the development of AD are the formation of the cytotoxic Î²-amyloid aggregates and of the neurofibrillary tangles, which originate from amyloid-Î² peptides and hyperphosphorylated tau protein, resp.  New therapeutic agents that target both major pathogenic mechanisms may be particularly efficient.  In this study, the authors introduce bis(hydroxyphenyl)-substituted thiophenes I [R1 = 3-Me, 3-MeO, 3-Me-4-MeO, 3-Et-4-MeO; R2 = 3-MeO, 4-MeO, 3-Me-4-MeO, 3-Et-4-MeO] as a novel class of selective, dual inhibitors of the tau kinase Dyrk1A and of the amyloid-Î² aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgPu3VSQ64rVg90H21EOLACvtfcHk0liWV3StOKEiBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K&md5=31754e003032609beeb9568418bc30d7</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fcn5001815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5001815%26sid%3Dliteratum%253Aachs%26aulast%3DMariano%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DMiralinaghi%26aufirst%3DP.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3DFirst%2520Selective%2520Dual%2520Inhibitors%2520of%2520Tau%2520Phosphorylation%2520and%2520Beta-Amyloid%2520Aggregation%252C%2520Two%2520Major%2520Pathogenic%2520Mechanisms%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D1198%26epage%3D1202%26doi%3D10.1021%2Fcn5001815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Coutadeur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyamine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delalonde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblond, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foucourt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casagrande, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taverne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pando, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ©sirÃ©, L.</span></span> <span> </span><span class="NLM_article-title">A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimerâs disease: effect on Tau and amyloid pathologies in vitro</span>. <i>Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">440</span>â <span class="NLM_lpage">451</span>, <span class="refDoi">Â DOI: 10.1111/jnc.13018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1111%2Fjnc.13018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=25556849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlKitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2015&pages=440-451&author=S.+Coutadeurauthor=H.+Benyamineauthor=L.+Delalondeauthor=C.+de+Oliveiraauthor=B.+Leblondauthor=A.+Foucourtauthor=T.+Bessonauthor=A.-S.+Casagrandeauthor=T.+Taverneauthor=A.+Girardauthor=M.+P.+Pandoauthor=L.+D%C3%A9sir%C3%A9&title=A+novel+DYRK1A+%28dual+specificity+tyrosine+phosphorylation-regulated+kinase+1A%29+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+effect+on+Tau+and+amyloid+pathologies+in+vitro&doi=10.1111%2Fjnc.13018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro</span></div><div class="casAuthors">Coutadeur, Severine; Benyamine, Helene; Delalonde, Laurence; de Oliveira, Catherine; Leblond, Bertrand; Foucourt, Alicia; Besson, Thierry; Casagrande, Anne-Sophie; Taverne, Thierry; Girard, Angelique; Pando, Matthew P.; Desire, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">440-451</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) gene is located within the Down Syndrome (DS) crit. region on chromosome 21 and is implicated in the generation of Tau and amyloid pathologies that are assocd. with the early onset Alzheimer's Disease (AD) obsd. in DS.  DYRK1A is also found assocd. with neurofibrillary tangles in sporadic AD and phosphorylates key AD players (Tau, amyloid precursor, protein, etc).  Thus, DYRK1A may be an important therapeutic target to modify the course of Tau and amyloid beta (AÎ²) pathologies.  Here, we describe EHT 5372 (Me 9-(2,4-dichlorophenylamino) thiazolo[5,4-f]quinazoline-2-carbimidate), a novel, highly potent (IC50 = 0.22 nM) DYRK1A inhibitor with a high degree of selectivity over 339 kinases.  Models in which inhibition of DYRK1A by siRNA reduced and DYRK1A over-expression induced Tau phosphorylation or AÎ² prodn. were used.  EHT 5372 inhibits DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites in biochem. and cellular assays.  EHT 5372 also normalizes both AÎ²-induced Tau phosphorylation and DYRK1A-stimulated AÎ² prodn.  DYRK1A is thus as a key element of AÎ²-mediated Tau hyperphosphorylation, which links Tau and amyloid pathologies.  EHT 5372 and other compds. in its class warrant in vivo investigation as a novel, high-potential therapy for AD and other Tau opathies.  Inhibition of the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is a new high-potential therapeutic approach for Alzheimer disease.  Here we describe EHT 5372, a novel potent and selective DYRK1A inhibitor.  EHT 5372 inhibits DYRK1A-induced Tau phosphorylation, AÎ² prodn. and AÎ² effects on phospho-Tau, including Tau aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVswt1MX4I7Vg90H21EOLACvtfcHk0liWV3StOKEiBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlKitbY%253D&md5=5953fc5e56b7ea3c86ea414bd3de7863</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13018%26sid%3Dliteratum%253Aachs%26aulast%3DCoutadeur%26aufirst%3DS.%26aulast%3DBenyamine%26aufirst%3DH.%26aulast%3DDelalonde%26aufirst%3DL.%26aulast%3Dde%2BOliveira%26aufirst%3DC.%26aulast%3DLeblond%26aufirst%3DB.%26aulast%3DFoucourt%26aufirst%3DA.%26aulast%3DBesson%26aufirst%3DT.%26aulast%3DCasagrande%26aufirst%3DA.-S.%26aulast%3DTaverne%26aufirst%3DT.%26aulast%3DGirard%26aufirst%3DA.%26aulast%3DPando%26aufirst%3DM.%2BP.%26aulast%3DD%25C3%25A9sir%25C3%25A9%26aufirst%3DL.%26atitle%3DA%2520novel%2520DYRK1A%2520%2528dual%2520specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25201A%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520effect%2520on%2520Tau%2520and%2520amyloid%2520pathologies%2520in%2520vitro%26jtitle%3DNeurochem.%26date%3D2015%26volume%3D133%26spage%3D440%26epage%3D451%26doi%3D10.1111%2Fjnc.13018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, Y.-W.</span></span> <span> </span><span class="NLM_article-title">The role of DYRK1A in neurodegenerative diseases</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1111/j.1742-4658.2010.07955.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1111%2Fj.1742-4658.2010.07955.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=21156028" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=236-245&author=J.+Weigelauthor=C.-X.+Gongauthor=Y.-W.+Hwang&title=The+role+of+DYRK1A+in+neurodegenerative+diseases&doi=10.1111%2Fj.1742-4658.2010.07955.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07955.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07955.x%26sid%3Dliteratum%253Aachs%26aulast%3DWeigel%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DC.-X.%26aulast%3DHwang%26aufirst%3DY.-W.%26atitle%3DThe%2520role%2520of%2520DYRK1A%2520in%2520neurodegenerative%2520diseases%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D236%26epage%3D245%26doi%3D10.1111%2Fj.1742-4658.2010.07955.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rachdi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariyawasam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AÃ¯ello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabar, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharfmann, R.</span></span> <span> </span><span class="NLM_article-title">Dyrk1A induces pancreatic Î² cell mass expansion and improves glucose tolerance</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2221</span>â <span class="NLM_lpage">2229</span>, <span class="refDoi">Â DOI: 10.4161/cc.29250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.4161%2Fcc.29250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=24870561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2221-2229&author=L.+Rachdiauthor=D.+Kariyawasamauthor=V.+A%C3%AFelloauthor=Y.+Heraultauthor=N.+Janelauthor=J.-M.+Delabarauthor=M.+Polakauthor=R.+Scharfmann&title=Dyrk1A+induces+pancreatic+%CE%B2+cell+mass+expansion+and+improves+glucose+tolerance&doi=10.4161%2Fcc.29250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Dyrk1A induces pancreatic Î² cell mass expansion and improves glucose tolerance</span></div><div class="casAuthors">Rachdi, Latif; Kariyawasam, Dulanjalee; Aiello, Virginie; Herault, Yann; Janel, Nathalie; Delabar, Jean-Maurice; Polak, Michel; Scharfmann, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2221-2229</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Type 2 diabetes is caused by a limited capacity of insulin-producing pancreatic Î² cells to increase their mass and function in response to insulin resistance.  The signaling pathways that pos. regulate functional Î² cell mass have not been fully elucidated.  DYRK1A (also called minibrain/MNB) is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family.  A significant amt. of data implicates DYRK1A in brain growth and Down syndrome, and recent data indicate that Dyrk1A haploinsufficient mice have a low functional Î² cell mass.  Here we ask whether Dyrk1A upregulation could be a way to increase functional Î² cell mass.  We used mice overexpressing Dyrk1A under the control of its own regulatory sequences (mBACTgDyrk1A).  These mice exhibit decreased glucose levels and hyperinsulinemia in the fasting state.  Improved glucose tolerance is obsd. in these mice as early as 4 wk of age.  Upregulation of Dyrk1A in Î² cells induces expansion of Î² cell mass through increased proliferation and cell size.  Importantly, mBACTgDyrk1A mice are protected against high-fat-diet-induced Î² cell failure through increase in Î² cell mass and insulin sensitivity.  These studies show the crucial role of the DYRK1A pathway in the regulation of Î² cell mass and carbohydrate metab. in vivo.  Activating the DYRK1A pathway could thus represent an innovative way to increase functional Î² cell mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre5nXGBuindrVg90H21EOLACvtfcHk0li8h1K9eA73yQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzP&md5=92dc7241ee0f258a91351b6bffd941d8</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.4161%2Fcc.29250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29250%26sid%3Dliteratum%253Aachs%26aulast%3DRachdi%26aufirst%3DL.%26aulast%3DKariyawasam%26aufirst%3DD.%26aulast%3DA%25C3%25AFello%26aufirst%3DV.%26aulast%3DHerault%26aufirst%3DY.%26aulast%3DJanel%26aufirst%3DN.%26aulast%3DDelabar%26aufirst%3DJ.-M.%26aulast%3DPolak%26aufirst%3DM.%26aulast%3DScharfmann%26aufirst%3DR.%26atitle%3DDyrk1A%2520induces%2520pancreatic%2520%25CE%25B2%2520cell%2520mass%2520expansion%2520and%2520improves%2520glucose%2520tolerance%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2221%26epage%3D2229%26doi%3D10.4161%2Fcc.29250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swafford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursalaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hering, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DYRK1A and GSK3B induces human Î²-cell proliferation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8372</span>, <span class="refDoi">Â DOI: 10.1038/ncomms9372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1038%2Fncomms9372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=26496802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8372&author=W.+Shenauthor=B.+Taylorauthor=Q.+Jinauthor=V.+Nguyen-Tranauthor=S.+Meeusenauthor=Y.-Q.+Zhangauthor=A.+Kamireddyauthor=A.+Swaffordauthor=A.+F.+Powersauthor=J.+Walkerauthor=J.+Lambauthor=B.+Bursalayaauthor=M.+DiDonatoauthor=G.+Harbauthor=M.+Qiuauthor=C.+M.+Filippiauthor=L.+Deatonauthor=C.+N.+Turkauthor=W.+L.+Suarez-Pinzonauthor=Y.+Liuauthor=X.+Haoauthor=T.+Moauthor=S.+Yanauthor=J.+Liauthor=A.+E.+Hermanauthor=B.+J.+Heringauthor=T.+Wuauthor=H.+M.+Seidelauthor=P.+McNamaraauthor=R.+Glynneauthor=B.+Laffitte&title=Inhibition+of+DYRK1A+and+GSK3B+induces+human+%CE%B2-cell+proliferation&doi=10.1038%2Fncomms9372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DYRK1A and GSK3B induces human Î²-cell proliferation</span></div><div class="casAuthors">Shen, Weijun; Taylor, Brandon; Jin, Qihui; Nguyen-Tran, Van; Meeusen, Shelly; Zhang, You-Qing; Kamireddy, Anwesh; Swafford, Austin; Powers, Andrew F.; Walker, John; Lamb, John; Bursalaya, Badry; DiDonato, Michael; Harb, George; Qiu, Minhua; Filippi, Christophe M.; Deaton, Lisa; Turk, Carolina N.; Suarez-Pinzon, Wilma L.; Liu, Yahu; Hao, Xueshi; Mo, Tingting; Yan, Shanshan; Li, Jing; Herman, Ann E.; Hering, Bernhard J.; Wu, Tom; Seidel, H. Martin; McNamara, Peter; Glynne, Richard; Laffitte, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8372</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insufficient pancreatic Î²-cell mass or function results in diabetes mellitus.  While significant progress has been made in regulating insulin secretion from Î²-cells in diabetic patients, no pharmacol. agents have been described that increase Î²-cell replication in humans.  Here we report aminopyrazine compds. that stimulate robust Î²-cell proliferation in adult primary islets, most likely as a result of combined inhibition of DYRK1A and GSK3B.  Aminopyrazine-treated human islets retain functionality in vitro and after transplantation into diabetic mice.  Oral dosing of these compds. in diabetic mice induces Î²-cell proliferation, increases Î²-cell mass and insulin content, and improves glycemic control.  Biochem., genetic and cell biol. data point to Dyrk1a as the key mol. target.  This study supports the feasibility of treating diabetes with an oral therapy to restore Î²-cell mass, and highlights a tractable pathway for future drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVHzP-VkH5nrVg90H21EOLACvtfcHk0li8h1K9eA73yQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK&md5=5ef960af3bfd2795b9fdce52876e5d59</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1038%2Fncomms9372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9372%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DSwafford%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DBursalaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DFilippi%26aufirst%3DC.%2BM.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DTurk%26aufirst%3DC.%2BN.%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHerman%26aufirst%3DA.%2BE.%26aulast%3DHering%26aufirst%3DB.%2BJ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DLaffitte%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520DYRK1A%2520and%2520GSK3B%2520induces%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8372%26doi%3D10.1038%2Fncomms9372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Perez, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenfeld, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivendran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-OcaÃ±a, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">388</span>, <span class="refDoi">Â DOI: 10.1038/nm.3820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1038%2Fnm.3820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=25751815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=383-388&author=P.+Wangauthor=J.-C.+Alvarez-Perezauthor=D.+P.+Felsenfeldauthor=H.+Liuauthor=S.+Sivendranauthor=A.+Benderauthor=A.+Kumarauthor=R.+Sanchezauthor=D.+K.+Scottauthor=A.+Garcia-Oca%C3%B1aauthor=A.+F.+Stewart&title=A+high-throughput+chemical+screen+reveals+that+harmine-mediated+inhibition+of+DYRK1A+increases+human+pancreatic+beta+cell+replication&doi=10.1038%2Fnm.3820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication</span></div><div class="casAuthors">Wang, Peng; Alvarez-Perez, Juan-Carlos; Felsenfeld, Dan P.; Liu, Hongtao; Sivendran, Sharmila; Bender, Aaron; Kumar, Anil; Sanchez, Roberto; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Types 1 and 2 diabetes affect some 380 million people worldwide.  Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells.  Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (â¼2%) engaged in the cell cycle in the first year of life.  In embryonic life and after early childhood, beta cell replication is barely detectable.  Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts.  Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo.  Here, using a high-throughput small-mol. screen (HTS), we find that analogs of the small mol. harmine function as a new class of human beta cell mitogenic compds.  We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation.  Using three different mouse and human islet in vivo-based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control.  These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy.  Enhancing the potency and beta cell specificity of these compds. are important future challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp11xY4tql3VbVg90H21EOLACvtfcHk0li26dwLvPgksQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D&md5=32a02c393defd14b8922ac9efff63389</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fnm.3820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3820%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DAlvarez-Perez%26aufirst%3DJ.-C.%26aulast%3DFelsenfeld%26aufirst%3DD.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSivendran%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Oca%25C3%25B1a%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DA%2520high-throughput%2520chemical%2520screen%2520reveals%2520that%2520harmine-mediated%2520inhibition%2520of%2520DYRK1A%2520increases%2520human%2520pancreatic%2520beta%2520cell%2520replication%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D383%26epage%3D388%26doi%3D10.1038%2Fnm.3820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez-MartÃ­nez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-GÃ³mez, P.</span></span> <span> </span><span class="NLM_article-title">DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis</span>. <i>Mol. Cell. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e970048</span> <span class="refDoi">Â DOI: 10.4161/23723548.2014.970048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.4161%2F23723548.2014.970048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=27308401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWqtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&author=P.+Fern%C3%A1ndez-Mart%C3%ADnezauthor=C.+Zahoneroauthor=P.+S%C3%A1nchez-G%C3%B3mez&title=DYRK1A%3A+the+double-edged+kinase+as+a+protagonist+in+cell+growth+and+tumorigenesis&doi=10.4161%2F23723548.2014.970048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis</span></div><div class="casAuthors">Fernandez-Martinez, P.; Zahonero, C.; Sanchez-Gomez, P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e970048/1-e970048/11</span>CODEN:
                <span class="NLM_cas:coden">MCOOCO</span>;
        ISSN:<span class="NLM_cas:issn">2372-3556</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">DYRK1A (dual-specificity tyrosine-regulated kinase 1A) is a kinase with multiple implications for embryonic development, esp. in the nervous system where it regulates the balance between proliferation and differentiation of neural progenitors.  The DYRK1A gene is located in the Down syndrome crit. region and may play a significant role in the developmental brain defects, early neurodegeneration, and cancer susceptibility of individuals with this syndrome.  DYRK1A is also expressed in adults, where it might participate in the regulation of cell cycle, survival, and tumorigenesis, thus representing a potential therapeutic target for certain types of cancer.  However, the final readout of DYRK1A overexpression or inhibition depends strongly on the cellular context, as it has both tumor suppressor and oncogenic activities.  Here, we will discuss the functions and substrates of DYRK1A assocd. with the control of cell growth and tumorigenesis with a focus on the potential use of DYRK1A inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1OUDGl-nB87Vg90H21EOLACvtfcHk0li26dwLvPgksQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWqtr0%253D&md5=27153f30af11f2572ba271ee09dd9939</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.4161%2F23723548.2014.970048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F23723548.2014.970048%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez-Mart%25C3%25ADnez%26aufirst%3DP.%26aulast%3DZahonero%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez-G%25C3%25B3mez%26aufirst%3DP.%26atitle%3DDYRK1A%253A%2520the%2520double-edged%2520kinase%2520as%2520a%2520protagonist%2520in%2520cell%2520growth%2520and%2520tumorigenesis%26jtitle%3DMol.%2520Cell.%2520Oncol.%26date%3D2015%26volume%3D2%26doi%3D10.4161%2F23723548.2014.970048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrasne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamoral-Theys, D.</span></span> <span> </span><span class="NLM_article-title">DYRK1A kinase inhibitors with emphasis on cancer</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1315</span>â <span class="NLM_lpage">1329</span>, <span class="refDoi">Â DOI: 10.2174/138955712804586639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.2174%2F138955712804586639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=23016545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1315-1329&author=A.+Ionescuauthor=F.+Dufrasneauthor=M.+Gelbckeauthor=I.+Jabinauthor=R.+Kissauthor=D.+Lamoral-Theys&title=DYRK1A+kinase+inhibitors+with+emphasis+on+cancer&doi=10.2174%2F138955712804586639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A kinase inhibitors with emphasis on cancer</span></div><div class="casAuthors">Ionescu, A.; Dufrasne, F.; Gelbcke, M.; Jabin, I.; Kiss, R.; Lamoral-Theys, D.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1315-1329</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Various types of cancers (including gliomas, melanomas, and esophageal, pancreas and non-small-cell lung cancers) display intrinsic resistance to pro-apoptotic stimuli, such as conventional chemotherapy and radiotherapy, and/or the activation of a multidrug resistance phenotype, which are major barriers to effective treatment and lead to poor patient prognosis.  The DYRK1A kinase is directly implicated in the resistance of cancer cells to pro-apoptotic stimuli and drives several pathways that enhance proliferation, migration, and the redn. of cell death, leading to very aggressive biol. behavior in cancer cell populations.  The DYRK1A kinase is also implicated in neurol. diseases and in neoangiogenic processes.  Thus, the DYRK1A kinase is of great interest for both cancer and neuroscience research.  During the last decade, numerous compds. that inhibit DYRK1A have been synthesized.  The present review discusses the available mols. known to interfere with DYRK1A activity and the implications of DYRK1A in cancer and other diseases and serves as a rational anal. for researchers who aim to improve the anti-DYRK1A activity of currently available compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBxH4Qznig8rVg90H21EOLACvtfcHk0li26dwLvPgksQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jI&md5=9acac0cacdc9fbfd558d6199ff4e3a96</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2174%2F138955712804586639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955712804586639%26sid%3Dliteratum%253Aachs%26aulast%3DIonescu%26aufirst%3DA.%26aulast%3DDufrasne%26aufirst%3DF.%26aulast%3DGelbcke%26aufirst%3DM.%26aulast%3DJabin%26aufirst%3DI.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DLamoral-Theys%26aufirst%3DD.%26atitle%3DDYRK1A%2520kinase%2520inhibitors%2520with%2520emphasis%2520on%2520cancer%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D1315%26epage%3D1329%26doi%3D10.2174%2F138955712804586639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plater, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLauchlan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klevernic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The selectivity of protein kinase inhibitors: a further update</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1042/bj20070797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1042%2FBJ20070797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=17850214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=297-315&author=J.+Bainauthor=L.+Platerauthor=M.+Elliottauthor=N.+Shpiroauthor=C.+J.+Hastieauthor=H.+McLauchlanauthor=I.+Klevernicauthor=J.+S.+C.+Arthurauthor=D.+R.+Alessiauthor=P.+Cohen&title=The+selectivity+of+protein+kinase+inhibitors%3A+a+further+update&doi=10.1042%2Fbj20070797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of protein kinase inhibitors: a further update</span></div><div class="casAuthors">Bain, Jenny; Plater, Lorna; Elliott, Matt; Shpiro, Natalia; Hastie, C. James; McLauchlan, Hilary; Klevernic, Iva; Arthur, J. Simon C.; Alessi, Dario R.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-315</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 65 compds. reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases.  On the basis of this information, the effects of compds. that we have studied in cells and other data in the literature, we recommend the use of the following small-mol. inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiol. roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)-raptor (regulatory assocd. protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor.  We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro.  The results have further emphasized the need for considerable caution in using small-mol. inhibitors of protein kinases to assess the physiol. roles of these enzymes.  Despite being used widely, many of the compds. that we analyzed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQPaieWftdVrVg90H21EOLACvtfcHk0ljogEInSsZYbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE&md5=e2334e35897dd1b9770bbcca8f82bb9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2FBJ20070797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070797%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DPlater%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DShpiro%26aufirst%3DN.%26aulast%3DHastie%26aufirst%3DC.%2BJ.%26aulast%3DMcLauchlan%26aufirst%3DH.%26aulast%3DKlevernic%26aufirst%3DI.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%253A%2520a%2520further%2520update%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D297%26epage%3D315%26doi%3D10.1042%2Fbj20070797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miralles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre-Coll, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moranta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensio, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">High-affinity binding of Î²-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>518</i></span>,  <span class="NLM_fpage">234</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2005.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1016%2Fj.ejphar.2005.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=16061219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVCksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2005&pages=234-242&author=A.+Mirallesauthor=S.+Estebanauthor=A.+Sastre-Collauthor=D.+Morantaauthor=V.+J.+Asensioauthor=J.+A.+Garc%C3%ADa-Sevilla&title=High-affinity+binding+of+%CE%B2-carbolines+to+imidazoline+I2B+receptors+and+MAO-A+in+rat+tissues%3A+Norharman+blocks+the+effect+of+morphine+withdrawal+on+DOPA%2Fnoradrenaline+synthesis+in+the+brain&doi=10.1016%2Fj.ejphar.2005.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity binding of Î²-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain</span></div><div class="casAuthors">Miralles, Antonio; Esteban, Susana; Sastre-Coll, Antonio; Moranta, David; Asensio, Victor Jose; Garcia-Sevilla, Jesus Andres</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">234-242</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study was designed to det. the affinity and binding profile of Î²-carbolines for imidazoline I2 receptors and catalytic sites of monoamine oxidase (MAO)-A/B in rat brain and liver.  Another objective was to assess the in vivo effects of norharman (Î²-carboline) and LSL 60101 (I2 ligand) on brain 3,4-dihydroxyphenylalanine (DOPA) synthesis in morphine-dependent rats.  Competition expts. against [3H]2-BFI revealed that Î²-carbolines recognize the high- and low-affinity components of the brain imidazoline I2 receptor with the rank order of potency (KiH in nM): noreleagnine (12) > norharman (20) > harmalol (82) > harmaline (177) Â» harmine (630) > harman (700) Â» FG-7142 (>100,000).  In liver, this rank was different: harmine (51) > harmaline (103) = noreleagnine (103) Â» harmalol (1290) > harman (2000) Â» norharman (12,382) Â» FG-7142 (> 100,000).  In brain and liver, competition curves for Î²-carbolines against [3H]Ro41-1049 (MAO-A) and [3H]Ro19-6327 (MAO-B) were monophasic and resulted in different drug potencies for the two MAO isoenzymes (higher affinities for MAO-A) and in similar pharmacol. profiles in both tissues.  In morphine-dependent rats, naloxone (2 mg/kg, 2 h)-pptd. withdrawal increased the synthesis of DOPA in the cerebral cortex and hippocampus (50%).  Pretreatment with norharman (20 mg/kg) or LSL 60101 (20 mg/kg) (30 min before naloxone) fully prevented the stimulatory effect of opiate withdrawal on DOPA synthesis.  Norharman and LSL 60101 also attenuated the severity of the withdrawal syndrome.  The results indicate that Î²-carbolines bind with high affinity to imidazoline I2B receptors, and similarly to I2 ligands (LSL 60101) can block the behavioral and biochem. effects of opiate withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCvzFB8nFMG7Vg90H21EOLACvtfcHk0ljogEInSsZYbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVCksbg%253D&md5=6ea00978e64eb6e63412ac04a425a584</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DMiralles%26aufirst%3DA.%26aulast%3DEsteban%26aufirst%3DS.%26aulast%3DSastre-Coll%26aufirst%3DA.%26aulast%3DMoranta%26aufirst%3DD.%26aulast%3DAsensio%26aufirst%3DV.%2BJ.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DHigh-affinity%2520binding%2520of%2520%25CE%25B2-carbolines%2520to%2520imidazoline%2520I2B%2520receptors%2520and%2520MAO-A%2520in%2520rat%2520tissues%253A%2520Norharman%2520blocks%2520the%2520effect%2520of%2520morphine%2520withdrawal%2520on%2520DOPA%252Fnoradrenaline%2520synthesis%2520in%2520the%2520brain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D518%26spage%3D234%26epage%3D242%26doi%3D10.1016%2Fj.ejphar.2005.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human Î²-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2986</span>â <span class="NLM_lpage">3003</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01379</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2986-3003&author=K.+Kumarauthor=P.+Wangauthor=J.+Wilsonauthor=V.+Zlatanicauthor=C.+Berrouetauthor=S.+Khamruiauthor=C.+Secorauthor=E.+A.+Swartzauthor=M.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=A.+Garcia-Ocanaauthor=R.+J.+DeVita&title=Synthesis+and+Biological+Validation+of+a+Harmine-Based%2C+Central+Nervous+System+%28CNS%29-Avoidant%2C+Selective%2C+Human+%CE%B2-Cell+Regenerative+Dual-Specificity+Tyrosine+Phosphorylation-Regulated+Kinase+A+%28DYRK1A%29+Inhibitor&doi=10.1021%2Facs.jmedchem.9b01379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human Î²-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Wilson, Jessica; Zlatanic, Viktor; Berrouet, Cecilia; Khamrui, Susmita; Secor, Cody; Swartz, Ethan A.; Lazarus, Michael; Sanchez, Roberto; Stewart, Andrew F.; Garcia-Ocana, Adolfo; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2986-3003</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, our group identified that harmine is able to induce Î²-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.  Since, harmine suffers from a lack of selectivity, both against other kinases and CNS off-targets, we therefore sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity for off-targets while retaining human Î²-cell proliferation activity.  We carried out optimization of the 9-N-position of harmine to synthesize 29 harmine-based analogs.  Several novel inhibitors showed excellent DYRK1A inhibition and human Î²-cell proliferation capability.  An optimized DYRK1A inhibitor, compd. I, was identified as a novel, efficacious in vivo lead candidate.  Compd. I also demonstrates improved selectivity for kinases and CNS off-targets, as well as in vivo efficacy for Î²-cell proliferation and regeneration at lower doses than harmine.  Collectively, these findings demonstrate that compd. I is a much improved in vivo lead candidate as compared to harmine for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXVR-g2rCbbVg90H21EOLACvtfcHk0ljogEInSsZYbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D&md5=c739edc1358acafc412a122c272edceb</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01379%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520and%2520Biological%2520Validation%2520of%2520a%2520Harmine-Based%252C%2520Central%2520Nervous%2520System%2520%2528CNS%2529-Avoidant%252C%2520Selective%252C%2520Human%2520%25CE%25B2-Cell%2520Regenerative%2520Dual-Specificity%2520Tyrosine%2520Phosphorylation-Regulated%2520Kinase%2520A%2520%2528DYRK1A%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2986%26epage%3D3003%26doi%3D10.1021%2Facs.jmedchem.9b01379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunckley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, C.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimerâs?</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">857</span>â <span class="NLM_lpage">872</span>, <span class="refDoi">Â DOI: 10.1021/cn300094k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300094k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=857-872&author=B.+Smithauthor=F.+Meddaauthor=V.+Gokhaleauthor=T.+Dunckleyauthor=C.+Hulme&title=Recent+Advances+in+the+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Selective+DYRK1A+Inhibitors%3A+A+New+Avenue+for+a+Disease+Modifying+Treatment+of+Alzheimer%E2%80%99s%3F&doi=10.1021%2Fcn300094k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?</span></div><div class="casAuthors">Smith, Breland; Medda, Federico; Gokhale, Vijay; Dunckley, Travis; Hulme, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">857-872</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  With 24.3 million people affected in 2005 and an estd. rise to 42.3 million in 2020, dementia is currently a leading unmet medical need and costly burden on public health.  Seventy percent of these cases have been attributed to Alzheimer's disease (AD), a neurodegenerative pathol. whose most evident symptom is a progressive decline in cognitive functions.  Dual specificity tyrosine phosphorylation regulated kinase-1A (DYRK1A) is important in neuronal development and plays a variety of functional roles within the adult central nervous system.  The DYRK1A gene is located within the Down syndrome crit. region (DSCR) on human chromosome 21 and current research suggests that overexpression of DYRK1A may be a significant factor leading to cognitive deficits in people with Alzheimer's disease (AD) and Down syndrome (DS).  Currently, treatment options for cognitive deficiencies assocd. with Down syndrome, as well as Alzheimer's disease, are extremely limited and represent a major unmet therapeutic need.  Small mol. inhibition of DYRK1A activity in the brain may provide an avenue for pharmaceutical intervention of mental impairment assocd. with AD and other neurodegenerative diseases.  We herein review the current state of the art in the development of DYRK1A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSAw8CXNiP7Vg90H21EOLACvtfcHk0lgkEldcpJUeFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K&md5=2009c25bc00389971cd71f64ead2da4a</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fcn300094k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300094k%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DMedda%26aufirst%3DF.%26aulast%3DGokhale%26aufirst%3DV.%26aulast%3DDunckley%26aufirst%3DT.%26aulast%3DHulme%26aufirst%3DC.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Selective%2520DYRK1A%2520Inhibitors%253A%2520A%2520New%2520Avenue%2520for%2520a%2520Disease%2520Modifying%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%253F%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D857%26epage%3D872%26doi%3D10.1021%2Fcn300094k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span> <span> </span><span class="NLM_article-title">Activation, regulation, and inhibition of DYRK1A</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">246</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1111/j.1742-4658.2010.07956.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1111%2Fj.1742-4658.2010.07956.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=21126318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFGru7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=246-256&author=W.+Beckerauthor=W.+Sippl&title=Activation%2C+regulation%2C+and+inhibition+of+DYRK1A&doi=10.1111%2Fj.1742-4658.2010.07956.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Activation, regulation, and inhibition of DYRK1A</span></div><div class="casAuthors">Becker, Walter; Sippl, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-256</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a protein kinase with diverse functions in neuronal development and adult brain physiol.  Higher than normal levels of DYRK1A are assocd. with the pathol. of neurodegenerative diseases and have been implicated in some neurobiol. alterations of Down syndrome, such as mental retardation.  It is therefore important to understand the mol. mechanisms that control the activity of DYRK1A.  Here, the authors review current knowledge about the initial self-activation of DYRK1A by tyrosine autophosphorylation and propose that this mechanism presents an ancestral feature of the CMGC group of kinases.  However, tyrosine phosphorylation does not appear to regulate the enzymic activity of DYRK1A.  Control of DYRK1A may take place on the level of gene expression, interaction with regulatory proteins, and regulated nuclear translocation.  Finally, the authors compare the properties of small mol. inhibitors that target DYRK1A and evaluate their potential application and limitations.  The Î²-carboline alkaloid, harmine, is currently the most selective and potent inhibitor of DYRK1A and has proven very useful in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-_Eqb_-j05bVg90H21EOLACvtfcHk0lgkEldcpJUeFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFGru7s%253D&md5=958db7f4577f941bd8dfb56afc461335</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07956.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07956.x%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DW.%26aulast%3DSippl%26aufirst%3DW.%26atitle%3DActivation%252C%2520regulation%252C%2520and%2520inhibition%2520of%2520DYRK1A%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D246%26epage%3D256%26doi%3D10.1111%2Fj.1742-4658.2010.07956.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tazarki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeinyeh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esvan, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶der, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khiari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josselin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anizon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span> <span> </span><span class="NLM_article-title">New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: Synthesis, biological evaluation and binding mode analysis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">304</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.01.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1016%2Fj.ejmech.2019.01.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=30731399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1aqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=304-317&author=H.+Tazarkiauthor=W.+Zeinyehauthor=Y.+J.+Esvanauthor=S.+Knappauthor=D.+Chatterjeeauthor=M.+Schr%C3%B6derauthor=A.+C.+Joergerauthor=J.+Khiariauthor=B.+Josselinauthor=B.+Baratteauthor=S.+Bachauthor=S.+Ruchaudauthor=F.+Anizonauthor=F.+Giraudauthor=P.+Moreau&title=New+pyrido%5B3%2C4-g%5Dquinazoline+derivatives+as+CLK1+and+DYRK1A+inhibitors%3A+Synthesis%2C+biological+evaluation+and+binding+mode+analysis&doi=10.1016%2Fj.ejmech.2019.01.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis</span></div><div class="casAuthors">Tazarki, Helmi; Zeinyeh, Wael; Esvan, Yannick J.; Knapp, Stefan; Chatterjee, Deep; Schroder, Martin; Joerger, Andreas C.; Khiari, Jameleddine; Josselin, Beatrice; Baratte, Blandine; Bach, Stephane; Ruchaud, Sandrine; Anizon, Fabrice; Giraud, Francis; Moreau, Pascale</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-317</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis of new pyrido[3,4-g]quinazoline derivs. I [R = (CH2)2-NMe2, (CH2)2-morpholin-1-yl, (CH2)3-NMe2, etc.; R1 = NH2, NO2] and the evaluation of the inhibitory potencies of these compds. toward CDK5, CK1, GSK3, CLK1 and DYRK1A were described.  Introduction of aminoalkylamino groups at the 2-position resulted in several compds. with low nanomolar affinity and selective inhibition of CLK1 and/or DYRK1A.  Their evaluation on several immortalized or cancerous cell lines showed varying degree of cell viability redn.  Co-crystal structures of CLK1 with two of the most potent compds. I [R = Me, R1 = NO2; R = (CH2)3-morpholin-1-yl, R2 = NH2] revealed two alternative binding modes of the pyrido[3,4-g]quinazoline scaffold that can be exploited for future inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK9VnCqI3-v7Vg90H21EOLACvtfcHk0lgkEldcpJUeFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1aqsLk%253D&md5=d572d06711c1ecdf401051af38655449</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.052%26sid%3Dliteratum%253Aachs%26aulast%3DTazarki%26aufirst%3DH.%26aulast%3DZeinyeh%26aufirst%3DW.%26aulast%3DEsvan%26aufirst%3DY.%2BJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DM.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DKhiari%26aufirst%3DJ.%26aulast%3DJosselin%26aufirst%3DB.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DBach%26aufirst%3DS.%26aulast%3DRuchaud%26aufirst%3DS.%26aulast%3DAnizon%26aufirst%3DF.%26aulast%3DGiraud%26aufirst%3DF.%26aulast%3DMoreau%26aufirst%3DP.%26atitle%3DNew%2520pyrido%255B3%252C4-g%255Dquinazoline%2520derivatives%2520as%2520CLK1%2520and%2520DYRK1A%2520inhibitors%253A%2520Synthesis%252C%2520biological%2520evaluation%2520and%2520binding%2520mode%2520analysis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D304%26epage%3D317%26doi%3D10.1016%2Fj.ejmech.2019.01.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Falke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoaÃ«c, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu Jhaisha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span> <span> </span><span class="NLM_article-title">10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3131</span>â <span class="NLM_lpage">3143</span>, <span class="refDoi">Â DOI: 10.1021/jm501994d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501994d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1GhtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3131-3143&author=H.+Falkeauthor=A.+Chaikuadauthor=A.+Beckerauthor=N.+Loa%C3%ABcauthor=O.+Lozachauthor=S.+Abu+Jhaishaauthor=W.+Beckerauthor=P.+G.+Jonesauthor=L.+Preuauthor=K.+Baumannauthor=S.+Knappauthor=L.+Meijerauthor=C.+Kunick&title=10-Iodo-11H-indolo%5B3%2C2-c%5Dquinoline-6-carboxylic+Acids+Are+Selective+Inhibitors+of+DYRK1A&doi=10.1021%2Fjm501994d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A</span></div><div class="casAuthors">Falke, Hannes; Chaikuad, Apirat; Becker, Anja; Loaec, Nadege; Lozach, Olivier; Abu Jhaisha, Samira; Becker, Walter; Jones, Peter G.; Preu, Lutz; Baumann, Knut; Knapp, Stefan; Meijer, Laurent; Kunick, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3131-3143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein kinase DYRK1A has been suggested to act as one of the intracellular regulators contributing to neurol. alterations found in individuals with Down syndrome.  For an assessment of the role of DYRK1A, selective synthetic inhibitors are valuable pharmacol. tools.  However, the DYRK1A inhibitors described in the literature so far either are not sufficiently selective or have not been tested against closely related kinases from the DYRK and the CLK protein kinase families.  The aim of this study was the identification of DYRK1A inhibitors exhibiting selectivity vs. the structurally and functionally closely related DYRK and CLK isoforms.  Structure modification of the screening hit 11H-indolo[3,2-c]quinoline-6-carboxylic acid revealed structure-activity relationships for kinase inhibition and enabled the design of 10-iodo-substituted derivs. as very potent DYRK1A inhibitors with considerable selectivity against CLKs.  X-ray structure detn. of three 11H-indolo[3,2-c]quinoline-6-carboxylic acids cocrystd. with DYRK1A confirmed the predicted binding mode within the ATP binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4rHbgYJUsbVg90H21EOLACvtfcHk0ljUsyvnA8L5Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1GhtrY%253D&md5=70efbb6ad590a1240764ccc78af019ec</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm501994d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501994d%26sid%3Dliteratum%253Aachs%26aulast%3DFalke%26aufirst%3DH.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DLoa%25C3%25ABc%26aufirst%3DN.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DAbu%2BJhaisha%26aufirst%3DS.%26aulast%3DBecker%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DP.%2BG.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DBaumann%26aufirst%3DK.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3D10-Iodo-11H-indolo%255B3%252C2-c%255Dquinoline-6-carboxylic%2520Acids%2520Are%2520Selective%2520Inhibitors%2520of%2520DYRK1A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3131%26epage%3D3143%26doi%3D10.1021%2Fjm501994d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">Development of a novel selective inhibitor of the down syndrome-related kinase DYRK1A</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi">Â DOI: 10.1038/ncomms1090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1038%2Fncomms1090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=20981014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=86&author=Y.+Ogawaauthor=Y.+Nonakaauthor=T.+Gotoauthor=E.+Ohnishiauthor=T.+Hiramatsuauthor=I.+Kiiauthor=M.+Yoshidaauthor=T.+Ikuraauthor=H.+Onogiauthor=H.+Shibuyaauthor=T.+Hosoyaauthor=N.+Itoauthor=M.+Hagiwara&title=Development+of+a+novel+selective+inhibitor+of+the+down+syndrome-related+kinase+DYRK1A&doi=10.1038%2Fncomms1090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A</span></div><div class="casAuthors">Ogawa Yasushi; Nonaka Yosuke; Goto Toshiyasu; Ohnishi Eriko; Hiramatsu Toshiyuki; Kii Isao; Yoshida Miyo; Ikura Teikichi; Onogi Hiroshi; Shibuya Hiroshi; Hosoya Takamitsu; Ito Nobutoshi; Hagiwara Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A) is a serine/threonine kinase essential for brain development and function, and its excessive activity is considered a pathogenic factor in Down syndrome.  The development of potent, selective inhibitors of Dyrk1A would help to elucidate the molecular mechanisms of normal and diseased brains, and may provide a new lead compound for molecular-targeted drug discovery.  Here, we report a novel Dyrk1A inhibitor, INDY, a benzothiazole derivative showing a potent ATP-competitive inhibitory effect with IC(50) and K(i) values of 0.24 and 0.18 Î¼M, respectively.  X-ray crystallography of the Dyrk1A/INDY complex revealed the binding of INDY in the ATP pocket of the enzyme.  INDY effectively reversed the aberrant tau-phosphorylation and rescued the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A overexpression.  Importantly, proINDY, a prodrug of INDY, effectively recovered Xenopus embryos from head malformation induced by Dyrk1A overexpression, resulting in normally developed embryos and demonstrating the utility of proINDY in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCqf6rsXbPtenUz0lpNqnfW6udTcc2eYtaxNyYQpGErntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D&md5=ac1d5972bec4085de101bb86194babd1</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1038%2Fncomms1090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1090%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DNonaka%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DOhnishi%26aufirst%3DE.%26aulast%3DHiramatsu%26aufirst%3DT.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DIkura%26aufirst%3DT.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520the%2520down%2520syndrome-related%2520kinase%2520DYRK1A%26jtitle%3DNat.%2520Commun.%26date%3D2010%26volume%3D1%26spage%3D86%26doi%3D10.1038%2Fncomms1090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Czarna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelencova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kildalsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seternes, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothweiler, U.</span></span> <span> </span><span class="NLM_article-title">Novel scaffolds for dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7560</span>â <span class="NLM_lpage">7572</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01847</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01847" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVygtrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7560-7572&author=A.+Czarnaauthor=J.+Wangauthor=D.+Zelencovaauthor=Y.+Liuauthor=X.+Dengauthor=H.+G.+Choiauthor=T.+Zhangauthor=W.+Zhouauthor=J.+W.+Changauthor=H.+Kildalsenauthor=O.+M.+Seternesauthor=N.+S.+Grayauthor=R.+A.+Enghauthor=U.+Rothweiler&title=Novel+scaffolds+for+dual+specificity+tyrosine-phosphorylation-regulated+kinase+%28DYRK1A%29+inhibitors&doi=10.1021%2Facs.jmedchem.7b01847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors</span></div><div class="casAuthors">Czarna, Anna; Wang, Jinhua; Zelencova, Diana; Liu, Yao; Deng, Xianming; Choi, Hwan Geun; Zhang, Tinghu; Zhou, Wenjun; Chang, Jae Won; Kildalsen, Hanne; Seternes, Ole Morten; Gray, Nathanael S.; Engh, Richard A.; Rothweiler, Ulli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7560-7572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A is one of five members of the dual-specificity tyrosine (Y) phosphorylation-regulated kinase (DYRK) family.  The DYRK1A gene is located in the Down syndrome crit. region and regulates cellular processes related to proliferation and differentiation of neuronal progenitor cells during early development.  This has focused research on its role in neuronal degenerative diseases, including Alzheimer's and Down syndrome.  Recent studies have also shown a possible role of DYRK1A in diabetes.  Here we report a variety of scaffolds not generally known for DYRK1A inhibition, demonstrating their effects in in vitro assays and also in cell cultures.  These inhibitors effectively block the tau phosphorylation that is a hallmark of Alzheimer's disease.  The crystal structures of these inhibitors support the design of optimized and novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC4Uq_4mv-grVg90H21EOLACvtfcHk0ljUsyvnA8L5Mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVygtrjF&md5=c4b55fc7510b9f9d80726933b32be508</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01847%26sid%3Dliteratum%253Aachs%26aulast%3DCzarna%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZelencova%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DKildalsen%26aufirst%3DH.%26aulast%3DSeternes%26aufirst%3DO.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DRothweiler%26aufirst%3DU.%26atitle%3DNovel%2520scaffolds%2520for%2520dual%2520specificity%2520tyrosine-phosphorylation-regulated%2520kinase%2520%2528DYRK1A%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7560%26epage%3D7572%26doi%3D10.1021%2Facs.jmedchem.7b01847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rothweiler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandsdal, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaksson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, J. S. M.</span></span> <span> </span><span class="NLM_article-title">Probing the atp-binding pocket of protein kinase DYRK1A with benzothiazole fragment molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9814</span>â <span class="NLM_lpage">9824</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01086</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01086" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9814-9824&author=U.+Rothweilerauthor=W.+Stensenauthor=B.+O.+Brandsdalauthor=J.+Isakssonauthor=F.+A.+Leesonauthor=R.+A.+Enghauthor=J.+S.+M.+Svendsen&title=Probing+the+atp-binding+pocket+of+protein+kinase+DYRK1A+with+benzothiazole+fragment+molecules&doi=10.1021%2Facs.jmedchem.6b01086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules</span></div><div class="casAuthors">Rothweiler, Ulli; Stensen, Wenche; Brandsdal, Bjoern Olav; Isaksson, Johan; Leeson, Frederick Alan; Engh, Richard Alan; Svendsen, John S. Mjoeen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9814-9824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A has emerged as a potential target for therapies of Alzheimer's disease using small mols.  Based on the observation of selective DYRK1A inhibition by firefly D-luciferin, we have explored static and dynamic structural properties of fragment sized variants of the benzothiazole scaffold with respect to DYRK1A using X-ray crystallog. and NMR techniques.  The compds. have excellent ligand efficiencies and show a remarkable diversity of binding modes in dynamic equil.  Binding geometries are detd. in part by interactions often considered "weak", including "orthogonal multipolar" types represented by e.g. F-CO, sulfur-aromat, and halogen-aromat interactions, together with hydrogen bonds that are modulated by variation of electron withdrawing groups.  These studies show how the benzothiazole scaffold is highly promising for the development of therapeutic DYRK1A inhibitors.  In addn., the subtleties of the binding interactions, including dynamics, show how full structural studies are required to fully interpret the essential phys. determinants of binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYSQe1_5bEjLVg90H21EOLACvtfcHk0lgPG0uQ5iCnvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr7P&md5=edb850b232f53b3e161a5023915972e6</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01086%26sid%3Dliteratum%253Aachs%26aulast%3DRothweiler%26aufirst%3DU.%26aulast%3DStensen%26aufirst%3DW.%26aulast%3DBrandsdal%26aufirst%3DB.%2BO.%26aulast%3DIsaksson%26aufirst%3DJ.%26aulast%3DLeeson%26aufirst%3DF.%2BA.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DSvendsen%26aufirst%3DJ.%2BS.%2BM.%26atitle%3DProbing%2520the%2520atp-binding%2520pocket%2520of%2520protein%2520kinase%2520DYRK1A%2520with%2520benzothiazole%2520fragment%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9814%26epage%3D9824%26doi%3D10.1021%2Facs.jmedchem.6b01086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡lint, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ©ber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruzalegui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbridge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotschy, A.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">932</span>â <span class="NLM_lpage">939</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201600539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fcmdc.201600539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=28264138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Wisro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=932-939&author=B.+B%C3%A1lintauthor=C.+W%C3%A9berauthor=F.+Cruzaleguiauthor=M.+Burbridgeauthor=A.+Kotschy&title=Structure-Based+Design+and+Synthesis+of+Harmine+Derivatives+with+Different+Selectivity+Profiles+in+Kinase+versus+Monoamine+Oxidase+Inhibition&doi=10.1002%2Fcmdc.201600539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition</span></div><div class="casAuthors">Balint, Balazs; Weber, Csaba; Cruzalegui, Francisco; Burbridge, Mike; Kotschy, Andras</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">932-939</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an emerging biol. target with implications in diverse therapeutic areas such as neurol. disorders (Down syndrome, in particular), metab., and oncol.  Harmine, a natural product that selectively inhibits DYRK1A amongst kinases, could serve as a tool compd. to better understand the biol. processes that arise from DYRK1A inhibition.  On the other hand, harmine is also a potent inhibitor of monoamine oxidase A (MAO-A).  Using structure-based design, we synthesized a collection of harmine analogs with tunable selectivity toward these two enzymes.  Modifications at the 7-position typically decreased affinity for DYRK1A, whereas substitution at the 9-position had a similar effect on MAO-A inhibition but DYRK1A inhibition was maintained.  The resulting collection of compds. can help to understand the biol. role of DYRK1A and also to assess the interference in the biol. effect originating in MAO-A inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsY4lpVOJVlbVg90H21EOLACvtfcHk0lgPG0uQ5iCnvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Wisro%253D&md5=f713602f24c608cbe5c97d965ea3727d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600539%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1lint%26aufirst%3DB.%26aulast%3DW%25C3%25A9ber%26aufirst%3DC.%26aulast%3DCruzalegui%26aufirst%3DF.%26aulast%3DBurbridge%26aufirst%3DM.%26aulast%3DKotschy%26aufirst%3DA.%26atitle%3DStructure-Based%2520Design%2520and%2520Synthesis%2520of%2520Harmine%2520Derivatives%2520with%2520Different%2520Selectivity%2520Profiles%2520in%2520Kinase%2520versus%2520Monoamine%2520Oxidase%2520Inhibition%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D932%26epage%3D939%26doi%3D10.1002%2Fcmdc.201600539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ©rault, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besson, T.</span></span> <span> </span><span class="NLM_article-title">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1183</span>â <span class="NLM_lpage">1199</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2017.1360285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1080%2F13543776.2017.1360285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=28766366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ojs7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1183-1199&author=T.+L.+Nguyenauthor=C.+Fruitauthor=Y.+H%C3%A9raultauthor=L.+Meijerauthor=T.+Besson&title=Dual-specificity+tyrosine+phosphorylation-regulated+kinase+1A+%28DYRK1A%29+inhibitors%3A+a+survey+of+recent+patent+literature&doi=10.1080%2F13543776.2017.1360285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature</span></div><div class="casAuthors">Nguyen, Thu Lan; Fruit, Corinne; Herault, Yann; Meijer, Laurent; Besson, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1183-1199</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a eukaryotic serine-threonine protein kinase belonging to the CMGC group.  DYRK1A hyperactivity appears to contribute to the development of a no. of human malignancies and to cognitive deficits obsd. in Down syndrome and Alzheimer's disease.  As a result, the DYRK1A kinase represents an attractive target for the synthesis and optimization of pharmacol. inhibitors of potential therapeutic interest.  Like most tyrosine kinase inhibitors developed up to the market, DYRK1A inhibitors are essentially acting by competing with ATP for binding at the catalytic site of the kinase.  This paper reviews patent activity assocd. with the discovery of synthetic novel heterocyclic mols. inhibiting the catalytic activity of DYRK1A.  Despite the important role of DYRK1A in biol. processes and the growing interest in the design of new therapeutic drugs, there are only few patented synthetic DYRK1A inhibitors and most of them were and are still developed by academic research groups, sometimes with industrial partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMS30KxawIbVg90H21EOLACvtfcHk0lgPG0uQ5iCnvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ojs7jO&md5=3cdf56f9f96f917133b4625dd5d4d09c</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1360285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1360285%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BL.%26aulast%3DFruit%26aufirst%3DC.%26aulast%3DH%25C3%25A9rault%26aufirst%3DY.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBesson%26aufirst%3DT.%26atitle%3DDual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25201A%2520%2528DYRK1A%2529%2520inhibitors%253A%2520a%2520survey%2520of%2520recent%2520patent%2520literature%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1183%26epage%3D1199%26doi%3D10.1080%2F13543776.2017.1360285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jarhad, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashelkar, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span> <span> </span><span class="NLM_article-title">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9791</span>â <span class="NLM_lpage">9810</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9791-9810&author=D.+B.+Jarhadauthor=K.+K.+Mashelkarauthor=H.-R.+Kimauthor=M.+Nohauthor=L.+S.+Jeong&title=Dual-specificity+tyrosine+phosphorylation-regulated+kinase+1A+%28DYRK1A%29+inhibitors+as+potential+therapeutics&doi=10.1021%2Facs.jmedchem.8b00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics</span></div><div class="casAuthors">Jarhad, Dnyandev B.; Mashelkar, Karishma K.; Kim, Hong-Rae; Noh, Minsoo; Jeong, Lak Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9791-9810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an evolutionarily conserved family of protein kinases that belongs to the CMGC group of kinases.  DYRK1A, encoded by a gene located in the human chromosome 21q22.2 region, has attracted attention due to its assocn. with both neuropathol. phenotypes and cancer susceptibility in patients with Down syndrome (DS).  Inhibition of DYRK1A attenuates cognitive dysfunctions in animal models for both DS and Alzheimer's disease (AD).  Furthermore, DYRK1A has been studied as a potential cancer therapeutic target because of its role in the regulation of cell cycle progression by affecting both tumor suppressors and oncogenes.  Consequently, selective synthetic inhibitors have been developed to det. the role of DYRK1A in various human diseases.  Our perspective includes a comprehensive review of potent and selective DYRK1A inhibitors and their forthcoming therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYrGtCZLBQ77Vg90H21EOLACvtfcHk0ljl7jMGI8fPmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO&md5=6ffb927f58fc34f16f19c5e5b8beebcf</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00185%26sid%3Dliteratum%253Aachs%26aulast%3DJarhad%26aufirst%3DD.%2BB.%26aulast%3DMashelkar%26aufirst%3DK.%2BK.%26aulast%3DKim%26aufirst%3DH.-R.%26aulast%3DNoh%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26atitle%3DDual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25201A%2520%2528DYRK1A%2529%2520inhibitors%2520as%2520potential%2520therapeutics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9791%26epage%3D9810%26doi%3D10.1021%2Facs.jmedchem.8b00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labute, P.</span></span> <span> </span><span class="NLM_article-title">Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">187</span>â <span class="NLM_lpage">205</span>, <span class="refDoi">Â DOI: 10.1002/prot.22234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fprot.22234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=18814299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2isrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=187-205&author=P.+Labute&title=Protonate3D%3A+Assignment+of+ionization+states+and+hydrogen+coordinates+to+macromolecular+structures&doi=10.1002%2Fprot.22234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures</span></div><div class="casAuthors">Labute, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-205</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A new method, called Protonate3D, is presented for the automated prediction of hydrogen coordinates given the 3D coordinates of the heavy atoms of a macromol. structure.  Protonate3D considers side-chain "flip," rotamer, tautomer, and ionization states of all chem. groups, ligands, and solvent, provided suitable templates are available in a parameter file.  The energy model includes van der Waals, Coulomb, solvation, rotamer, tautomer, and titrn. effects.  The results of computational validation expts. suggest that Protonate3D can accurately predict the location of hydrogen atoms in macromol. structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmnIRzxpxpCrVg90H21EOLACvtfcHk0ljl7jMGI8fPmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2isrs%253D&md5=89803fe2028fb9257eb09854a27ef2dd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fprot.22234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22234%26sid%3Dliteratum%253Aachs%26aulast%3DLabute%26aufirst%3DP.%26atitle%3DProtonate3D%253A%2520Assignment%2520of%2520ionization%2520states%2520and%2520hydrogen%2520coordinates%2520to%2520macromolecular%2520structures%26jtitle%3DProteins%26date%3D2009%26volume%3D75%26spage%3D187%26epage%3D205%26doi%3D10.1002%2Fprot.22234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brault, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span> <span> </span><span class="NLM_article-title">7,8-Dichloro-1-oxo-Î²-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">403</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1021/jm201286z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201286z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKkt7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=403-413&author=K.+Huberauthor=L.+Braultauthor=O.+Fedorovauthor=C.+Gasserauthor=P.+Filippakopoulosauthor=A.+N.+Bullockauthor=D.+Fabbroauthor=J.+Trappeauthor=J.+Schwallerauthor=S.+Knappauthor=F.+Bracher&title=7%2C8-Dichloro-1-oxo-%CE%B2-carbolines+as+a+Versatile+Scaffold+for+the+Development+of+Potent+and+Selective+Kinase+Inhibitors+with+Unusual+Binding+Modes&doi=10.1021%2Fjm201286z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">7,8-Dichloro-1-oxo-Î²-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes</span></div><div class="casAuthors">Huber, Kilian; Brault, Laurent; Fedorov, Oleg; Gasser, Christelle; Filippakopoulos, Panagis; Bullock, Alex N.; Fabbro, Doriano; Trappe, Joerg; Schwaller, Juerg; Knapp, Stefan; Bracher, Franz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">403-413</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of both potent and selective kinase inhibitors is a challenging task in modern drug discovery.  The innate promiscuity of kinase inhibitors largely results from ATP-mimetic binding to the kinase hinge region.  We present a novel class of substituted 7,8-dichloro-1-oxo-Î²-carbolines based on the distinct structural features of the alkaloid bauerine C whose kinase inhibitory activity does not rely on canonical ATP-mimetic hinge interactions.  Intriguingly, cocrystal structures revealed an unexpected inverted binding mode and the presence of halogen bonds with kinase backbone residues.  The compds. exhibit excellent selectivity over a comprehensive panel of human protein kinases while inhibiting selected kinases such as the oncogenic PIM1 at low nanomolar concns.  Together, our biochem. and structural data suggest that this scaffold may serve as a valuable template for the design and development of specific inhibitors of various kinases including the PIM family of kinases, CLKs, DAPK3 (ZIPK), BMP2K (BIKE), and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWBwRMy-TWurVg90H21EOLACvtfcHk0ljl7jMGI8fPmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKkt7zM&md5=70fedaa0388ba604cff1fb72533bf7ac</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm201286z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201286z%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DBrault%26aufirst%3DL.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DGasser%26aufirst%3DC.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3D7%252C8-Dichloro-1-oxo-%25CE%25B2-carbolines%2520as%2520a%2520Versatile%2520Scaffold%2520for%2520the%2520Development%2520of%2520Potent%2520and%2520Selective%2520Kinase%2520Inhibitors%2520with%2520Unusual%2520Binding%2520Modes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D403%26epage%3D413%26doi%3D10.1021%2Fjm201286z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶hm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brode, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesse, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span> <span> </span><span class="NLM_article-title">Oxygen and nitrogen in competitive situations: which is the hydrogen-bond acceptor?</span>. <i>Chem.âEur. J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1509</span>â <span class="NLM_lpage">1513</span>, <span class="refDoi">Â DOI: 10.1002/chem.19960021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fchem.19960021206" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=1509-1513&author=H.-J.+B%C3%B6hmauthor=S.+Brodeauthor=U.+Hesseauthor=G.+Klebe&title=Oxygen+and+nitrogen+in+competitive+situations%3A+which+is+the+hydrogen-bond+acceptor%3F&doi=10.1002%2Fchem.19960021206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fchem.19960021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.19960021206%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBrode%26aufirst%3DS.%26aulast%3DHesse%26aufirst%3DU.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DOxygen%2520and%2520nitrogen%2520in%2520competitive%2520situations%253A%2520which%2520is%2520the%2520hydrogen-bond%2520acceptor%253F%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D1996%26volume%3D2%26spage%3D1509%26epage%3D1513%26doi%3D10.1002%2Fchem.19960021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altafaj, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Luna, S.</span></span> <span> </span><span class="NLM_article-title">DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1167</span>â <span class="NLM_lpage">1178</span>, <span class="refDoi">Â DOI: 10.1091/mbc.e06-08-0668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1091%2Fmbc.e06-08-0668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=17229891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVSmtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=1167-1178&author=M.+Alvarezauthor=X.+Altafajauthor=S.+Arandaauthor=S.+de+la+Luna&title=DYRK1A+autophosphorylation+on+serine+residue+520+modulates+its+kinase+activity+via+14-3-3+binding&doi=10.1091%2Fmbc.e06-08-0668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding</span></div><div class="casAuthors">Alvarez, Monica; Altafaj, Xavier; Aranda, Sergi; de la Luna, Susana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1167-1178</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine-phosphorylated and regulated kinase (DYRK) proteins are an evolutionarily conserved family of protein kinases, with members identified from yeast to humans, that participate in a variety of cellular processes.  DYRKs are serine/threonine protein kinases that are activated by autophosphorylation on a tyrosine residue in the activation loop.  The family member DYRK1A has been shown to phosphorylate several cytosolic proteins and a no. of splicing and transcription factors, including members of the nuclear factor of activated T cells family.  In the present study, we show that DYRK1A autophosphorylates, via an intramol. mechanism, on Ser-520, in the PEST domain of the protein.  We also show that phosphorylation of this residue, which we show is subjected to dynamic changes in vivo, mediates the interaction of DYRK1A with 14-3-3Î².  A second 14-3-3 binding site is present within the N-terminal of the protein.  In the context of the DYRK1A mol., neither site can act independently of the other.  Bacterially produced DYRK1A and the mutant DYRK1A/S520A have similar kinase activities, suggesting that Ser-520 phosphorylation does not affect the intrinsic kinase activity on its own.  Instead, we demonstrate that this phosphorylation allows the binding of 14-3-3Î², which in turn stimulates the catalytic activity of DYRK1A.  These findings provide evidence for a novel mechanism for the regulation of DYRK1A kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3iiUoSe8NbbVg90H21EOLACvtfcHk0lh9woa5ChO_nA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVSmtrc%253D&md5=7ed3a1f45bc539f97aaeea6972f9e78c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e06-08-0668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e06-08-0668%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DM.%26aulast%3DAltafaj%26aufirst%3DX.%26aulast%3DAranda%26aufirst%3DS.%26aulast%3Dde%2Bla%2BLuna%26aufirst%3DS.%26atitle%3DDYRK1A%2520autophosphorylation%2520on%2520serine%2520residue%2520520%2520modulates%2520its%2520kinase%2520activity%2520via%252014-3-3%2520binding%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2007%26volume%3D18%26spage%3D1167%26epage%3D1178%26doi%3D10.1091%2Fmbc.e06-08-0668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>â <span class="NLM_lpage">670</span>, <span class="refDoi">Â DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+structural+and+functional+studies+of+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+inhibitors+suggest+the+basis+for+isotype+selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-Î²-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0lh9woa5ChO_nA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520structural%2520and%2520functional%2520studies%2520of%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520inhibitors%2520suggest%2520the%2520basis%2520for%2520isotype%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">NÄmec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HylsovÃ¡, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶der, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ValÄÃ­kovÃ¡, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uldrijan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DrÃ¡pela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SouÄek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span> <span> </span><span class="NLM_article-title">Furo[3,2-b]pyridine: a privileged scaffold for highly selective kinase inhibitors and effective modulators of the hedgehog pathway</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1062</span>â <span class="NLM_lpage">1066</span>, <span class="refDoi">Â DOI: 10.1002/anie.201810312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fanie.201810312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=30569600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A280%3ADC%252BB3cnktVaitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1062-1066&author=V.+N%C4%9Bmecauthor=M.+Hylsov%C3%A1author=L.+Maierauthor=J.+Flegelauthor=S.+Sieversauthor=S.+Zieglerauthor=M.+Schr%C3%B6derauthor=B.+T.+Bergerauthor=A.+Chaikuadauthor=B.+Val%C4%8D%C3%ADkov%C3%A1author=S.+Uldrijanauthor=S.+Dr%C3%A1pelaauthor=K.+Sou%C4%8Dekauthor=H.+Waldmannauthor=S.+Knappauthor=K.+Paruch&title=Furo%5B3%2C2-b%5Dpyridine%3A+a+privileged+scaffold+for+highly+selective+kinase+inhibitors+and+effective+modulators+of+the+hedgehog+pathway&doi=10.1002%2Fanie.201810312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway</span></div><div class="casAuthors">Nemec Vaclav; Hylsova Michaela; Maier Lukas; Paruch Kamil; Nemec Vaclav; Hylsova Michaela; Maier Lukas; Valcikova Barbora; Uldrijan Stjepan; Drapela Stanislav; Soucek Karel; Paruch Kamil; Flegel Jana; Sievers Sonja; Ziegler Slava; Waldmann Herbert; Schroder Martin; Berger Benedict-Tilman; Chaikuad Apirat; Knapp Stefan; Valcikova Barbora; Uldrijan Stjepan; Drapela Stanislav; Soucek Karel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1062-1066</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Reported is the identification of the furo[3,2-b]pyridine core as a novel scaffold for potent and highly selective inhibitors of cdc-like kinases (CLKs) and efficient modulators of the Hedgehog signaling pathway.  Initially, a diverse target compound set was prepared by synthetic sequences based on chemoselective metal-mediated couplings, including assembly of the furo[3,2-b]pyridine scaffold by copper-mediated oxidative cyclization.  Optimization of the subseries containing 3,5-disubstituted furo[3,2-b]pyridines afforded potent, cell-active, and highly selective inhibitors of CLKs.  Profiling of the kinase-inactive subset of 3,5,7-trisubstituted furo[3,2-b]pyridines revealed sub-micromolar modulators of the Hedgehog pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3yixuupDQ3gyMywPm6HgQfW6udTcc2eYBYC1GnL1S47ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnktVaitw%253D%253D&md5=62b69671525c989112ea5538ea1d3654</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fanie.201810312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201810312%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C4%259Bmec%26aufirst%3DV.%26aulast%3DHylsov%25C3%25A1%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DL.%26aulast%3DFlegel%26aufirst%3DJ.%26aulast%3DSievers%26aufirst%3DS.%26aulast%3DZiegler%26aufirst%3DS.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DVal%25C4%258D%25C3%25ADkov%25C3%25A1%26aufirst%3DB.%26aulast%3DUldrijan%26aufirst%3DS.%26aulast%3DDr%25C3%25A1pela%26aufirst%3DS.%26aulast%3DSou%25C4%258Dek%26aufirst%3DK.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DParuch%26aufirst%3DK.%26atitle%3DFuro%255B3%252C2-b%255Dpyridine%253A%2520a%2520privileged%2520scaffold%2520for%2520highly%2520selective%2520kinase%2520inhibitors%2520and%2520effective%2520modulators%2520of%2520the%2520hedgehog%2520pathway%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D2019%26volume%3D58%26spage%3D1062%26epage%3D1066%26doi%3D10.1002%2Fanie.201810312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span> Prepared following<span class="NLM_contrib-group"><span class="NLM_string-name">Pauvert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span> <span> </span><span class="NLM_article-title">Toward an artificial oxidative DNA photolyase</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">548</span>, <span class="refDoi">Â DOI: 10.1021/jo0354600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0354600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWisb3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=543-548&author=M.+Pauvertauthor=P.+Laineauthor=M.+Jonasauthor=O.+Wiest&title=Toward+an+artificial+oxidative+DNA+photolyase&doi=10.1021%2Fjo0354600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Toward an Artificial Oxidative DNA Photolyase</span></div><div class="casAuthors">Pauvert, Mickaeel; Laine, Patrick; Jonas, Marco; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-548</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, structure, and binding affinity of two ditopic receptors for the selective mol. recognition of the cis,syn cyclobutane pyrimidine dimer are reported.  The design is based on two 2,6-di(acetamino)pyridine recognition units that are covalently linked via triple bonds to an anthraquinone functional spacer unit.  The convergent synthesis uses a modified Sonogashira reaction involving a zinc transmetalation as the key step.  The crystal structure of one of the receptors reveals a supramol. 1D polymer with strong interactions mediated by shape self-complementarity, Ï-stacking, and hydrogen bonding between adjacent mols.  Hydrogen bonding between adjacent strands enforces a parallel orientation, which leads to a non-centrosym. crystal structure of the highly polar compd.  The receptor has an assocn. const. of Ka = 1.0 Ã 103 M-1 with the cis,syn pyrimidine dimer, whereas binding of the trans,syn isomer is â¼1 order of magnitude weaker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwu5NU43J_OLVg90H21EOLACvtfcHk0lhoHFRoLaXMqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWisb3L&md5=190d74734fe457e335276b3b92deaae4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjo0354600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0354600%26sid%3Dliteratum%253Aachs%26aulast%3DPauvert%26aufirst%3DM.%26aulast%3DLaine%26aufirst%3DP.%26aulast%3DJonas%26aufirst%3DM.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DToward%2520an%2520artificial%2520oxidative%2520DNA%2520photolyase%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D543%26epage%3D548%26doi%3D10.1021%2Fjo0354600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span>; <span class="NLM_string-name">Murray, M.</span>; <span class="NLM_string-name">Dokurno, P.</span>; <span class="NLM_string-name">Massey, A. J.</span>; <span class="NLM_string-name">Benwell, K.</span>; <span class="NLM_string-name">Fiumana, A.</span>; <span class="NLM_string-name">Foloppe, N.</span>; <span class="NLM_string-name">Ray, S.</span>; <span class="NLM_string-name">Smith, J.</span>; <span class="NLM_string-name">Surgenor, A.</span>; <span class="NLM_string-name">Edmonds, T.</span>; <span class="NLM_string-name">Demarles, D.</span>; <span class="NLM_string-name">Burbridge, M.</span>; <span class="NLM_string-name">Cruzalegui, F.</span>; <span class="NLM_string-name">Kotschy, A.</span>; <span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">Fragment derived selective inhibitors of dual specificity kinases DYRK1A and DYRK1B</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, accepted for publication.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=33975430" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=D.+L.+Walmsley&author=M.+Murray&author=P.+Dokurno&author=A.+J.+Massey&author=K.+Benwell&author=A.+Fiumana&author=N.+Foloppe&author=S.+Ray&author=J.+Smith&author=A.+Surgenor&author=T.+Edmonds&author=D.+Demarles&author=M.+Burbridge&author=F.+Cruzalegui&author=A.+Kotschy&author=R.+E.+Hubbard&title=Fragment+derived+selective+inhibitors+of+dual+specificity+kinases+DYRK1A+and+DYRK1B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26atitle%3DFragment%2520derived%2520selective%2520inhibitors%2520of%2520dual%2520specificity%2520kinases%2520DYRK1A%2520and%2520DYRK1B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10a','cit10b','cit10c','cit10d','cit10e'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">David Lee Walmsley, James B. Murray, Pawel Dokurno, Andrew J. Massey, Karen Benwell, Andrea Fiumana, Nicolas Foloppe, Stuart Ray, Julia Smith, Allan E. Surgenor, Thomas Edmonds, Didier Demarles, Mike Burbridge, Francisco Cruzalegui, Andras Kotschy, <span class="NLM_string-name hlFld-ContribAuthor">Roderick E. Hubbard</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 8971-8991. <a href="https://doi.org/10.1021/acs.jmedchem.1c00024" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00024%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment-Derived%252BSelective%252BInhibitors%252Bof%252BDual-Specificity%252BKinases%252BDYRK1A%252Band%252BDYRK1B%26aulast%3DLee%2BWalmsley%26aufirst%3DDavid%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D07012021%26date%3D18062021%26volume%3D64%26issue%3D13%26spage%3D8971%26epage%3D8991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural characterization of fragment <b>1</b> bound to Dyrk1a, as determined by X-ray crystallography (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7A4W">7A4W</a>). (A) Overall view of the structure, with <b>1</b> shown in green (space filling) and the ATP site of Dyrk1a as the molecular surface. (B) Overlay of Dyrk1a-bound harmine (orange, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR">3ANR</a>) onto <b>1</b> (green) highlighting the hinge region in magenta and salt-bridge region in blue. (C) Specific interactions between <b>1</b> and Dyrk1a showing selected hydrogen atoms (added with software MOE<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>). Black dotted lines depict hydrogen bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structures of Dyrk1a complexes of compounds derived by the early elaboration of fragment <b>1.</b> Only selected structural elements and hydrogen atoms are shown. Hydrogen bonds of interest are depicted with black dotted lines. (A) <b>3</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ2">7AJ2</a>) showing double occupancy, with its amine buried (green) or pointing toward the solvent (magenta). (B) Overlay of <b>1</b> (green) and <b>5</b> (orange, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ4">7AJ4</a>). (C) Overlay of <b>10</b> (orange sticks, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ5">7AJ5</a>) and <b>25</b> (green ball and stick, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ8">7AJ8</a>). The amine of <b>25</b> points toward Glu203. (D) <b>16</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ7">7AJ7</a>) with the imidazole methyl substituent offering a vector for growth toward the glycine loop (blue) and the opening of the ATP binding site including Asn244 and Asn292. (E) <b>28</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJA">7AJA</a>) highlighting the desolvation of polar groups (red arrow) and a water molecule trapped between <b>28</b> and Glu203. (F) <b>32</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJM">7AJM</a>). It is unclear if the desolvation of the cationic amine by Phe170 is compensated by cationâÏ interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural basis for the design of compounds selective for DYRK1A over CDK9. Black dotted lines denote hydrogen bonds. (A) Alignment the ATP-binding sites of Dyrk1a bound to <b>10</b> (green) and unliganded CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH">3BLH</a>). Residues within 5 Ã of <b>10</b> are shown for both proteins; differing residue pairs (Dyrk1a residues labeled) are in red and same residue types are in gray. (B) Overlay of CDK9 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH">3BLH</a>) onto Dyrk1a bound to <b>10</b> (gold sticks) or <b>33</b> (green ball and sticks, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJS">7AJS</a>). Only the hinge backbone of Dyrk1a (grey) and CDK9 (magenta) is shown. The red oval highlights the clash between the methyl group of <b>33</b> and the hinge backbone carbonyl Cys106 in CDK9. (C) Overlay of Dyrk1a bound to <b>33</b> (green sticks) and <b>38</b> (brown ball and sticks, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJV">7AJV</a>). The butyl substituent at position 2 crosses the path of the protein chain (gray ribbon) into the solvent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Use of X-ray structures for the design of Dyrk1a inhibitors selective over Dyrk2. Black and green dotted lines depict hydrogen bonds and van der Waals contacts, respectively. (A) Overlay of <b>50</b> bound to Dyrk1a (green, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKL">7AKL</a>) and Dyrk2 (magenta, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKF">7AKF</a>). (B) Overlay of <b>46</b> (green, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJW">7AJW</a>) and <b>53</b> (orange, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AK2">7AK2</a>) bound to Dyrk1a. (C) Overlay of <b>56</b> (green, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKB">7AKB</a>) and <b>58</b> (orange, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKE">7AKE</a>) bound to Dyrk1a. (D) Overlay of <b>58</b> bound to Dyrk1a (green) and Dyrk2 (magenta, PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKH">7AKH</a>). The glycine loop is shown in blue ribbons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Strategies Applied in the Preparation of Our DYRK1A Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/medium/jm1c00023_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Tumor volume changes in mice xenografted with A2780 cells on treatment with <b>40</b>. BALB/C nude mice bearing established A2780 xenografted tumors were dosed BID with the indicated amounts of <b>40</b> for 14 days (black triangles). Tumor volume was determined as described in the Experimental section.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00023/20210520/images/large/jm1c00023_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00023&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08405" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08405" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 20 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eirmbter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejedor, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joost, H.-G.</span></span> <span> </span><span class="NLM_article-title">Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">25893</span>â <span class="NLM_lpage">25902</span>, <span class="refDoi">Â DOI: 10.1074/jbc.273.40.25893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1074%2Fjbc.273.40.25893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=9748265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADyaK1cXms1egt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=25893-25902&author=W.+Beckerauthor=Y.+Weberauthor=K.+Wetzelauthor=K.+Eirmbterauthor=F.+J.+Tejedorauthor=H.-G.+Joost&title=Sequence+characteristics%2C+subcellular+localization%2C+and+substrate+specificity+of+DYRK-related+kinases%2C+a+novel+family+of+dual+specificity+protein+kinases&doi=10.1074%2Fjbc.273.40.25893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases</span></div><div class="casAuthors">Becker, Walter; Weber, Yvonne; Wetzel, Kristiane; Eirmbter, Klaus; Tejedor, Francisco J.; Joost, Hans-Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">25893-25902</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">DYRK1 is a dual specificity protein kinase presumably involved in brain development.  The kinase belongs to a new family of protein kinases comprising at least seven mammalian isoforms (DYRK1A, DYRK1B, DYRK1C, DYRK2, DYRK3, DYRK4A, and DYRK4B), the yeast homolog Yak1p, and the Drosophila kinase minibrain (MNB).  In rat tissues, DYRK1A is expressed ubiquitously, whereas transcripts for DYRK1B, DYRK2, DYRK3, and DYRK4 were detected predominantly in testes of adult but not prepuberal rats.  By fluorescence microscopy and subcellular fractionation, a green fluorescent protein (GFP) fusion protein of DYRK1A was found to accumulate in the nucleus of transfected COS-7 and HEK293 cells, whereas GFP-DYRK2 was predominantly detected in the cytoplasm.  DYRK1A exhibited a punctate pattern of GFP fluorescence inside the nucleus and was co-purified with the nuclear matrix.  Anal. of GFP-DYRK1A deletion constructs showed that the nuclear localization of DYRK1A was mediated by its nuclear targeting signal (amino acids 105-139) but that its characteristics subnuclear distribution depended on addnl. N-terminal elements (amino acids 1-104).  When expressed in Escherichia coli, DYRK1A, DYRK2, DYRK3, MNB, and Yak1p catalyzed their autophosphorylation on tyrosine residues.  The kinases differed in their substrate specificity in that DYRK2 and DYRK3, but not DYRK1A and MNB, catalyzed phosphorylation of histone H2B.  The heterogeneity of their subcellular localization and substrate specificity suggests that the kinases are involved in different cellular functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Q1vPoFEv4LVg90H21EOLACvtfcHk0lhScYg7ZuKR0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1egt7g%253D&md5=4b8029c26149c1ecb9d65baf50dd978d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.40.25893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.40.25893%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DW.%26aulast%3DWeber%26aufirst%3DY.%26aulast%3DWetzel%26aufirst%3DK.%26aulast%3DEirmbter%26aufirst%3DK.%26aulast%3DTejedor%26aufirst%3DF.%2BJ.%26aulast%3DJoost%26aufirst%3DH.-G.%26atitle%3DSequence%2520characteristics%252C%2520subcellular%2520localization%252C%2520and%2520substrate%2520specificity%2520of%2520DYRK-related%2520kinases%252C%2520a%2520novel%2520family%2520of%2520dual%2520specificity%2520protein%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D25893%26epage%3D25902%26doi%3D10.1074%2Fjbc.273.40.25893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alford, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, E. M. C.</span></span> <span> </span><span class="NLM_article-title">Down syndrome--recent progress and future prospects</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">R75</span>â <span class="NLM_lpage">R83</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddp010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1093%2Fhmg%2Fddp010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=19297404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFSnt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=R75-R83&author=F.+K.+Wisemanauthor=K.+A.+Alfordauthor=V.+L.+J.+Tybulewiczauthor=E.+M.+C.+Fisher&title=Down+syndrome%2D%2Drecent+progress+and+future+prospects&doi=10.1093%2Fhmg%2Fddp010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Down syndrome-recent progress and future prospects</span></div><div class="casAuthors">Wiseman, Frances K.; Alford, Kate A.; Tybulewicz, Victor L. J.; Fisher, Elizabeth M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">Rev. Iss. 1</span>),
    <span class="NLM_cas:pages">R75-R83</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Down syndrome (DS) is caused by trisomy of chromosome 21 (Hsa21) and is assocd. with a no. of deleterious phenotypes, including learning disability, heart defects, early-onset Alzheimer's disease and childhood leukemia.  Individuals with DS are affected by these phenotypes to a variable extent; understanding the cause of this variation is a key challenge.  Here, we review recent research progress in DS, both in patients and relevant animal models.  In particular, we highlight exciting advances in therapy to improve cognitive function in people with DS and the significant developments in understanding the gene content of Hsa21.  Moreover, we discuss future research directions in light of new technologies.  In particular, the use of chromosome engineering to generate new trisomic mouse models and large-scale studies of genotype-phenotype relationships in patients are likely to significantly contribute to the future understanding of DS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgWPB7T5JFA7Vg90H21EOLACvtfcHk0lhScYg7ZuKR0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFSnt7w%253D&md5=8a17f1eb33786dda74d661dbc97b4844</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddp010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddp010%26sid%3Dliteratum%253Aachs%26aulast%3DWiseman%26aufirst%3DF.%2BK.%26aulast%3DAlford%26aufirst%3DK.%2BA.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26aulast%3DFisher%26aufirst%3DE.%2BM.%2BC.%26atitle%3DDown%2520syndrome--recent%2520progress%2520and%2520future%2520prospects%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2009%26volume%3D18%26spage%3DR75%26epage%3DR83%26doi%3D10.1093%2Fhmg%2Fddp010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mariano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralinaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, M.</span></span> <span> </span><span class="NLM_article-title">First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimerâs Disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1198</span>â <span class="NLM_lpage">1202</span>, <span class="refDoi">Â DOI: 10.1021/cn5001815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5001815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1198-1202&author=M.+Marianoauthor=C.+Schmittauthor=P.+Miralinaghiauthor=M.+Cattoauthor=R.+W.+Hartmannauthor=A.+Carottiauthor=M.+Engel&title=First+Selective+Dual+Inhibitors+of+Tau+Phosphorylation+and+Beta-Amyloid+Aggregation%2C+Two+Major+Pathogenic+Mechanisms+in+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fcn5001815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer's Disease</span></div><div class="casAuthors">Mariano, Marica; Schmitt, Christian; Miralinaghi, Parisa; Catto, Marco; Hartmann, Rolf W.; Carotti, Angelo; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1198-1202</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In Alzheimer's disease (AD), multiple factors account for the accumulation of neurocellular changes, which may begin several years before symptoms appear.  The most important pathogenic brain changes that are contributing to the development of AD are the formation of the cytotoxic Î²-amyloid aggregates and of the neurofibrillary tangles, which originate from amyloid-Î² peptides and hyperphosphorylated tau protein, resp.  New therapeutic agents that target both major pathogenic mechanisms may be particularly efficient.  In this study, the authors introduce bis(hydroxyphenyl)-substituted thiophenes I [R1 = 3-Me, 3-MeO, 3-Me-4-MeO, 3-Et-4-MeO; R2 = 3-MeO, 4-MeO, 3-Me-4-MeO, 3-Et-4-MeO] as a novel class of selective, dual inhibitors of the tau kinase Dyrk1A and of the amyloid-Î² aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgPu3VSQ64rVg90H21EOLACvtfcHk0lhScYg7ZuKR0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K&md5=31754e003032609beeb9568418bc30d7</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1021%2Fcn5001815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5001815%26sid%3Dliteratum%253Aachs%26aulast%3DMariano%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DMiralinaghi%26aufirst%3DP.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3DFirst%2520Selective%2520Dual%2520Inhibitors%2520of%2520Tau%2520Phosphorylation%2520and%2520Beta-Amyloid%2520Aggregation%252C%2520Two%2520Major%2520Pathogenic%2520Mechanisms%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D1198%26epage%3D1202%26doi%3D10.1021%2Fcn5001815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Coutadeur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyamine, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delalonde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblond, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foucourt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casagrande, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taverne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pando, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ©sirÃ©, L.</span></span> <span> </span><span class="NLM_article-title">A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimerâs disease: effect on Tau and amyloid pathologies in vitro</span>. <i>Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">440</span>â <span class="NLM_lpage">451</span>, <span class="refDoi">Â DOI: 10.1111/jnc.13018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1111%2Fjnc.13018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=25556849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlKitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2015&pages=440-451&author=S.+Coutadeurauthor=H.+Benyamineauthor=L.+Delalondeauthor=C.+de+Oliveiraauthor=B.+Leblondauthor=A.+Foucourtauthor=T.+Bessonauthor=A.-S.+Casagrandeauthor=T.+Taverneauthor=A.+Girardauthor=M.+P.+Pandoauthor=L.+D%C3%A9sir%C3%A9&title=A+novel+DYRK1A+%28dual+specificity+tyrosine+phosphorylation-regulated+kinase+1A%29+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+effect+on+Tau+and+amyloid+pathologies+in+vitro&doi=10.1111%2Fjnc.13018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro</span></div><div class="casAuthors">Coutadeur, Severine; Benyamine, Helene; Delalonde, Laurence; de Oliveira, Catherine; Leblond, Bertrand; Foucourt, Alicia; Besson, Thierry; Casagrande, Anne-Sophie; Taverne, Thierry; Girard, Angelique; Pando, Matthew P.; Desire, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">440-451</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) gene is located within the Down Syndrome (DS) crit. region on chromosome 21 and is implicated in the generation of Tau and amyloid pathologies that are assocd. with the early onset Alzheimer's Disease (AD) obsd. in DS.  DYRK1A is also found assocd. with neurofibrillary tangles in sporadic AD and phosphorylates key AD players (Tau, amyloid precursor, protein, etc).  Thus, DYRK1A may be an important therapeutic target to modify the course of Tau and amyloid beta (AÎ²) pathologies.  Here, we describe EHT 5372 (Me 9-(2,4-dichlorophenylamino) thiazolo[5,4-f]quinazoline-2-carbimidate), a novel, highly potent (IC50 = 0.22 nM) DYRK1A inhibitor with a high degree of selectivity over 339 kinases.  Models in which inhibition of DYRK1A by siRNA reduced and DYRK1A over-expression induced Tau phosphorylation or AÎ² prodn. were used.  EHT 5372 inhibits DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites in biochem. and cellular assays.  EHT 5372 also normalizes both AÎ²-induced Tau phosphorylation and DYRK1A-stimulated AÎ² prodn.  DYRK1A is thus as a key element of AÎ²-mediated Tau hyperphosphorylation, which links Tau and amyloid pathologies.  EHT 5372 and other compds. in its class warrant in vivo investigation as a novel, high-potential therapy for AD and other Tau opathies.  Inhibition of the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is a new high-potential therapeutic approach for Alzheimer disease.  Here we describe EHT 5372, a novel potent and selective DYRK1A inhibitor.  EHT 5372 inhibits DYRK1A-induced Tau phosphorylation, AÎ² prodn. and AÎ² effects on phospho-Tau, including Tau aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVswt1MX4I7Vg90H21EOLACvtfcHk0ljxaCRRSfmZHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlKitbY%253D&md5=5953fc5e56b7ea3c86ea414bd3de7863</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13018%26sid%3Dliteratum%253Aachs%26aulast%3DCoutadeur%26aufirst%3DS.%26aulast%3DBenyamine%26aufirst%3DH.%26aulast%3DDelalonde%26aufirst%3DL.%26aulast%3Dde%2BOliveira%26aufirst%3DC.%26aulast%3DLeblond%26aufirst%3DB.%26aulast%3DFoucourt%26aufirst%3DA.%26aulast%3DBesson%26aufirst%3DT.%26aulast%3DCasagrande%26aufirst%3DA.-S.%26aulast%3DTaverne%26aufirst%3DT.%26aulast%3DGirard%26aufirst%3DA.%26aulast%3DPando%26aufirst%3DM.%2BP.%26aulast%3DD%25C3%25A9sir%25C3%25A9%26aufirst%3DL.%26atitle%3DA%2520novel%2520DYRK1A%2520%2528dual%2520specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25201A%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520effect%2520on%2520Tau%2520and%2520amyloid%2520pathologies%2520in%2520vitro%26jtitle%3DNeurochem.%26date%3D2015%26volume%3D133%26spage%3D440%26epage%3D451%26doi%3D10.1111%2Fjnc.13018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, Y.-W.</span></span> <span> </span><span class="NLM_article-title">The role of DYRK1A in neurodegenerative diseases</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1111/j.1742-4658.2010.07955.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1111%2Fj.1742-4658.2010.07955.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=21156028" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=236-245&author=J.+Weigelauthor=C.-X.+Gongauthor=Y.-W.+Hwang&title=The+role+of+DYRK1A+in+neurodegenerative+diseases&doi=10.1111%2Fj.1742-4658.2010.07955.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07955.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07955.x%26sid%3Dliteratum%253Aachs%26aulast%3DWeigel%26aufirst%3DJ.%26aulast%3DGong%26aufirst%3DC.-X.%26aulast%3DHwang%26aufirst%3DY.-W.%26atitle%3DThe%2520role%2520of%2520DYRK1A%2520in%2520neurodegenerative%2520diseases%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D236%26epage%3D245%26doi%3D10.1111%2Fj.1742-4658.2010.07955.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rachdi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariyawasam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AÃ¯ello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabar, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharfmann, R.</span></span> <span> </span><span class="NLM_article-title">Dyrk1A induces pancreatic Î² cell mass expansion and improves glucose tolerance</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2221</span>â <span class="NLM_lpage">2229</span>, <span class="refDoi">Â DOI: 10.4161/cc.29250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.4161%2Fcc.29250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=24870561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2221-2229&author=L.+Rachdiauthor=D.+Kariyawasamauthor=V.+A%C3%AFelloauthor=Y.+Heraultauthor=N.+Janelauthor=J.-M.+Delabarauthor=M.+Polakauthor=R.+Scharfmann&title=Dyrk1A+induces+pancreatic+%CE%B2+cell+mass+expansion+and+improves+glucose+tolerance&doi=10.4161%2Fcc.29250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Dyrk1A induces pancreatic Î² cell mass expansion and improves glucose tolerance</span></div><div class="casAuthors">Rachdi, Latif; Kariyawasam, Dulanjalee; Aiello, Virginie; Herault, Yann; Janel, Nathalie; Delabar, Jean-Maurice; Polak, Michel; Scharfmann, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2221-2229</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Type 2 diabetes is caused by a limited capacity of insulin-producing pancreatic Î² cells to increase their mass and function in response to insulin resistance.  The signaling pathways that pos. regulate functional Î² cell mass have not been fully elucidated.  DYRK1A (also called minibrain/MNB) is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family.  A significant amt. of data implicates DYRK1A in brain growth and Down syndrome, and recent data indicate that Dyrk1A haploinsufficient mice have a low functional Î² cell mass.  Here we ask whether Dyrk1A upregulation could be a way to increase functional Î² cell mass.  We used mice overexpressing Dyrk1A under the control of its own regulatory sequences (mBACTgDyrk1A).  These mice exhibit decreased glucose levels and hyperinsulinemia in the fasting state.  Improved glucose tolerance is obsd. in these mice as early as 4 wk of age.  Upregulation of Dyrk1A in Î² cells induces expansion of Î² cell mass through increased proliferation and cell size.  Importantly, mBACTgDyrk1A mice are protected against high-fat-diet-induced Î² cell failure through increase in Î² cell mass and insulin sensitivity.  These studies show the crucial role of the DYRK1A pathway in the regulation of Î² cell mass and carbohydrate metab. in vivo.  Activating the DYRK1A pathway could thus represent an innovative way to increase functional Î² cell mass.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre5nXGBuindrVg90H21EOLACvtfcHk0ljxaCRRSfmZHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WisLzP&md5=92dc7241ee0f258a91351b6bffd941d8</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.4161%2Fcc.29250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.29250%26sid%3Dliteratum%253Aachs%26aulast%3DRachdi%26aufirst%3DL.%26aulast%3DKariyawasam%26aufirst%3DD.%26aulast%3DA%25C3%25AFello%26aufirst%3DV.%26aulast%3DHerault%26aufirst%3DY.%26aulast%3DJanel%26aufirst%3DN.%26aulast%3DDelabar%26aufirst%3DJ.-M.%26aulast%3DPolak%26aufirst%3DM.%26aulast%3DScharfmann%26aufirst%3DR.%26atitle%3DDyrk1A%2520induces%2520pancreatic%2520%25CE%25B2%2520cell%2520mass%2520expansion%2520and%2520improves%2520glucose%2520tolerance%26jtitle%3DCell%2520Cycle%26date%3D2014%26volume%3D13%26spage%3D2221%26epage%3D2229%26doi%3D10.4161%2Fcc.29250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swafford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursalaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hering, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DYRK1A and GSK3B induces human Î²-cell proliferation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8372</span>, <span class="refDoi">Â DOI: 10.1038/ncomms9372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1038%2Fncomms9372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=26496802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8372&author=W.+Shenauthor=B.+Taylorauthor=Q.+Jinauthor=V.+Nguyen-Tranauthor=S.+Meeusenauthor=Y.-Q.+Zhangauthor=A.+Kamireddyauthor=A.+Swaffordauthor=A.+F.+Powersauthor=J.+Walkerauthor=J.+Lambauthor=B.+Bursalayaauthor=M.+DiDonatoauthor=G.+Harbauthor=M.+Qiuauthor=C.+M.+Filippiauthor=L.+Deatonauthor=C.+N.+Turkauthor=W.+L.+Suarez-Pinzonauthor=Y.+Liuauthor=X.+Haoauthor=T.+Moauthor=S.+Yanauthor=J.+Liauthor=A.+E.+Hermanauthor=B.+J.+Heringauthor=T.+Wuauthor=H.+M.+Seidelauthor=P.+McNamaraauthor=R.+Glynneauthor=B.+Laffitte&title=Inhibition+of+DYRK1A+and+GSK3B+induces+human+%CE%B2-cell+proliferation&doi=10.1038%2Fncomms9372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DYRK1A and GSK3B induces human Î²-cell proliferation</span></div><div class="casAuthors">Shen, Weijun; Taylor, Brandon; Jin, Qihui; Nguyen-Tran, Van; Meeusen, Shelly; Zhang, You-Qing; Kamireddy, Anwesh; Swafford, Austin; Powers, Andrew F.; Walker, John; Lamb, John; Bursalaya, Badry; DiDonato, Michael; Harb, George; Qiu, Minhua; Filippi, Christophe M.; Deaton, Lisa; Turk, Carolina N.; Suarez-Pinzon, Wilma L.; Liu, Yahu; Hao, Xueshi; Mo, Tingting; Yan, Shanshan; Li, Jing; Herman, Ann E.; Hering, Bernhard J.; Wu, Tom; Seidel, H. Martin; McNamara, Peter; Glynne, Richard; Laffitte, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8372</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insufficient pancreatic Î²-cell mass or function results in diabetes mellitus.  While significant progress has been made in regulating insulin secretion from Î²-cells in diabetic patients, no pharmacol. agents have been described that increase Î²-cell replication in humans.  Here we report aminopyrazine compds. that stimulate robust Î²-cell proliferation in adult primary islets, most likely as a result of combined inhibition of DYRK1A and GSK3B.  Aminopyrazine-treated human islets retain functionality in vitro and after transplantation into diabetic mice.  Oral dosing of these compds. in diabetic mice induces Î²-cell proliferation, increases Î²-cell mass and insulin content, and improves glycemic control.  Biochem., genetic and cell biol. data point to Dyrk1a as the key mol. target.  This study supports the feasibility of treating diabetes with an oral therapy to restore Î²-cell mass, and highlights a tractable pathway for future drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVHzP-VkH5nrVg90H21EOLACvtfcHk0lgJX5t7aLj13Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK&md5=5ef960af3bfd2795b9fdce52876e5d59</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1038%2Fncomms9372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9372%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DSwafford%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DBursalaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DFilippi%26aufirst%3DC.%2BM.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DTurk%26aufirst%3DC.%2BN.%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHerman%26aufirst%3DA.%2BE.%26aulast%3DHering%26aufirst%3DB.%2BJ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DLaffitte%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520DYRK1A%2520and%2520GSK3B%2520induces%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8372%26doi%3D10.1038%2Fncomms9372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Perez, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenfeld, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivendran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-OcaÃ±a, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">388</span>, <span class="refDoi">Â DOI: 10.1038/nm.3820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1038%2Fnm.3820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=25751815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=383-388&author=P.+Wangauthor=J.-C.+Alvarez-Perezauthor=D.+P.+Felsenfeldauthor=H.+Liuauthor=S.+Sivendranauthor=A.+Benderauthor=A.+Kumarauthor=R.+Sanchezauthor=D.+K.+Scottauthor=A.+Garcia-Oca%C3%B1aauthor=A.+F.+Stewart&title=A+high-throughput+chemical+screen+reveals+that+harmine-mediated+inhibition+of+DYRK1A+increases+human+pancreatic+beta+cell+replication&doi=10.1038%2Fnm.3820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication</span></div><div class="casAuthors">Wang, Peng; Alvarez-Perez, Juan-Carlos; Felsenfeld, Dan P.; Liu, Hongtao; Sivendran, Sharmila; Bender, Aaron; Kumar, Anil; Sanchez, Roberto; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Types 1 and 2 diabetes affect some 380 million people worldwide.  Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells.  Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (â¼2%) engaged in the cell cycle in the first year of life.  In embryonic life and after early childhood, beta cell replication is barely detectable.  Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts.  Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo.  Here, using a high-throughput small-mol. screen (HTS), we find that analogs of the small mol. harmine function as a new class of human beta cell mitogenic compds.  We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation.  Using three different mouse and human islet in vivo-based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control.  These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy.  Enhancing the potency and beta cell specificity of these compds. are important future challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp11xY4tql3VbVg90H21EOLACvtfcHk0lgJX5t7aLj13Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D&md5=32a02c393defd14b8922ac9efff63389</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fnm.3820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3820%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DAlvarez-Perez%26aufirst%3DJ.-C.%26aulast%3DFelsenfeld%26aufirst%3DD.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSivendran%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Oca%25C3%25B1a%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DA%2520high-throughput%2520chemical%2520screen%2520reveals%2520that%2520harmine-mediated%2520inhibition%2520of%2520DYRK1A%2520increases%2520human%2520pancreatic%2520beta%2520cell%2520replication%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D383%26epage%3D388%26doi%3D10.1038%2Fnm.3820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez-MartÃ­nez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-GÃ³mez, P.</span></span> <span> </span><span class="NLM_article-title">DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis</span>. <i>Mol. Cell. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e970048</span> <span class="refDoi">Â DOI: 10.4161/23723548.2014.970048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.4161%2F23723548.2014.970048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=27308401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWqtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&author=P.+Fern%C3%A1ndez-Mart%C3%ADnezauthor=C.+Zahoneroauthor=P.+S%C3%A1nchez-G%C3%B3mez&title=DYRK1A%3A+the+double-edged+kinase+as+a+protagonist+in+cell+growth+and+tumorigenesis&doi=10.4161%2F23723548.2014.970048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis</span></div><div class="casAuthors">Fernandez-Martinez, P.; Zahonero, C.; Sanchez-Gomez, P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e970048/1-e970048/11</span>CODEN:
                <span class="NLM_cas:coden">MCOOCO</span>;
        ISSN:<span class="NLM_cas:issn">2372-3556</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">DYRK1A (dual-specificity tyrosine-regulated kinase 1A) is a kinase with multiple implications for embryonic development, esp. in the nervous system where it regulates the balance between proliferation and differentiation of neural progenitors.  The DYRK1A gene is located in the Down syndrome crit. region and may play a significant role in the developmental brain defects, early neurodegeneration, and cancer susceptibility of individuals with this syndrome.  DYRK1A is also expressed in adults, where it might participate in the regulation of cell cycle, survival, and tumorigenesis, thus representing a potential therapeutic target for certain types of cancer.  However, the final readout of DYRK1A overexpression or inhibition depends strongly on the cellular context, as it has both tumor suppressor and oncogenic activities.  Here, we will discuss the functions and substrates of DYRK1A assocd. with the control of cell growth and tumorigenesis with a focus on the potential use of DYRK1A inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1OUDGl-nB87Vg90H21EOLACvtfcHk0lgJX5t7aLj13Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWqtr0%253D&md5=27153f30af11f2572ba271ee09dd9939</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.4161%2F23723548.2014.970048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F23723548.2014.970048%26sid%3Dliteratum%253Aachs%26aulast%3DFern%25C3%25A1ndez-Mart%25C3%25ADnez%26aufirst%3DP.%26aulast%3DZahonero%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez-G%25C3%25B3mez%26aufirst%3DP.%26atitle%3DDYRK1A%253A%2520the%2520double-edged%2520kinase%2520as%2520a%2520protagonist%2520in%2520cell%2520growth%2520and%2520tumorigenesis%26jtitle%3DMol.%2520Cell.%2520Oncol.%26date%3D2015%26volume%3D2%26doi%3D10.4161%2F23723548.2014.970048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrasne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamoral-Theys, D.</span></span> <span> </span><span class="NLM_article-title">DYRK1A kinase inhibitors with emphasis on cancer</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1315</span>â <span class="NLM_lpage">1329</span>, <span class="refDoi">Â DOI: 10.2174/138955712804586639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.2174%2F138955712804586639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=23016545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1315-1329&author=A.+Ionescuauthor=F.+Dufrasneauthor=M.+Gelbckeauthor=I.+Jabinauthor=R.+Kissauthor=D.+Lamoral-Theys&title=DYRK1A+kinase+inhibitors+with+emphasis+on+cancer&doi=10.2174%2F138955712804586639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A kinase inhibitors with emphasis on cancer</span></div><div class="casAuthors">Ionescu, A.; Dufrasne, F.; Gelbcke, M.; Jabin, I.; Kiss, R.; Lamoral-Theys, D.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1315-1329</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Various types of cancers (including gliomas, melanomas, and esophageal, pancreas and non-small-cell lung cancers) display intrinsic resistance to pro-apoptotic stimuli, such as conventional chemotherapy and radiotherapy, and/or the activation of a multidrug resistance phenotype, which are major barriers to effective treatment and lead to poor patient prognosis.  The DYRK1A kinase is directly implicated in the resistance of cancer cells to pro-apoptotic stimuli and drives several pathways that enhance proliferation, migration, and the redn. of cell death, leading to very aggressive biol. behavior in cancer cell populations.  The DYRK1A kinase is also implicated in neurol. diseases and in neoangiogenic processes.  Thus, the DYRK1A kinase is of great interest for both cancer and neuroscience research.  During the last decade, numerous compds. that inhibit DYRK1A have been synthesized.  The present review discusses the available mols. known to interfere with DYRK1A activity and the implications of DYRK1A in cancer and other diseases and serves as a rational anal. for researchers who aim to improve the anti-DYRK1A activity of currently available compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBxH4Qznig8rVg90H21EOLACvtfcHk0lgz5g3nnIGffA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12hu7jI&md5=9acac0cacdc9fbfd558d6199ff4e3a96</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2174%2F138955712804586639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955712804586639%26sid%3Dliteratum%253Aachs%26aulast%3DIonescu%26aufirst%3DA.%26aulast%3DDufrasne%26aufirst%3DF.%26aulast%3DGelbcke%26aufirst%3DM.%26aulast%3DJabin%26aufirst%3DI.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DLamoral-Theys%26aufirst%3DD.%26atitle%3DDYRK1A%2520kinase%2520inhibitors%2520with%2520emphasis%2520on%2520cancer%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26spage%3D1315%26epage%3D1329%26doi%3D10.2174%2F138955712804586639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plater, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLauchlan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klevernic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">The selectivity of protein kinase inhibitors: a further update</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1042/bj20070797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1042%2FBJ20070797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=17850214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=297-315&author=J.+Bainauthor=L.+Platerauthor=M.+Elliottauthor=N.+Shpiroauthor=C.+J.+Hastieauthor=H.+McLauchlanauthor=I.+Klevernicauthor=J.+S.+C.+Arthurauthor=D.+R.+Alessiauthor=P.+Cohen&title=The+selectivity+of+protein+kinase+inhibitors%3A+a+further+update&doi=10.1042%2Fbj20070797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of protein kinase inhibitors: a further update</span></div><div class="casAuthors">Bain, Jenny; Plater, Lorna; Elliott, Matt; Shpiro, Natalia; Hastie, C. James; McLauchlan, Hilary; Klevernic, Iva; Arthur, J. Simon C.; Alessi, Dario R.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-315</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 65 compds. reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases.  On the basis of this information, the effects of compds. that we have studied in cells and other data in the literature, we recommend the use of the following small-mol. inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiol. roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)-raptor (regulatory assocd. protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor.  We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro.  The results have further emphasized the need for considerable caution in using small-mol. inhibitors of protein kinases to assess the physiol. roles of these enzymes.  Despite being used widely, many of the compds. that we analyzed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQPaieWftdVrVg90H21EOLACvtfcHk0lgz5g3nnIGffA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE&md5=e2334e35897dd1b9770bbcca8f82bb9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2FBJ20070797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070797%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DPlater%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DShpiro%26aufirst%3DN.%26aulast%3DHastie%26aufirst%3DC.%2BJ.%26aulast%3DMcLauchlan%26aufirst%3DH.%26aulast%3DKlevernic%26aufirst%3DI.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%253A%2520a%2520further%2520update%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D297%26epage%3D315%26doi%3D10.1042%2Fbj20070797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miralles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre-Coll, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moranta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensio, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Sevilla, J. A.</span></span> <span> </span><span class="NLM_article-title">High-affinity binding of Î²-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>518</i></span>,  <span class="NLM_fpage">234</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2005.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1016%2Fj.ejphar.2005.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=16061219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD2MXosVCksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=2005&pages=234-242&author=A.+Mirallesauthor=S.+Estebanauthor=A.+Sastre-Collauthor=D.+Morantaauthor=V.+J.+Asensioauthor=J.+A.+Garc%C3%ADa-Sevilla&title=High-affinity+binding+of+%CE%B2-carbolines+to+imidazoline+I2B+receptors+and+MAO-A+in+rat+tissues%3A+Norharman+blocks+the+effect+of+morphine+withdrawal+on+DOPA%2Fnoradrenaline+synthesis+in+the+brain&doi=10.1016%2Fj.ejphar.2005.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity binding of Î²-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: Norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain</span></div><div class="casAuthors">Miralles, Antonio; Esteban, Susana; Sastre-Coll, Antonio; Moranta, David; Asensio, Victor Jose; Garcia-Sevilla, Jesus Andres</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">234-242</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study was designed to det. the affinity and binding profile of Î²-carbolines for imidazoline I2 receptors and catalytic sites of monoamine oxidase (MAO)-A/B in rat brain and liver.  Another objective was to assess the in vivo effects of norharman (Î²-carboline) and LSL 60101 (I2 ligand) on brain 3,4-dihydroxyphenylalanine (DOPA) synthesis in morphine-dependent rats.  Competition expts. against [3H]2-BFI revealed that Î²-carbolines recognize the high- and low-affinity components of the brain imidazoline I2 receptor with the rank order of potency (KiH in nM): noreleagnine (12) > norharman (20) > harmalol (82) > harmaline (177) Â» harmine (630) > harman (700) Â» FG-7142 (>100,000).  In liver, this rank was different: harmine (51) > harmaline (103) = noreleagnine (103) Â» harmalol (1290) > harman (2000) Â» norharman (12,382) Â» FG-7142 (> 100,000).  In brain and liver, competition curves for Î²-carbolines against [3H]Ro41-1049 (MAO-A) and [3H]Ro19-6327 (MAO-B) were monophasic and resulted in different drug potencies for the two MAO isoenzymes (higher affinities for MAO-A) and in similar pharmacol. profiles in both tissues.  In morphine-dependent rats, naloxone (2 mg/kg, 2 h)-pptd. withdrawal increased the synthesis of DOPA in the cerebral cortex and hippocampus (50%).  Pretreatment with norharman (20 mg/kg) or LSL 60101 (20 mg/kg) (30 min before naloxone) fully prevented the stimulatory effect of opiate withdrawal on DOPA synthesis.  Norharman and LSL 60101 also attenuated the severity of the withdrawal syndrome.  The results indicate that Î²-carbolines bind with high affinity to imidazoline I2B receptors, and similarly to I2 ligands (LSL 60101) can block the behavioral and biochem. effects of opiate withdrawal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCvzFB8nFMG7Vg90H21EOLACvtfcHk0lgz5g3nnIGffA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXosVCksbg%253D&md5=6ea00978e64eb6e63412ac04a425a584</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DMiralles%26aufirst%3DA.%26aulast%3DEsteban%26aufirst%3DS.%26aulast%3DSastre-Coll%26aufirst%3DA.%26aulast%3DMoranta%26aufirst%3DD.%26aulast%3DAsensio%26aufirst%3DV.%2BJ.%26aulast%3DGarc%25C3%25ADa-Sevilla%26aufirst%3DJ.%2BA.%26atitle%3DHigh-affinity%2520binding%2520of%2520%25CE%25B2-carbolines%2520to%2520imidazoline%2520I2B%2520receptors%2520and%2520MAO-A%2520in%2520rat%2520tissues%253A%2520Norharman%2520blocks%2520the%2520effect%2520of%2520morphine%2520withdrawal%2520on%2520DOPA%252Fnoradrenaline%2520synthesis%2520in%2520the%2520brain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D518%26spage%3D234%26epage%3D242%26doi%3D10.1016%2Fj.ejphar.2005.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human Î²-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2986</span>â <span class="NLM_lpage">3003</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01379</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2986-3003&author=K.+Kumarauthor=P.+Wangauthor=J.+Wilsonauthor=V.+Zlatanicauthor=C.+Berrouetauthor=S.+Khamruiauthor=C.+Secorauthor=E.+A.+Swartzauthor=M.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=A.+Garcia-Ocanaauthor=R.+J.+DeVita&title=Synthesis+and+Biological+Validation+of+a+Harmine-Based%2C+Central+Nervous+System+%28CNS%29-Avoidant%2C+Selective%2C+Human+%CE%B2-Cell+Regenerative+Dual-Specificity+Tyrosine+Phosphorylation-Regulated+Kinase+A+%28DYRK1A%29+Inhibitor&doi=10.1021%2Facs.jmedchem.9b01379"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human Î²-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Wilson, Jessica; Zlatanic, Viktor; Berrouet, Cecilia; Khamrui, Susmita; Secor, Cody; Swartz, Ethan A.; Lazarus, Michael; Sanchez, Roberto; Stewart, Andrew F.; Garcia-Ocana, Adolfo; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2986-3003</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, our group identified that harmine is able to induce Î²-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.  Since, harmine suffers from a lack of selectivity, both against other kinases and CNS off-targets, we therefore sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity for off-targets while retaining human Î²-cell proliferation activity.  We carried out optimization of the 9-N-position of harmine to synthesize 29 harmine-based analogs.  Several novel inhibitors showed excellent DYRK1A inhibition and human Î²-cell proliferation capability.  An optimized DYRK1A inhibitor, compd. I, was identified as a novel, efficacious in vivo lead candidate.  Compd. I also demonstrates improved selectivity for kinases and CNS off-targets, as well as in vivo efficacy for Î²-cell proliferation and regeneration at lower doses than harmine.  Collectively, these findings demonstrate that compd. I is a much improved in vivo lead candidate as compared to harmine for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXVR-g2rCbbVg90H21EOLACvtfcHk0lgPkBx30JmN_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOgsr8%253D&md5=c739edc1358acafc412a122c272edceb</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01379%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520and%2520Biological%2520Validation%2520of%2520a%2520Harmine-Based%252C%2520Central%2520Nervous%2520System%2520%2528CNS%2529-Avoidant%252C%2520Selective%252C%2520Human%2520%25CE%25B2-Cell%2520Regenerative%2520Dual-Specificity%2520Tyrosine%2520Phosphorylation-Regulated%2520Kinase%2520A%2520%2528DYRK1A%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2986%26epage%3D3003%26doi%3D10.1021%2Facs.jmedchem.9b01379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokhale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunckley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, C.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimerâs?</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">857</span>â <span class="NLM_lpage">872</span>, <span class="refDoi">Â DOI: 10.1021/cn300094k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300094k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=857-872&author=B.+Smithauthor=F.+Meddaauthor=V.+Gokhaleauthor=T.+Dunckleyauthor=C.+Hulme&title=Recent+Advances+in+the+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Selective+DYRK1A+Inhibitors%3A+A+New+Avenue+for+a+Disease+Modifying+Treatment+of+Alzheimer%E2%80%99s%3F&doi=10.1021%2Fcn300094k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?</span></div><div class="casAuthors">Smith, Breland; Medda, Federico; Gokhale, Vijay; Dunckley, Travis; Hulme, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">857-872</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  With 24.3 million people affected in 2005 and an estd. rise to 42.3 million in 2020, dementia is currently a leading unmet medical need and costly burden on public health.  Seventy percent of these cases have been attributed to Alzheimer's disease (AD), a neurodegenerative pathol. whose most evident symptom is a progressive decline in cognitive functions.  Dual specificity tyrosine phosphorylation regulated kinase-1A (DYRK1A) is important in neuronal development and plays a variety of functional roles within the adult central nervous system.  The DYRK1A gene is located within the Down syndrome crit. region (DSCR) on human chromosome 21 and current research suggests that overexpression of DYRK1A may be a significant factor leading to cognitive deficits in people with Alzheimer's disease (AD) and Down syndrome (DS).  Currently, treatment options for cognitive deficiencies assocd. with Down syndrome, as well as Alzheimer's disease, are extremely limited and represent a major unmet therapeutic need.  Small mol. inhibition of DYRK1A activity in the brain may provide an avenue for pharmaceutical intervention of mental impairment assocd. with AD and other neurodegenerative diseases.  We herein review the current state of the art in the development of DYRK1A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSAw8CXNiP7Vg90H21EOLACvtfcHk0lgPkBx30JmN_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KmsL3K&md5=2009c25bc00389971cd71f64ead2da4a</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fcn300094k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300094k%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DMedda%26aufirst%3DF.%26aulast%3DGokhale%26aufirst%3DV.%26aulast%3DDunckley%26aufirst%3DT.%26aulast%3DHulme%26aufirst%3DC.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Selective%2520DYRK1A%2520Inhibitors%253A%2520A%2520New%2520Avenue%2520for%2520a%2520Disease%2520Modifying%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%253F%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D857%26epage%3D872%26doi%3D10.1021%2Fcn300094k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span> <span> </span><span class="NLM_article-title">Activation, regulation, and inhibition of DYRK1A</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">246</span>â <span class="NLM_lpage">256</span>, <span class="refDoi">Â DOI: 10.1111/j.1742-4658.2010.07956.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1111%2Fj.1742-4658.2010.07956.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=21126318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFGru7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=246-256&author=W.+Beckerauthor=W.+Sippl&title=Activation%2C+regulation%2C+and+inhibition+of+DYRK1A&doi=10.1111%2Fj.1742-4658.2010.07956.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Activation, regulation, and inhibition of DYRK1A</span></div><div class="casAuthors">Becker, Walter; Sippl, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-256</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a protein kinase with diverse functions in neuronal development and adult brain physiol.  Higher than normal levels of DYRK1A are assocd. with the pathol. of neurodegenerative diseases and have been implicated in some neurobiol. alterations of Down syndrome, such as mental retardation.  It is therefore important to understand the mol. mechanisms that control the activity of DYRK1A.  Here, the authors review current knowledge about the initial self-activation of DYRK1A by tyrosine autophosphorylation and propose that this mechanism presents an ancestral feature of the CMGC group of kinases.  However, tyrosine phosphorylation does not appear to regulate the enzymic activity of DYRK1A.  Control of DYRK1A may take place on the level of gene expression, interaction with regulatory proteins, and regulated nuclear translocation.  Finally, the authors compare the properties of small mol. inhibitors that target DYRK1A and evaluate their potential application and limitations.  The Î²-carboline alkaloid, harmine, is currently the most selective and potent inhibitor of DYRK1A and has proven very useful in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-_Eqb_-j05bVg90H21EOLACvtfcHk0liatDMJwfhp_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFGru7s%253D&md5=958db7f4577f941bd8dfb56afc461335</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07956.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07956.x%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DW.%26aulast%3DSippl%26aufirst%3DW.%26atitle%3DActivation%252C%2520regulation%252C%2520and%2520inhibition%2520of%2520DYRK1A%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D246%26epage%3D256%26doi%3D10.1111%2Fj.1742-4658.2010.07956.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tazarki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeinyeh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esvan, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶der, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khiari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josselin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anizon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span> <span> </span><span class="NLM_article-title">New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: Synthesis, biological evaluation and binding mode analysis</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">304</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2019.01.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1016%2Fj.ejmech.2019.01.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=30731399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1aqsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=304-317&author=H.+Tazarkiauthor=W.+Zeinyehauthor=Y.+J.+Esvanauthor=S.+Knappauthor=D.+Chatterjeeauthor=M.+Schr%C3%B6derauthor=A.+C.+Joergerauthor=J.+Khiariauthor=B.+Josselinauthor=B.+Baratteauthor=S.+Bachauthor=S.+Ruchaudauthor=F.+Anizonauthor=F.+Giraudauthor=P.+Moreau&title=New+pyrido%5B3%2C4-g%5Dquinazoline+derivatives+as+CLK1+and+DYRK1A+inhibitors%3A+Synthesis%2C+biological+evaluation+and+binding+mode+analysis&doi=10.1016%2Fj.ejmech.2019.01.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis</span></div><div class="casAuthors">Tazarki, Helmi; Zeinyeh, Wael; Esvan, Yannick J.; Knapp, Stefan; Chatterjee, Deep; Schroder, Martin; Joerger, Andreas C.; Khiari, Jameleddine; Josselin, Beatrice; Baratte, Blandine; Bach, Stephane; Ruchaud, Sandrine; Anizon, Fabrice; Giraud, Francis; Moreau, Pascale</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-317</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Synthesis of new pyrido[3,4-g]quinazoline derivs. I [R = (CH2)2-NMe2, (CH2)2-morpholin-1-yl, (CH2)3-NMe2, etc.; R1 = NH2, NO2] and the evaluation of the inhibitory potencies of these compds. toward CDK5, CK1, GSK3, CLK1 and DYRK1A were described.  Introduction of aminoalkylamino groups at the 2-position resulted in several compds. with low nanomolar affinity and selective inhibition of CLK1 and/or DYRK1A.  Their evaluation on several immortalized or cancerous cell lines showed varying degree of cell viability redn.  Co-crystal structures of CLK1 with two of the most potent compds. I [R = Me, R1 = NO2; R = (CH2)3-morpholin-1-yl, R2 = NH2] revealed two alternative binding modes of the pyrido[3,4-g]quinazoline scaffold that can be exploited for future inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK9VnCqI3-v7Vg90H21EOLACvtfcHk0liatDMJwfhp_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1aqsLk%253D&md5=d572d06711c1ecdf401051af38655449</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.052%26sid%3Dliteratum%253Aachs%26aulast%3DTazarki%26aufirst%3DH.%26aulast%3DZeinyeh%26aufirst%3DW.%26aulast%3DEsvan%26aufirst%3DY.%2BJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DM.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DKhiari%26aufirst%3DJ.%26aulast%3DJosselin%26aufirst%3DB.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DBach%26aufirst%3DS.%26aulast%3DRuchaud%26aufirst%3DS.%26aulast%3DAnizon%26aufirst%3DF.%26aulast%3DGiraud%26aufirst%3DF.%26aulast%3DMoreau%26aufirst%3DP.%26atitle%3DNew%2520pyrido%255B3%252C4-g%255Dquinazoline%2520derivatives%2520as%2520CLK1%2520and%2520DYRK1A%2520inhibitors%253A%2520Synthesis%252C%2520biological%2520evaluation%2520and%2520binding%2520mode%2520analysis%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D304%26epage%3D317%26doi%3D10.1016%2Fj.ejmech.2019.01.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Falke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoaÃ«c, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu Jhaisha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span> <span> </span><span class="NLM_article-title">10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3131</span>â <span class="NLM_lpage">3143</span>, <span class="refDoi">Â DOI: 10.1021/jm501994d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501994d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1GhtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3131-3143&author=H.+Falkeauthor=A.+Chaikuadauthor=A.+Beckerauthor=N.+Loa%C3%ABcauthor=O.+Lozachauthor=S.+Abu+Jhaishaauthor=W.+Beckerauthor=P.+G.+Jonesauthor=L.+Preuauthor=K.+Baumannauthor=S.+Knappauthor=L.+Meijerauthor=C.+Kunick&title=10-Iodo-11H-indolo%5B3%2C2-c%5Dquinoline-6-carboxylic+Acids+Are+Selective+Inhibitors+of+DYRK1A&doi=10.1021%2Fjm501994d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A</span></div><div class="casAuthors">Falke, Hannes; Chaikuad, Apirat; Becker, Anja; Loaec, Nadege; Lozach, Olivier; Abu Jhaisha, Samira; Becker, Walter; Jones, Peter G.; Preu, Lutz; Baumann, Knut; Knapp, Stefan; Meijer, Laurent; Kunick, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3131-3143</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein kinase DYRK1A has been suggested to act as one of the intracellular regulators contributing to neurol. alterations found in individuals with Down syndrome.  For an assessment of the role of DYRK1A, selective synthetic inhibitors are valuable pharmacol. tools.  However, the DYRK1A inhibitors described in the literature so far either are not sufficiently selective or have not been tested against closely related kinases from the DYRK and the CLK protein kinase families.  The aim of this study was the identification of DYRK1A inhibitors exhibiting selectivity vs. the structurally and functionally closely related DYRK and CLK isoforms.  Structure modification of the screening hit 11H-indolo[3,2-c]quinoline-6-carboxylic acid revealed structure-activity relationships for kinase inhibition and enabled the design of 10-iodo-substituted derivs. as very potent DYRK1A inhibitors with considerable selectivity against CLKs.  X-ray structure detn. of three 11H-indolo[3,2-c]quinoline-6-carboxylic acids cocrystd. with DYRK1A confirmed the predicted binding mode within the ATP binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4rHbgYJUsbVg90H21EOLACvtfcHk0liatDMJwfhp_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1GhtrY%253D&md5=70efbb6ad590a1240764ccc78af019ec</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm501994d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501994d%26sid%3Dliteratum%253Aachs%26aulast%3DFalke%26aufirst%3DH.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DBecker%26aufirst%3DA.%26aulast%3DLoa%25C3%25ABc%26aufirst%3DN.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DAbu%2BJhaisha%26aufirst%3DS.%26aulast%3DBecker%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DP.%2BG.%26aulast%3DPreu%26aufirst%3DL.%26aulast%3DBaumann%26aufirst%3DK.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKunick%26aufirst%3DC.%26atitle%3D10-Iodo-11H-indolo%255B3%252C2-c%255Dquinoline-6-carboxylic%2520Acids%2520Are%2520Selective%2520Inhibitors%2520of%2520DYRK1A%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3131%26epage%3D3143%26doi%3D10.1021%2Fjm501994d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">Development of a novel selective inhibitor of the down syndrome-related kinase DYRK1A</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi">Â DOI: 10.1038/ncomms1090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1038%2Fncomms1090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=20981014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=86&author=Y.+Ogawaauthor=Y.+Nonakaauthor=T.+Gotoauthor=E.+Ohnishiauthor=T.+Hiramatsuauthor=I.+Kiiauthor=M.+Yoshidaauthor=T.+Ikuraauthor=H.+Onogiauthor=H.+Shibuyaauthor=T.+Hosoyaauthor=N.+Itoauthor=M.+Hagiwara&title=Development+of+a+novel+selective+inhibitor+of+the+down+syndrome-related+kinase+DYRK1A&doi=10.1038%2Fncomms1090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A</span></div><div class="casAuthors">Ogawa Yasushi; Nonaka Yosuke; Goto Toshiyasu; Ohnishi Eriko; Hiramatsu Toshiyuki; Kii Isao; Yoshida Miyo; Ikura Teikichi; Onogi Hiroshi; Shibuya Hiroshi; Hosoya Takamitsu; Ito Nobutoshi; Hagiwara Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A) is a serine/threonine kinase essential for brain development and function, and its excessive activity is considered a pathogenic factor in Down syndrome.  The development of potent, selective inhibitors of Dyrk1A would help to elucidate the molecular mechanisms of normal and diseased brains, and may provide a new lead compound for molecular-targeted drug discovery.  Here, we report a novel Dyrk1A inhibitor, INDY, a benzothiazole derivative showing a potent ATP-competitive inhibitory effect with IC(50) and K(i) values of 0.24 and 0.18 Î¼M, respectively.  X-ray crystallography of the Dyrk1A/INDY complex revealed the binding of INDY in the ATP pocket of the enzyme.  INDY effectively reversed the aberrant tau-phosphorylation and rescued the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A overexpression.  Importantly, proINDY, a prodrug of INDY, effectively recovered Xenopus embryos from head malformation induced by Dyrk1A overexpression, resulting in normally developed embryos and demonstrating the utility of proINDY in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCqf6rsXbPtenUz0lpNqnfW6udTcc2eYUGWk952Bp3Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D&md5=ac1d5972bec4085de101bb86194babd1</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1038%2Fncomms1090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1090%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DNonaka%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DOhnishi%26aufirst%3DE.%26aulast%3DHiramatsu%26aufirst%3DT.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DIkura%26aufirst%3DT.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520the%2520down%2520syndrome-related%2520kinase%2520DYRK1A%26jtitle%3DNat.%2520Commun.%26date%3D2010%26volume%3D1%26spage%3D86%26doi%3D10.1038%2Fncomms1090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Czarna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelencova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kildalsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seternes, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothweiler, U.</span></span> <span> </span><span class="NLM_article-title">Novel scaffolds for dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7560</span>â <span class="NLM_lpage">7572</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01847</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01847" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVygtrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7560-7572&author=A.+Czarnaauthor=J.+Wangauthor=D.+Zelencovaauthor=Y.+Liuauthor=X.+Dengauthor=H.+G.+Choiauthor=T.+Zhangauthor=W.+Zhouauthor=J.+W.+Changauthor=H.+Kildalsenauthor=O.+M.+Seternesauthor=N.+S.+Grayauthor=R.+A.+Enghauthor=U.+Rothweiler&title=Novel+scaffolds+for+dual+specificity+tyrosine-phosphorylation-regulated+kinase+%28DYRK1A%29+inhibitors&doi=10.1021%2Facs.jmedchem.7b01847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors</span></div><div class="casAuthors">Czarna, Anna; Wang, Jinhua; Zelencova, Diana; Liu, Yao; Deng, Xianming; Choi, Hwan Geun; Zhang, Tinghu; Zhou, Wenjun; Chang, Jae Won; Kildalsen, Hanne; Seternes, Ole Morten; Gray, Nathanael S.; Engh, Richard A.; Rothweiler, Ulli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7560-7572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A is one of five members of the dual-specificity tyrosine (Y) phosphorylation-regulated kinase (DYRK) family.  The DYRK1A gene is located in the Down syndrome crit. region and regulates cellular processes related to proliferation and differentiation of neuronal progenitor cells during early development.  This has focused research on its role in neuronal degenerative diseases, including Alzheimer's and Down syndrome.  Recent studies have also shown a possible role of DYRK1A in diabetes.  Here we report a variety of scaffolds not generally known for DYRK1A inhibition, demonstrating their effects in in vitro assays and also in cell cultures.  These inhibitors effectively block the tau phosphorylation that is a hallmark of Alzheimer's disease.  The crystal structures of these inhibitors support the design of optimized and novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC4Uq_4mv-grVg90H21EOLACvtfcHk0lg68o7sKGRpKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVygtrjF&md5=c4b55fc7510b9f9d80726933b32be508</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01847%26sid%3Dliteratum%253Aachs%26aulast%3DCzarna%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZelencova%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DKildalsen%26aufirst%3DH.%26aulast%3DSeternes%26aufirst%3DO.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DRothweiler%26aufirst%3DU.%26atitle%3DNovel%2520scaffolds%2520for%2520dual%2520specificity%2520tyrosine-phosphorylation-regulated%2520kinase%2520%2528DYRK1A%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7560%26epage%3D7572%26doi%3D10.1021%2Facs.jmedchem.7b01847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rothweiler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandsdal, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaksson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, J. S. M.</span></span> <span> </span><span class="NLM_article-title">Probing the atp-binding pocket of protein kinase DYRK1A with benzothiazole fragment molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9814</span>â <span class="NLM_lpage">9824</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01086</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01086" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9814-9824&author=U.+Rothweilerauthor=W.+Stensenauthor=B.+O.+Brandsdalauthor=J.+Isakssonauthor=F.+A.+Leesonauthor=R.+A.+Enghauthor=J.+S.+M.+Svendsen&title=Probing+the+atp-binding+pocket+of+protein+kinase+DYRK1A+with+benzothiazole+fragment+molecules&doi=10.1021%2Facs.jmedchem.6b01086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules</span></div><div class="casAuthors">Rothweiler, Ulli; Stensen, Wenche; Brandsdal, Bjoern Olav; Isaksson, Johan; Leeson, Frederick Alan; Engh, Richard Alan; Svendsen, John S. Mjoeen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9814-9824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A has emerged as a potential target for therapies of Alzheimer's disease using small mols.  Based on the observation of selective DYRK1A inhibition by firefly D-luciferin, we have explored static and dynamic structural properties of fragment sized variants of the benzothiazole scaffold with respect to DYRK1A using X-ray crystallog. and NMR techniques.  The compds. have excellent ligand efficiencies and show a remarkable diversity of binding modes in dynamic equil.  Binding geometries are detd. in part by interactions often considered "weak", including "orthogonal multipolar" types represented by e.g. F-CO, sulfur-aromat, and halogen-aromat interactions, together with hydrogen bonds that are modulated by variation of electron withdrawing groups.  These studies show how the benzothiazole scaffold is highly promising for the development of therapeutic DYRK1A inhibitors.  In addn., the subtleties of the binding interactions, including dynamics, show how full structural studies are required to fully interpret the essential phys. determinants of binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYSQe1_5bEjLVg90H21EOLACvtfcHk0lg68o7sKGRpKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr7P&md5=edb850b232f53b3e161a5023915972e6</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01086%26sid%3Dliteratum%253Aachs%26aulast%3DRothweiler%26aufirst%3DU.%26aulast%3DStensen%26aufirst%3DW.%26aulast%3DBrandsdal%26aufirst%3DB.%2BO.%26aulast%3DIsaksson%26aufirst%3DJ.%26aulast%3DLeeson%26aufirst%3DF.%2BA.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26aulast%3DSvendsen%26aufirst%3DJ.%2BS.%2BM.%26atitle%3DProbing%2520the%2520atp-binding%2520pocket%2520of%2520protein%2520kinase%2520DYRK1A%2520with%2520benzothiazole%2520fragment%2520molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9814%26epage%3D9824%26doi%3D10.1021%2Facs.jmedchem.6b01086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡lint, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ©ber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruzalegui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbridge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotschy, A.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">932</span>â <span class="NLM_lpage">939</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201600539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fcmdc.201600539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=28264138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Wisro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=932-939&author=B.+B%C3%A1lintauthor=C.+W%C3%A9berauthor=F.+Cruzaleguiauthor=M.+Burbridgeauthor=A.+Kotschy&title=Structure-Based+Design+and+Synthesis+of+Harmine+Derivatives+with+Different+Selectivity+Profiles+in+Kinase+versus+Monoamine+Oxidase+Inhibition&doi=10.1002%2Fcmdc.201600539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition</span></div><div class="casAuthors">Balint, Balazs; Weber, Csaba; Cruzalegui, Francisco; Burbridge, Mike; Kotschy, Andras</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">932-939</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an emerging biol. target with implications in diverse therapeutic areas such as neurol. disorders (Down syndrome, in particular), metab., and oncol.  Harmine, a natural product that selectively inhibits DYRK1A amongst kinases, could serve as a tool compd. to better understand the biol. processes that arise from DYRK1A inhibition.  On the other hand, harmine is also a potent inhibitor of monoamine oxidase A (MAO-A).  Using structure-based design, we synthesized a collection of harmine analogs with tunable selectivity toward these two enzymes.  Modifications at the 7-position typically decreased affinity for DYRK1A, whereas substitution at the 9-position had a similar effect on MAO-A inhibition but DYRK1A inhibition was maintained.  The resulting collection of compds. can help to understand the biol. role of DYRK1A and also to assess the interference in the biol. effect originating in MAO-A inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsY4lpVOJVlbVg90H21EOLACvtfcHk0lg68o7sKGRpKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Wisro%253D&md5=f713602f24c608cbe5c97d965ea3727d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600539%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1lint%26aufirst%3DB.%26aulast%3DW%25C3%25A9ber%26aufirst%3DC.%26aulast%3DCruzalegui%26aufirst%3DF.%26aulast%3DBurbridge%26aufirst%3DM.%26aulast%3DKotschy%26aufirst%3DA.%26atitle%3DStructure-Based%2520Design%2520and%2520Synthesis%2520of%2520Harmine%2520Derivatives%2520with%2520Different%2520Selectivity%2520Profiles%2520in%2520Kinase%2520versus%2520Monoamine%2520Oxidase%2520Inhibition%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D932%26epage%3D939%26doi%3D10.1002%2Fcmdc.201600539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruit, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HÃ©rault, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besson, T.</span></span> <span> </span><span class="NLM_article-title">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1183</span>â <span class="NLM_lpage">1199</span>, <span class="refDoi">Â DOI: 10.1080/13543776.2017.1360285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1080%2F13543776.2017.1360285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=28766366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ojs7jO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1183-1199&author=T.+L.+Nguyenauthor=C.+Fruitauthor=Y.+H%C3%A9raultauthor=L.+Meijerauthor=T.+Besson&title=Dual-specificity+tyrosine+phosphorylation-regulated+kinase+1A+%28DYRK1A%29+inhibitors%3A+a+survey+of+recent+patent+literature&doi=10.1080%2F13543776.2017.1360285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature</span></div><div class="casAuthors">Nguyen, Thu Lan; Fruit, Corinne; Herault, Yann; Meijer, Laurent; Besson, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1183-1199</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a eukaryotic serine-threonine protein kinase belonging to the CMGC group.  DYRK1A hyperactivity appears to contribute to the development of a no. of human malignancies and to cognitive deficits obsd. in Down syndrome and Alzheimer's disease.  As a result, the DYRK1A kinase represents an attractive target for the synthesis and optimization of pharmacol. inhibitors of potential therapeutic interest.  Like most tyrosine kinase inhibitors developed up to the market, DYRK1A inhibitors are essentially acting by competing with ATP for binding at the catalytic site of the kinase.  This paper reviews patent activity assocd. with the discovery of synthetic novel heterocyclic mols. inhibiting the catalytic activity of DYRK1A.  Despite the important role of DYRK1A in biol. processes and the growing interest in the design of new therapeutic drugs, there are only few patented synthetic DYRK1A inhibitors and most of them were and are still developed by academic research groups, sometimes with industrial partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMS30KxawIbVg90H21EOLACvtfcHk0liQq4H21knnqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ojs7jO&md5=3cdf56f9f96f917133b4625dd5d4d09c</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1360285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1360285%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BL.%26aulast%3DFruit%26aufirst%3DC.%26aulast%3DH%25C3%25A9rault%26aufirst%3DY.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBesson%26aufirst%3DT.%26atitle%3DDual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25201A%2520%2528DYRK1A%2529%2520inhibitors%253A%2520a%2520survey%2520of%2520recent%2520patent%2520literature%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1183%26epage%3D1199%26doi%3D10.1080%2F13543776.2017.1360285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jarhad, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashelkar, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span> <span> </span><span class="NLM_article-title">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9791</span>â <span class="NLM_lpage">9810</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9791-9810&author=D.+B.+Jarhadauthor=K.+K.+Mashelkarauthor=H.-R.+Kimauthor=M.+Nohauthor=L.+S.+Jeong&title=Dual-specificity+tyrosine+phosphorylation-regulated+kinase+1A+%28DYRK1A%29+inhibitors+as+potential+therapeutics&doi=10.1021%2Facs.jmedchem.8b00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics</span></div><div class="casAuthors">Jarhad, Dnyandev B.; Mashelkar, Karishma K.; Kim, Hong-Rae; Noh, Minsoo; Jeong, Lak Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9791-9810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an evolutionarily conserved family of protein kinases that belongs to the CMGC group of kinases.  DYRK1A, encoded by a gene located in the human chromosome 21q22.2 region, has attracted attention due to its assocn. with both neuropathol. phenotypes and cancer susceptibility in patients with Down syndrome (DS).  Inhibition of DYRK1A attenuates cognitive dysfunctions in animal models for both DS and Alzheimer's disease (AD).  Furthermore, DYRK1A has been studied as a potential cancer therapeutic target because of its role in the regulation of cell cycle progression by affecting both tumor suppressors and oncogenes.  Consequently, selective synthetic inhibitors have been developed to det. the role of DYRK1A in various human diseases.  Our perspective includes a comprehensive review of potent and selective DYRK1A inhibitors and their forthcoming therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYrGtCZLBQ77Vg90H21EOLACvtfcHk0liQq4H21knnqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO&md5=6ffb927f58fc34f16f19c5e5b8beebcf</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00185%26sid%3Dliteratum%253Aachs%26aulast%3DJarhad%26aufirst%3DD.%2BB.%26aulast%3DMashelkar%26aufirst%3DK.%2BK.%26aulast%3DKim%26aufirst%3DH.-R.%26aulast%3DNoh%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26atitle%3DDual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%25201A%2520%2528DYRK1A%2529%2520inhibitors%2520as%2520potential%2520therapeutics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9791%26epage%3D9810%26doi%3D10.1021%2Facs.jmedchem.8b00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labute, P.</span></span> <span> </span><span class="NLM_article-title">Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">187</span>â <span class="NLM_lpage">205</span>, <span class="refDoi">Â DOI: 10.1002/prot.22234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fprot.22234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=18814299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2isrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2009&pages=187-205&author=P.+Labute&title=Protonate3D%3A+Assignment+of+ionization+states+and+hydrogen+coordinates+to+macromolecular+structures&doi=10.1002%2Fprot.22234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures</span></div><div class="casAuthors">Labute, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-205</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A new method, called Protonate3D, is presented for the automated prediction of hydrogen coordinates given the 3D coordinates of the heavy atoms of a macromol. structure.  Protonate3D considers side-chain "flip," rotamer, tautomer, and ionization states of all chem. groups, ligands, and solvent, provided suitable templates are available in a parameter file.  The energy model includes van der Waals, Coulomb, solvation, rotamer, tautomer, and titrn. effects.  The results of computational validation expts. suggest that Protonate3D can accurately predict the location of hydrogen atoms in macromol. structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmnIRzxpxpCrVg90H21EOLACvtfcHk0liQq4H21knnqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2isrs%253D&md5=89803fe2028fb9257eb09854a27ef2dd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fprot.22234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22234%26sid%3Dliteratum%253Aachs%26aulast%3DLabute%26aufirst%3DP.%26atitle%3DProtonate3D%253A%2520Assignment%2520of%2520ionization%2520states%2520and%2520hydrogen%2520coordinates%2520to%2520macromolecular%2520structures%26jtitle%3DProteins%26date%3D2009%26volume%3D75%26spage%3D187%26epage%3D205%26doi%3D10.1002%2Fprot.22234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brault, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span> <span> </span><span class="NLM_article-title">7,8-Dichloro-1-oxo-Î²-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">403</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1021/jm201286z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201286z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKkt7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=403-413&author=K.+Huberauthor=L.+Braultauthor=O.+Fedorovauthor=C.+Gasserauthor=P.+Filippakopoulosauthor=A.+N.+Bullockauthor=D.+Fabbroauthor=J.+Trappeauthor=J.+Schwallerauthor=S.+Knappauthor=F.+Bracher&title=7%2C8-Dichloro-1-oxo-%CE%B2-carbolines+as+a+Versatile+Scaffold+for+the+Development+of+Potent+and+Selective+Kinase+Inhibitors+with+Unusual+Binding+Modes&doi=10.1021%2Fjm201286z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">7,8-Dichloro-1-oxo-Î²-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes</span></div><div class="casAuthors">Huber, Kilian; Brault, Laurent; Fedorov, Oleg; Gasser, Christelle; Filippakopoulos, Panagis; Bullock, Alex N.; Fabbro, Doriano; Trappe, Joerg; Schwaller, Juerg; Knapp, Stefan; Bracher, Franz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">403-413</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of both potent and selective kinase inhibitors is a challenging task in modern drug discovery.  The innate promiscuity of kinase inhibitors largely results from ATP-mimetic binding to the kinase hinge region.  We present a novel class of substituted 7,8-dichloro-1-oxo-Î²-carbolines based on the distinct structural features of the alkaloid bauerine C whose kinase inhibitory activity does not rely on canonical ATP-mimetic hinge interactions.  Intriguingly, cocrystal structures revealed an unexpected inverted binding mode and the presence of halogen bonds with kinase backbone residues.  The compds. exhibit excellent selectivity over a comprehensive panel of human protein kinases while inhibiting selected kinases such as the oncogenic PIM1 at low nanomolar concns.  Together, our biochem. and structural data suggest that this scaffold may serve as a valuable template for the design and development of specific inhibitors of various kinases including the PIM family of kinases, CLKs, DAPK3 (ZIPK), BMP2K (BIKE), and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWBwRMy-TWurVg90H21EOLACvtfcHk0lg1vEZoVrbVGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKkt7zM&md5=70fedaa0388ba604cff1fb72533bf7ac</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm201286z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201286z%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DBrault%26aufirst%3DL.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DGasser%26aufirst%3DC.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DSchwaller%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3D7%252C8-Dichloro-1-oxo-%25CE%25B2-carbolines%2520as%2520a%2520Versatile%2520Scaffold%2520for%2520the%2520Development%2520of%2520Potent%2520and%2520Selective%2520Kinase%2520Inhibitors%2520with%2520Unusual%2520Binding%2520Modes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D403%26epage%3D413%26doi%3D10.1021%2Fjm201286z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶hm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brode, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesse, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span> <span> </span><span class="NLM_article-title">Oxygen and nitrogen in competitive situations: which is the hydrogen-bond acceptor?</span>. <i>Chem.âEur. J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1509</span>â <span class="NLM_lpage">1513</span>, <span class="refDoi">Â DOI: 10.1002/chem.19960021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fchem.19960021206" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=1509-1513&author=H.-J.+B%C3%B6hmauthor=S.+Brodeauthor=U.+Hesseauthor=G.+Klebe&title=Oxygen+and+nitrogen+in+competitive+situations%3A+which+is+the+hydrogen-bond+acceptor%3F&doi=10.1002%2Fchem.19960021206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fchem.19960021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.19960021206%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBrode%26aufirst%3DS.%26aulast%3DHesse%26aufirst%3DU.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DOxygen%2520and%2520nitrogen%2520in%2520competitive%2520situations%253A%2520which%2520is%2520the%2520hydrogen-bond%2520acceptor%253F%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D1996%26volume%3D2%26spage%3D1509%26epage%3D1513%26doi%3D10.1002%2Fchem.19960021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altafaj, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Luna, S.</span></span> <span> </span><span class="NLM_article-title">DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1167</span>â <span class="NLM_lpage">1178</span>, <span class="refDoi">Â DOI: 10.1091/mbc.e06-08-0668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1091%2Fmbc.e06-08-0668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=17229891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVSmtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=1167-1178&author=M.+Alvarezauthor=X.+Altafajauthor=S.+Arandaauthor=S.+de+la+Luna&title=DYRK1A+autophosphorylation+on+serine+residue+520+modulates+its+kinase+activity+via+14-3-3+binding&doi=10.1091%2Fmbc.e06-08-0668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding</span></div><div class="casAuthors">Alvarez, Monica; Altafaj, Xavier; Aranda, Sergi; de la Luna, Susana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1167-1178</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine-phosphorylated and regulated kinase (DYRK) proteins are an evolutionarily conserved family of protein kinases, with members identified from yeast to humans, that participate in a variety of cellular processes.  DYRKs are serine/threonine protein kinases that are activated by autophosphorylation on a tyrosine residue in the activation loop.  The family member DYRK1A has been shown to phosphorylate several cytosolic proteins and a no. of splicing and transcription factors, including members of the nuclear factor of activated T cells family.  In the present study, we show that DYRK1A autophosphorylates, via an intramol. mechanism, on Ser-520, in the PEST domain of the protein.  We also show that phosphorylation of this residue, which we show is subjected to dynamic changes in vivo, mediates the interaction of DYRK1A with 14-3-3Î².  A second 14-3-3 binding site is present within the N-terminal of the protein.  In the context of the DYRK1A mol., neither site can act independently of the other.  Bacterially produced DYRK1A and the mutant DYRK1A/S520A have similar kinase activities, suggesting that Ser-520 phosphorylation does not affect the intrinsic kinase activity on its own.  Instead, we demonstrate that this phosphorylation allows the binding of 14-3-3Î², which in turn stimulates the catalytic activity of DYRK1A.  These findings provide evidence for a novel mechanism for the regulation of DYRK1A kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3iiUoSe8NbbVg90H21EOLACvtfcHk0lg1vEZoVrbVGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVSmtrc%253D&md5=7ed3a1f45bc539f97aaeea6972f9e78c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e06-08-0668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e06-08-0668%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DM.%26aulast%3DAltafaj%26aufirst%3DX.%26aulast%3DAranda%26aufirst%3DS.%26aulast%3Dde%2Bla%2BLuna%26aufirst%3DS.%26atitle%3DDYRK1A%2520autophosphorylation%2520on%2520serine%2520residue%2520520%2520modulates%2520its%2520kinase%2520activity%2520via%252014-3-3%2520binding%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2007%26volume%3D18%26spage%3D1167%26epage%3D1178%26doi%3D10.1091%2Fmbc.e06-08-0668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E.</span></span> <span> </span><span class="NLM_article-title">Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">660</span>â <span class="NLM_lpage">670</span>, <span class="refDoi">Â DOI: 10.1021/jm301495v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301495v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=660-670&author=A.+J.+Holeauthor=S.+Baumliauthor=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wangauthor=J.+A.+Endicottauthor=M.+E.+Noble&title=Comparative+structural+and+functional+studies+of+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidine-5-carbonitrile+CDK9+inhibitors+suggest+the+basis+for+isotype+selectivity&doi=10.1021%2Fjm301495v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity</span></div><div class="casAuthors">Hole, Alison J.; Baumli, Sonja; Shao, Hao; Shi, Shenhua; Huang, Shiliang; Pepper, Chris; Fischer, Peter M.; Wang, Shudong; Endicott, Jane A.; Noble, Martin E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">660-670</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 9/cyclin T, the protein kinase heterodimer that constitutes pos. transcription elongation factor b, is a well-validated target for treatment of several diseases, including cancer and cardiac hypertrophy.  In order to aid inhibitor design and rationalize the basis for CDK9 selectivity, we have studied the CDK-binding properties of six different members of a 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series that bind to both CDK9/cyclin T and CDK2/cyclin A.  We find that for a given CDK, the melting temp. of a CDK/cyclin/inhibitor complex correlates well with inhibitor potency, suggesting that differential scanning fluorometry (DSF) is a useful orthogonal measure of inhibitory activity for this series.  We have used DSF to demonstrate that the binding of these compds. is independent of the presence or absence of the C-terminal tail region of CDK9, unlike the binding of the CDK9-selective inhibitor 5,6-dichlorobenzimidazone-1-Î²-D-ribofuranoside (DRB).  Finally, on the basis of 11 cocrystal structures bound to CDK9/cyclin T or CDK2/cyclin A, we conclude that selective inhibition of CDK9/cyclin T by members of the 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile series results from the relative malleability of the CDK9 active site rather than from the formation of specific polar contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGJy-t5isJBbVg90H21EOLACvtfcHk0lg1vEZoVrbVGg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVKhurjE&md5=8c09b13b5f828b7a013607cab64b0b80</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm301495v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301495v%26sid%3Dliteratum%253Aachs%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26atitle%3DComparative%2520structural%2520and%2520functional%2520studies%2520of%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidine-5-carbonitrile%2520CDK9%2520inhibitors%2520suggest%2520the%2520basis%2520for%2520isotype%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D660%26epage%3D670%26doi%3D10.1021%2Fjm301495v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">NÄmec, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HylsovÃ¡, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶der, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ValÄÃ­kovÃ¡, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uldrijan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DrÃ¡pela, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SouÄek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span> <span> </span><span class="NLM_article-title">Furo[3,2-b]pyridine: a privileged scaffold for highly selective kinase inhibitors and effective modulators of the hedgehog pathway</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1062</span>â <span class="NLM_lpage">1066</span>, <span class="refDoi">Â DOI: 10.1002/anie.201810312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=10.1002%2Fanie.201810312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=30569600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A280%3ADC%252BB3cnktVaitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1062-1066&author=V.+N%C4%9Bmecauthor=M.+Hylsov%C3%A1author=L.+Maierauthor=J.+Flegelauthor=S.+Sieversauthor=S.+Zieglerauthor=M.+Schr%C3%B6derauthor=B.+T.+Bergerauthor=A.+Chaikuadauthor=B.+Val%C4%8D%C3%ADkov%C3%A1author=S.+Uldrijanauthor=S.+Dr%C3%A1pelaauthor=K.+Sou%C4%8Dekauthor=H.+Waldmannauthor=S.+Knappauthor=K.+Paruch&title=Furo%5B3%2C2-b%5Dpyridine%3A+a+privileged+scaffold+for+highly+selective+kinase+inhibitors+and+effective+modulators+of+the+hedgehog+pathway&doi=10.1002%2Fanie.201810312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway</span></div><div class="casAuthors">Nemec Vaclav; Hylsova Michaela; Maier Lukas; Paruch Kamil; Nemec Vaclav; Hylsova Michaela; Maier Lukas; Valcikova Barbora; Uldrijan Stjepan; Drapela Stanislav; Soucek Karel; Paruch Kamil; Flegel Jana; Sievers Sonja; Ziegler Slava; Waldmann Herbert; Schroder Martin; Berger Benedict-Tilman; Chaikuad Apirat; Knapp Stefan; Valcikova Barbora; Uldrijan Stjepan; Drapela Stanislav; Soucek Karel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1062-1066</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Reported is the identification of the furo[3,2-b]pyridine core as a novel scaffold for potent and highly selective inhibitors of cdc-like kinases (CLKs) and efficient modulators of the Hedgehog signaling pathway.  Initially, a diverse target compound set was prepared by synthetic sequences based on chemoselective metal-mediated couplings, including assembly of the furo[3,2-b]pyridine scaffold by copper-mediated oxidative cyclization.  Optimization of the subseries containing 3,5-disubstituted furo[3,2-b]pyridines afforded potent, cell-active, and highly selective inhibitors of CLKs.  Profiling of the kinase-inactive subset of 3,5,7-trisubstituted furo[3,2-b]pyridines revealed sub-micromolar modulators of the Hedgehog pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3yixuupDQ3gyMywPm6HgQfW6udTcc2ebSVWAihEl9gbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnktVaitw%253D%253D&md5=62b69671525c989112ea5538ea1d3654</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fanie.201810312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201810312%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C4%259Bmec%26aufirst%3DV.%26aulast%3DHylsov%25C3%25A1%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DL.%26aulast%3DFlegel%26aufirst%3DJ.%26aulast%3DSievers%26aufirst%3DS.%26aulast%3DZiegler%26aufirst%3DS.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DVal%25C4%258D%25C3%25ADkov%25C3%25A1%26aufirst%3DB.%26aulast%3DUldrijan%26aufirst%3DS.%26aulast%3DDr%25C3%25A1pela%26aufirst%3DS.%26aulast%3DSou%25C4%258Dek%26aufirst%3DK.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DParuch%26aufirst%3DK.%26atitle%3DFuro%255B3%252C2-b%255Dpyridine%253A%2520a%2520privileged%2520scaffold%2520for%2520highly%2520selective%2520kinase%2520inhibitors%2520and%2520effective%2520modulators%2520of%2520the%2520hedgehog%2520pathway%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D2019%26volume%3D58%26spage%3D1062%26epage%3D1066%26doi%3D10.1002%2Fanie.201810312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span> Prepared following<span class="NLM_contrib-group"><span class="NLM_string-name">Pauvert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span> <span> </span><span class="NLM_article-title">Toward an artificial oxidative DNA photolyase</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">548</span>, <span class="refDoi">Â DOI: 10.1021/jo0354600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0354600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWisb3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=543-548&author=M.+Pauvertauthor=P.+Laineauthor=M.+Jonasauthor=O.+Wiest&title=Toward+an+artificial+oxidative+DNA+photolyase&doi=10.1021%2Fjo0354600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Toward an Artificial Oxidative DNA Photolyase</span></div><div class="casAuthors">Pauvert, Mickaeel; Laine, Patrick; Jonas, Marco; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-548</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, structure, and binding affinity of two ditopic receptors for the selective mol. recognition of the cis,syn cyclobutane pyrimidine dimer are reported.  The design is based on two 2,6-di(acetamino)pyridine recognition units that are covalently linked via triple bonds to an anthraquinone functional spacer unit.  The convergent synthesis uses a modified Sonogashira reaction involving a zinc transmetalation as the key step.  The crystal structure of one of the receptors reveals a supramol. 1D polymer with strong interactions mediated by shape self-complementarity, Ï-stacking, and hydrogen bonding between adjacent mols.  Hydrogen bonding between adjacent strands enforces a parallel orientation, which leads to a non-centrosym. crystal structure of the highly polar compd.  The receptor has an assocn. const. of Ka = 1.0 Ã 103 M-1 with the cis,syn pyrimidine dimer, whereas binding of the trans,syn isomer is â¼1 order of magnitude weaker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwu5NU43J_OLVg90H21EOLACvtfcHk0lgpbNg5TqNkQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWisb3L&md5=190d74734fe457e335276b3b92deaae4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjo0354600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0354600%26sid%3Dliteratum%253Aachs%26aulast%3DPauvert%26aufirst%3DM.%26aulast%3DLaine%26aufirst%3DP.%26aulast%3DJonas%26aufirst%3DM.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DToward%2520an%2520artificial%2520oxidative%2520DNA%2520photolyase%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D543%26epage%3D548%26doi%3D10.1021%2Fjo0354600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span>; <span class="NLM_string-name">Murray, M.</span>; <span class="NLM_string-name">Dokurno, P.</span>; <span class="NLM_string-name">Massey, A. J.</span>; <span class="NLM_string-name">Benwell, K.</span>; <span class="NLM_string-name">Fiumana, A.</span>; <span class="NLM_string-name">Foloppe, N.</span>; <span class="NLM_string-name">Ray, S.</span>; <span class="NLM_string-name">Smith, J.</span>; <span class="NLM_string-name">Surgenor, A.</span>; <span class="NLM_string-name">Edmonds, T.</span>; <span class="NLM_string-name">Demarles, D.</span>; <span class="NLM_string-name">Burbridge, M.</span>; <span class="NLM_string-name">Cruzalegui, F.</span>; <span class="NLM_string-name">Kotschy, A.</span>; <span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">Fragment derived selective inhibitors of dual specificity kinases DYRK1A and DYRK1B</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, accepted for publication.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;key=33975430" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=D.+L.+Walmsley&author=M.+Murray&author=P.+Dokurno&author=A.+J.+Massey&author=K.+Benwell&author=A.+Fiumana&author=N.+Foloppe&author=S.+Ray&author=J.+Smith&author=A.+Surgenor&author=T.+Edmonds&author=D.+Demarles&author=M.+Burbridge&author=F.+Cruzalegui&author=A.+Kotschy&author=R.+E.+Hubbard&title=Fragment+derived+selective+inhibitors+of+dual+specificity+kinases+DYRK1A+and+DYRK1B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26atitle%3DFragment%2520derived%2520selective%2520inhibitors%2520of%2520dual%2520specificity%2520kinases%2520DYRK1A%2520and%2520DYRK1B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7A4W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7A4W','PDB','7A4W'); return false;">PDB: 7A4W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR','PDB','3ANR'); return false;">PDB: 3ANR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ2','PDB','7AJ2'); return false;">PDB: 7AJ2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ4','PDB','7AJ4'); return false;">PDB: 7AJ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ5','PDB','7AJ5'); return false;">PDB: 7AJ5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ8','PDB','7AJ8'); return false;">PDB: 7AJ8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJ7','PDB','7AJ7'); return false;">PDB: 7AJ7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJA','PDB','7AJA'); return false;">PDB: 7AJA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJM','PDB','7AJM'); return false;">PDB: 7AJM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLH','PDB','3BLH'); return false;">PDB: 3BLH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLQ','PDB','3BLQ'); return false;">PDB: 3BLQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BLR','PDB','3BLR'); return false;">PDB: 3BLR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF','PDB','4BCF'); return false;">PDB: 4BCF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJS','PDB','7AJS'); return false;">PDB: 7AJS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJV','PDB','7AJV'); return false;">PDB: 7AJV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJW','PDB','7AJW'); return false;">PDB: 7AJW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKL','PDB','7AKL'); return false;">PDB: 7AKL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKF','PDB','7AKF'); return false;">PDB: 7AKF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AK2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AK2','PDB','7AK2'); return false;">PDB: 7AK2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKB','PDB','7AKB'); return false;">PDB: 7AKB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKE','PDB','7AKE'); return false;">PDB: 7AKE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKH','PDB','7AKH'); return false;">PDB: 7AKH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AJY','PDB','7AJY'); return false;">PDB: 7AJY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AKA','PDB','7AKA'); return false;">PDB: 7AKA</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i117"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00023">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77267"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00023?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00023</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Description of data tables, structural determination details, LC chromatograms, and <sup>1</sup>H NMR spectra of key compounds, (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_001.pdf">jm1c00023_si_001.pdf (7.28 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00023/suppl_file/jm1c00023_si_002.csv">jm1c00023_si_002.csv (4.03 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The X-ray structures mentioned in this paper have been deposited in the PDB with the following codes. Dyrk1a: <b>3</b>: 7AJ2, <b>5</b>: 7AJ4, <b>10</b>: 7AJ5, <b>16</b>: 7AJ7; <b>25</b>: 7AJ8, <b>28</b>: 7AJA, <b>32</b>: 7AJM, <b>33</b>: 7AJS; <b>38</b>: 7AJV, <b>46</b>: 7AJW, <b>50</b>: 7AKL; <b>51</b>: 7AJY; <b>53</b>: 7AK2, <b>54</b>: 7AKA, <b>56</b>: 7AKB, <b>58</b>: 7AKE. Dyrk2: <b>50</b>: 7AKF; <b>58</b>: 7AKH. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00023&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-10%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00023%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00023" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b72cfac821be","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
